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A B S T R A C T
Background
The current paradigm for cardiovascular disease (CVD) emphasises absolute risk assessment to guide treatment decisions in primary
prevention. Although the derivation and validation ofmultivariable risk assessment tools, or CVDrisk scores, have attracted considerable
attention, their effect on clinical outcomes is uncertain.
Objectives
To assess the effects of evaluating and providing CVD risk scores in adults without prevalent CVD on cardiovascular outcomes, risk
factor levels, preventive medication prescribing, and health behaviours.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2016, Issue 2), MEDLINE
Ovid (1946 to March week 1 2016), Embase (embase.com) (1974 to 15 March 2016), and Conference Proceedings Citation Index-
Science (CPCI-S) (1990 to 15 March 2016). We imposed no language restrictions. We searched clinical trial registers in March 2016
and handsearched reference lists of primary studies to identify additional reports.
Selection criteria
We included randomised and quasi-randomised trials comparing the systematic provision of CVD risk scores by a clinician, healthcare
professional, or healthcare system compared with usual care (i.e. no systematic provision of CVD risk scores) in adults without CVD.
Data collection and analysis
Three review authors independently selected studies, extracted data, and evaluated study quality. We used the Cochrane ’Risk of bias’
tool to assess study limitations. The primary outcomes were: CVD events, change in CVD risk factor levels (total cholesterol, systolic
blood pressure, and multivariable CVD risk), and adverse events. Secondary outcomes included: lipid-lowering and antihypertensive
medication prescribing in higher-risk people. We calculated risk ratios (RR) for dichotomous data and mean differences (MD) or
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standardised mean differences (SMD) for continuous data using 95% confidence intervals. We used a fixed-effects model when
heterogeneity (I²) was at least 50% and a random-effects model for substantial heterogeneity (I² > 50%). We evaluated the quality of
evidence using the GRADE framework.
Main results
We identified 41 randomised controlled trials (RCTs) involving 194,035 participants from 6422 reports. We assessed studies as having
high or unclear risk of bias across multiple domains. Low-quality evidence evidence suggests that providing CVD risk scores may have
little or no effect on CVD events compared with usual care (5.4% versus 5.3%; RR 1.01, 95% confidence interval (CI) 0.95 to 1.08;
I² = 25%; 3 trials, N = 99,070). Providing CVD risk scores may reduce CVD risk factor levels by a small amount compared with
usual care. Providing CVD risk scores reduced total cholesterol (MD−0.10 mmol/L, 95% CI−0.20 to 0.00; I² = 94%; 12 trials, N =
20,437, low-quality evidence), systolic blood pressure (MD−2.77 mmHg, 95% CI−4.16 to−1.38; I² = 93%; 16 trials, N = 32,954,
low-quality evidence), and multivariable CVD risk (SMD−0.21, 95% CI −0.39 to−0.02; I² = 94%; 9 trials, N = 9549, low-quality
evidence). Providing CVD risk scores may reduce adverse events compared with usual care, but results were imprecise (1.9% versus
2.7%; RR 0.72, 95% CI 0.49 to 1.04; I² = 0%; 4 trials, N = 4630, low-quality evidence). Compared with usual care, providing CVD
risk scores may increase new or intensified lipid-lowering medications (15.7% versus 10.7%; RR 1.47, 95% CI 1.15 to 1.87; I² = 40%;
11 trials, N = 14,175, low-quality evidence) and increase new or increased antihypertensive medications (17.2% versus 11.4%; RR
1.51, 95% CI 1.08 to 2.11; I² = 53%; 8 trials, N = 13,255, low-quality evidence).
Authors’ conclusions
There is uncertainty whether current strategies for providing CVD risk scores affect CVD events. Providing CVD risk scores may
slightly reduce CVD risk factor levels and may increase preventive medication prescribing in higher-risk people without evidence of
harm. There were multiple study limitations in the identified studies and substantial heterogeneity in the interventions, outcomes, and
analyses, so readers should interpret results with caution. New models for implementing and evaluating CVD risk scores in adequately
powered studies are needed to define the role of applying CVD risk scores in primary CVD prevention.
P L A I N L A N G U A G E S U M M A R Y
Clinical effects of cardiovascular risk scores in people without cardiovascular disease
Review question
What is the evidence about the potential clinical benefits and harms of providing cardiovascular disease (CVD) risk scores in people
without a history of heart disease or stroke?
Background
Cardiovascular disease (CVD) is a group of conditions that includes heart disease and stroke. CVD prevention guidelines emphasise
the use of risk scores, equations that use clinical variables to estimate the chance of a first heart attack or stroke, to guide treatment
decisions in the general population. While there has been much attention to developing different types of CVD risk scores, there is
uncertainty about the effects of providing a CVD risk score in clinical practice.
The aim of this systematic review was to assess the effects of evaluating CVD risk scores in adults without a history of heart disease or
stroke on cardiovascular outcomes, risk factor levels, preventive medication prescribing, and health behaviours.
Study characteristics
We searched scientific databases for randomised trials (clinical studies that randomly put people into different treatment groups) that
systematically provided CVD risk scores or usual care to adults without a history of heart disease or stroke. The evidence is current to
March 2016. Funding for the majority of trials came from government sources or pharmaceutical companies.
Key results
We identified 41 trials that included 194,035 participants. Many of the studies had limitations. Low-quality evidence suggests that
providing CVD risk scores had little or no effect on the number of people who develop heart disease or stroke. Providing CVD risk
scores may reduce CVD risk factor levels (like cholesterol, blood pressure, and multivariable CVD risk) by a small amount and may
increase cholesterol-lowering and blood pressure-lowering medication prescribing in higher risk people. Providing CVD risk scores
may reduce harms, but the results were imprecise.
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Quality of the evidence
There is low-quality evidence to guide the use of CVD risk scores in clinical practice. Studies hadmultiple limitations and used different
methods to provide CVD risk scores. It is likely that further research will influence these results.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
CVD risk scoring for the primary prevention of cardiovascular disease
Patient or population: adults without prevalent cardiovascular disease (primary cardiovascular disease prevent ion)
Setting: outpat ient
Intervention: providing CVD risk scores
Comparison: not providing CVD risk scores/ usual care
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
N of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with not providing
CVD risk scores/ usual
care
Risk with providing
CVD risk scores
CVD events
follow-up: range 1-10
years
Study populat ion RR 1.01
(0.95 to 1.08)
99,070
(3 RCTs)
⊕⊕©©
Lowa,b
-
53 per 1000 54 per 1000
(51 to 58)
Total cholesterol
(mmol/ L)
follow-up: median 1
years
In the comparison
group, the range of
mean total cholesterol
level was 5.1 to 6.6
mmol/ L and the range
of mean change f rom
baseline in total choles-
terol level was 0.09
lower to 0.14 mmol/ L
higher
The mean dif ference in
total cholesterol in the
intervent ion group was
0.10 mmol/ L lower
(0.20 lower to 0.00)
- 20,437
(12 RCTs)
⊕⊕©©
Lowc,d
-
Systolic blood pressure
(mmHg)
follow-up: median 1
years
In the comparison
group, the range of
mean systolic blood
pressure level was 124.
1 to 159.0 mmHg and
the range of mean
The mean dif ference
in systolic blood pres-
sure in the intervent ion
group was 2.77 mmHg
lower
(4.16 lower to 1.38
- 32,954
(16 RCTs)
⊕⊕©©
Lowc,d
-
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change f rom baseline in
systolic blood pressure
level was 5.3 lower to
1.0 higher mmHg
lower)
Change in mult ivariable
CVD risk (SD)
follow-up: median 1
years
In the comparison
group, the range of
mean change f rom
baseline in mult ivari-
able CVD risk was 5.
3 lower to 0.77 higher
SDs
The mean dif ference
in mult ivariable CVD
risk in the intervent ion
group was 0.21 SDs
lower
(0.39 lower to 0.02
lower)
- 9549
(9 RCTs)
⊕⊕©©
Lowc,d
Standardised mean dif -
ferences were calcu-
lated for this outcome
due to the use of dif f er-
ent mult ivariable CVD
risk scales. An ef fect
size of ~ 0.20 SD units
ref lects a small ef fect
Invest igator-def ined
adverse events
follow-up: range 1
month to 1 year
Study populat ion RR 0.72
(0.49 to 1.04)
4630
(4 RCTs)
⊕⊕©©
Lowe,f
Adverse events were
def ined het-
erogeneously by inves-
t igators and included
some events that may
have been due to newly
prescribed medicat ions
rather than the provi-
sion of a CVD risk score
itself
27 per 1000 19 per 1000
(13 to 28)
New/ intensif ied lipid-
lowering medicat ion
follow-up: median 6
months
Study populat ion RR 1.47
(1.15 to 1.87)
14,175
(11 RCTs)
⊕⊕©©
Lowd,e
Prescribing rates in the
comparison group var-
ied among the included
trials (range 4% to 22%)
. Median prescribing
rate presented
107 per 1000 157 per 1000
(123 to 200)
New/ intensif ied ant ihy-
pertensive medicat ion
follow-up: median 1
years
Study populat ion RR 1.51
(1.08 to 2.11)
13,255
(8 RCTs)
⊕⊕©©
Lowd,e
Prescribing rates in the
comparison group var-
ied among the included
trials (range 0% to 27%)
. Median prescribing
rate presented
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114 per 1000 172 per 1000
(123 to 240)
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: conf idence interval; RCT : randomised controlled trial; RR: risk rat io; SD: standard deviat ion.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded due to study lim itat ions, primarily driven by high risk of select ion bias in Holt 2010 and high risk of report ing
bias in Bucher 2010 and Jorgensen 2014.
bDowngraded due to imprecision; trials reported being underpowered for CVD events.
cDowngraded due to study lim itat ions, primarily in the domains of attrit ion bias (m issing data for follow-up risk factor levels)
and other sources of bias (poor intervent ion f idelity, potent ial conf licts of interest).
dDowngraded due to heterogeneity in pooled est imates.
eDowngraded due to study lim itat ions, primarily in the domains of attrit ion bias (m issing data for medicat ion prescribing in
follow-up) and other sources of bias (poor intervent ion f idelity, potent ial conf licts of interest).
f Downgraded due to imprecision, because conf idence interval includes 1 and sample size does not meet threshold for opt imal
information size.
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B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD), which includes ischaemic heart
disease and stroke, is the leading cause of mortality and disabil-
ity worldwide (Murray 2012; Naghavi 2015). According to the
Global Burden of Disease study, ischaemic heart disease and stroke
accounted for 12.9 million deaths worldwide in 2013, or one in
every four of the total (Naghavi 2015). CVD is also costly, and the
World Economic Forum estimates that the direct cost attributable
to CVD is USD 863 billion worldwide, with a projected rise of
22% by 2030 (Bloom 2011).
The incidence of CVD is largely explained by several modifiable
risk factors, which include abnormal cholesterol, elevated blood
pressure, diabetes mellitus, smoking, unhealthy diet, excessive al-
cohol intake, abdominal obesity, psychosocial stress, and lack of
physical activity. These nine modifiable risk factors increase the
risk of future CVD events and contribute to an estimated 90% of
the population attributable risk fraction of ischaemic heart disease
and stroke worldwide (O’Donnell 2010; Yusuf 2004). Prevention,
treatment, and control of these risk factors before clinical mani-
festation are therefore primary targets of interventions to reduce
the burden of CVD.
Description of the intervention
CVD events are often determined by the confluence of multiple,
co-existing risk factors (Smith 2004). The multifactorial nature of
CVD has led to the development and application of multivariable
risk assessment tools, or CVD risk scores, to calculate CVD risk.
CVD risk scores allow clinicians to integrate information from
multiple CVD risk factors and quantitatively estimate a person’s
absolute risk for, or likelihood of experiencing, a CVD event dur-
ing a defined period of time.
The first widely used multivariable CVD risk score was derived
from the Framingham Heart Study in the USA (Anderson 1991;
Wilson 1998). The Framingham risk score incorporated the ef-
fects of age, sex, systolic blood pressure, total cholesterol, high-
density lipoprotein (HDL) cholesterol, smoking status, antihy-
pertensive treatment status, and diabetes mellitus to estimate 10-
year risk of coronary heart disease. During the past two decades,
there has been widespread development of additional CVD risk
scores such as the European Systematic COronary Risk Evalua-
tion (SCORE) algorithm (Conroy 2003); the German Prospec-
tive CardiovascularMunster (PROCAM)model (Assmann 2002);
the UK QRISK and QRISK2 equations (Hippisley-Cox 2007;
Hippisley-Cox 2008); the World Health Organization (WHO)
risk chart (WHO 2007); the American College of Cardiology
(ACC)/American Heart Association (AHA) 2013 Pooled Cohort
risk equations (Goff 2014); and the Globorisk cardiovascular risk
equation for use globally, including in low- and middle-income
countries (Hajifathalian 2015). CVD prevention guidelines rec-
ommend use of these risk scores to guide treatment decisions for
primary prevention in people who do not yet have clinical man-
ifestations of CVD (Anderson 2013; NCEP 2002; NICE 2014;
Piepoli 2016; Stone 2014; WHO 2007).
How the intervention might work
The current paradigm for CVD risk reduction in primary preven-
tion matches the intensity of prevention efforts to a person’s abso-
lute risk for developing CVD (Bethesda 1996; Smith 2004). Risk-
based prevention, therefore, directs treatments toward people at
increased risk who derive greater benefit from treatment, while
sparing people at lower risk for whom benefits may not outweigh
the costs and harms of treatment. Qualitative assessment of CVD
risk, however, is fraught with error, thereby providing a rationale
for quantitative risk assessment tools (Grover 1995;Meland 1994;
Pignone 2003; Van der Weijden 2008). Prevention guidelines in
the USA, the UK, Europe, Canada, and the developing world
promote the use of multivariable CVD risk scores to guide treat-
ment decisions in primary prevention (Anderson 2013; NCEP
2002; NICE 2014; Piepoli 2016; Stone 2014; WHO 2007). The
2013 ACC/AHACholesterol Guidelines in the USA, described in
Stone 2014, and the National Institute for Health and Care Ex-
cellence (NICE) recommendations for the prevention of CVD in
the UK, laid out in NICE 2014, both advocate risk-based preven-
tion strategies that incorporate multivariable CVD risk scores to
estimate short- and long-term CVD risk, providing a quantitative
framework to guide clinician-patient discussions regarding statins
in primary prevention.
Analyses of randomised clinical trials (RCTs) provide empiric sup-
port for risk stratification by demonstrating that the absolute risk
reduction from preventive medications is relatedmore to themag-
nitude of pretreatment risk than the relative risk reduction associ-
ated with treating a single risk factor (BPLTTC 2014; CTT 2012;
Jackson 2005). Therefore, use of CVD risk scores not only has
the potential to effectively and efficiently direct preventive care to
those in greatest need but may help maximise benefit of treatment
in high-risk people and minimise harms of over-treatment in peo-
ple at low risk. Additional purported benefits of CVD risk scores
also include raising awareness of disease, improving communi-
cation between clinician and patient, and motivating adherence
to recommended lifestyle changes or preventive therapies (Goff
2014).
Why it is important to do this review
Although considerable research has focused on the derivation and
validation of multivariable CVD risk prediction tools in different
populations, the effects of CVD risk scores to direct clinical prac-
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tice is poorly understood, and few studies have examined their
utility in clinical practice (Damen 2016). In 2006 and 2008, two
related systematic reviews performedwith Cochranemethodology
identified only four RCTs testing the clinical effects of CVD risk
scores and found no clear evidence that CVD risk assessment im-
proved health outcomes (Beswick 2008; Brindle 2006). In 2008, a
systematic review examining the clinical benefits or harms of pro-
viding CVD risk scores identified six trials showing that physicians
presented with risk information tended to appropriately prescribe
preventive therapies (Sheridan 2008). Another systematic review
examining the effect of giving CVD risk information to adults
in clinical practice identified 18 studies (14 RCTs) demonstrating
that global CVD risk information improved accuracy of risk per-
ception and increased patients’ intent to start pharmacotherapy
(Sheridan 2010). However, in both reviews the effect of CVD risk
scores on health outcomes, risk factors, and health behaviours was
unclear.
In spite of widespread recommendations for the use of multi-
variable CVD risk scores in clinical practice guidelines (Anderson
2013;NCEP2002;NICE2014; Piepoli 2016; Stone 2014;WHO
2007), uncertainty remains about their effects on health-related
outcomes. Given the publication of new trials and the continued
prominence of multivariable CVD risk scores in primary CVD
prevention guidelines, a systematic review of the literature is war-
ranted.
O B J E C T I V E S
To assess the effects of evaluating and providing CVD risk scores
in adults without prevalent CVD on cardiovascular outcomes,
risk factor levels, preventive medication prescribing, and health
behaviours.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs and quasi-RCTs (systematic allocation) with
individual or cluster allocation. We included studies reported as
full text and abstracts as well as unpublished data.
Types of participants
We included studies that reported results for adults (18 years of
age and older) in outpatient settings free of clinical CVD (de-
fined as prior heart attack, stroke, heart failure, symptomatic pe-
ripheral vascular disease, or atrial fibrillation). Participants with
diabetes mellitus or elevated risk factors as well as those already
on background preventive medications were eligible for inclusion.
For studies that included a combination of participants with and
without prevalent CVD, we included studies that reported results
for primary prevention participants. When studies included both
primary and secondary prevention populations, we included only
those studies with < 30% of the study population having prevalent
CVD.
Types of interventions
We included trials that compared the systematic provision of a
multivariable CVD risk score by a clinician, healthcare profes-
sional, or healthcare system versus usual care (i.e. no systematic
provision of a CVD risk score) in primary CVD prevention. We
excluded health risk appraisals not based on a risk score and studies
testing risk of hypothetical patients.
Types of outcome measures
Primary outcomes
1. CVD events (a composite of fatal and non-fatal myocardial
infarction and stroke)
2. Change in risk factor levels
i) Cholesterol: total cholesterol, low-density lipoprotein
(LDL) cholesterol
ii) Blood pressure: systolic blood pressure, diastolic blood
pressure
iii) Change in multivariable CVD risk: a summary score
or risk estimate that incorporates multiple and simultaneous
changes in different CVD risk factor levels
3. Investigator-defined adverse events, including but not
limited to physical or psychosocial events, including anxiety or
depression
Secondary outcomes
1. Preventive medication prescribing in higher risk people
i) Lipid-lowering medications
ii) Antihypertensive medications
iii) Aspirin
2. Medication adherence
3. Health-related behaviours
i) Smoking cessation
ii) Exercise
iii) Diet
4. Decisional conflict, measured according to the decisional
conflict scale
5. Health-related quality of life, measured according to any
validated scale concerning quality of life
6. Costs
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Search methods for identification of studies
Key inclusion criteria were studies that were relevant to CVD
primary prevention, employed a prospective design, and provided
or incorporated a CVD risk score to guide treatment decisions in
CVD prevention.
Exclusion criteria were studies that were unrelated to CVD risk
scores; those addressing health risk appraisals not based on a quan-
titative risk score; those relying only on self-reported risk factors
and lifestyle; and those involving clinical vignettes or hypothetical
patients rather than real patients.
Electronic searches
We identified trials through systematic searches of the following
bibliographic databases on 15 March 2016.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016 Issue 2) in the Cochrane Library (Wiley).
• Ovid MEDLINE(R) (1946 to March Week 1 2016).
• Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations (14 March 2016).
• Embase, including Embase Classic, via embase.com (1947
to 15 March 2016).
• Conference Proceedings Citation Index-Science (CPCI-S)
via Web of Science (1990 to 15 March 2016).
Two authors (KNK, MAB) designed the database searches based
on the MEDLINE search strategy used in a previous systematic
review published with Cochrane methodology (Beswick 2008).
The search strategies for each database are available in Appendix
1. For the MEDLINE search, we applied the Cochrane sensitivity
and precision maximizing RCT filter (Lefebvre 2011). For Em-
base, we translated from Ovid to embase.com syntax, the multi-
term Embase filter with the best balance of sensitivity and speci-
ficity (Wong 2006), and we limited the search to records indexed
in Embase. For Conference Proceedings Citation Index-Science
we used a combination of terms for identifying trials described in
section 6.3.2.2 of the Cochrane Handbook for Systematic Reviews of
Interventions (Lefebvre 2011). We applied no filters to the CEN-
TRAL search.
We searched all databases from their inception to March 2016,
and we imposed no restriction on language of publication.
Searching other resources
We tried to identify other potentially eligible trials or ancil-
lary publications by searching the reference lists of retrieved in-
cluded studies and relevant review articles for additional references.
We also searched ClinicalTrials.gov (www.ClinicalTrials.gov) and
the WHO International Clinical Trials Registry Platform (IC-
TRP) Search Portal (apps.who.int/trialsearch/) on16March 2016.
Lastly, we contacted study authors of included or registered trials
to identify further studies or unpublished data that could con-
tribute to our review.
Data collection and analysis
Selection of studies
Three authors (KNK and SDP or MDH) independently screened
titles and abstracts of every record retrieved to determine which
studies to assess further, resolving disagreements by consensus. We
then retrieved full-text study reports/publications of all eligible
or potentially eligible reports. Three authors (KNK and SDP or
MDH) independently screened full-text articles, identified studies
for inclusion, and recorded reasons for exclusion of the ineligible
studies. We resolved any disagreements through discussion or, if
required, recourse to the third author (SDP or MDH). We identi-
fied and excluded duplicate reports and collated multiple reports
of the same study so that each study, rather than each report, was
the unit of analysis. We recorded the selection process in sufficient
detail to complete a PRISMA flow diagram and Characteristics of
excluded studies table.
Data extraction and management
For studies that fulfilled the inclusion criteria, we used standardised
data extraction forms to record study characteristics and outcome
data. We extracted the following study characteristics.
1. Methods: study design, total duration of study, details of
any run-in period, number of study centres and location, study
country and setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, sex, severity of
condition, diagnostic criteria, baseline CVD risk, smoking
history, inclusion criteria, and exclusion criteria.
3. Interventions: CVD risk score used, comparator group.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Three authors (KNK and SDP orMDH) independently extracted
outcome data from included studies in duplicate. We resolved
disagreements by consensus or by involving the third author. One
author (KNK) transferred data into Review Manager 5 (RevMan
2014), and another author (SDP) spot-checked to ensure that
study characteristics and study data were entered correctly.
Assessment of risk of bias in included studies
Three authors (KNK and SDP or MDH) independently assessed
risk of bias for each study using the criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved disagreements by consensus or by involving the third
author. We assessed risk of bias according to the following do-
mains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
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4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias (e.g. industry funding).
We judged risk of bias criteria as low risk, unclear risk, or high risk
and evaluated individual bias items as described in Higgins 2011.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome. For clus-
ter-RCTs, we followed Cochrane recommendations for assessing
risk of bias, with particular attention across the domains of recruit-
ment, baseline imbalances, loss of cluster, incorrect analyses, and
comparability with individually RCTs (Higgins 2011). Two of the
review authors (SDP and DLJ) performed two studies included in
this review (Persell 2013; Persell 2015). For these two studies, data
extraction and risk of bias assessment were performed by review
authors who were not involved with the conduct of either study
(KNK and MDH).
Assessment of bias in conducting the systematic
review
We conducted the review according to a published protocol and re-
ported any deviations from it in the Differences between protocol
and review section.
Measures of treatment effect
We analysed dichotomous data as risk ratios (RRs) with 95% con-
fidence intervals (CIs). We used inverse variance methods to facil-
itate meta-analysis of outcomes from individual RCTs and appro-
priately analysed cluster-RCTs (Chapter 16.3.3 of Higgins 2011).
We used RevMan 2014 to convert the reported effect estimates
to a common risk ratio format. We analysed continuous data as
mean difference (MD) or standardised mean difference (SMD)
with 95% CIs. We entered data presented as a scale with a consis-
tent direction of effect. For meta-analyses of mean differences, we
pooled results of studies that reported final values with those re-
porting changes from baseline (Chapter 9.4.5.2 of Higgins 2011).
For meta-analyses of SMDs, we pooled results of studies that re-
ported change from baseline (change scores).
Unit of analysis issues
We includedRCTswith parallel design and cluster-RCTs. For clus-
ter-RCTs, we recorded whether investigators accounted for clus-
tering in their analyses (e.g. multilevel model, generalised estimat-
ing equations). If analyses adjusted for clustering, then we meta-
analysed individual RCTs with cluster-RCTs. For continuous out-
comes, we used the inverse-variance method to calculate MDs
and SMDs. For dichotomous outcomes, we used the generic in-
verse-variancemethod tometa-analyse the reported effect estimate
(and corresponding standard error or confidence interval) from
the appropriately-analysed cluster-RCT and the reported or cal-
culated effect estimate from the individual RCT (Chapter 16.3.3
of Higgins 2011).
Dealing with missing data
We contacted investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data where
possible (e.g. when a study is identified as abstract only).We inves-
tigated attrition rates, losses to follow-up, withdrawals, and criti-
cally appraised methods for handling missing data and imputation
methods. If standard deviations for outcomes were not available,
we imputed these values from data within the trial using methods
outlined in Chapter 16.1.3 of Higgins 2011 and through RevMan
2014
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials
in each analysis. If we identified substantial (I² > 50%) hetero-
geneity, we reported it and explored possible causes by subgroup
analyses.
Assessment of reporting biases
We created and examined a funnel plot to explore possible publi-
cation and small study bias for the primary outcomes.
Data synthesis
We undertook meta-analyses only if the treatments, participants,
and the underlying clinical questions in the studies were similar
enough for pooling to be appropriate. If there was no or moderate
heterogeneity (I² < 50%), we performed fixed-effect model meta-
analyses. If there was substantial heterogeneity (I² > 50%), we
performed a random-effects model meta-analyses with cautious
interpretation.
Subgroup analysis and investigation of heterogeneity
We had planned on performing the following pre-specified sub-
group analyses on our primary outcomes.
1. Sex (patient).
2. RCTs versus quasi-RCTs.
3. Trials providing CVD risk scores to clinicians versus trials
providing CVD risk scores to patients.
4. Trials that incorporated a multivariable CVD risk score
within a clinical decision support tool (either clinician-facing or
patient-facing).
Among these prespecified subgroups, wewere only able to perform
a subgroup analysis among trials that used or did not use a clinical
decision support tool. We did not have sufficient data from each
trial to perform subgroup analysis by sex. We identified only one
quasi-RCT. Lastly, many studies and protocols were unclear as to
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whether CVD risk scores were exclusively directed to a clinician
or patient. Frequently, such risk scores were provided to both clin-
icians and patients during a clinical encounter.
Based on the substantial heterogeneity identified in our meta-
analysis, we also performed two post hoc subgroup analyses on:
1. Trials that utilised health information technology (IT) for
risk assessment or risk communication.
2. Trials that exclusively enrolled participants with higher risk
(defined as 10-year CVD risk ≥ 10% or a high-risk condition
such as diabetes mellitus).
We used the formal test for subgroup interactions in RevMan
2014.
Sensitivity analysis
We had planned to carry out sensitivity analyses excluding studies
assessed as being at unclear or high risk of bias in any domain.
However, we assessed nearly all studies as being at unclear or high
risk of bias, so this sensitivity analysis was not performed.
Summary of findings table
We assessed the quality of the evidence for each outcome according
to the GRADE approach and presented results in a ’Summary of
findings’ table (Guyatt 2008). We rated the quality of evidence
as: high, moderate, low, or very low after consideration of within-
study risk of bias (methodological quality), directness of evidence,
heterogeneity, precision of effect estimates, and risk of publication
bias.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
We identified 8723 records through database searching and an
additional 13 records from prior systematic reviews of this topic
(Brindle 2006; Beswick 2008; Sheridan 2008; Sheridan 2010;
Willis 2012; Usher-Smith 2015). The article selection process is
depicted in the PRISMA flowchart in Figure 1. After removing
duplicates, we screened 6422 records and excluded 6238 based on
title and abstract. We removed an additional 5 duplicate records
and assessed 179 full-text records and 4 trial registry records for
eligibility.We excluded 94 records of 77 studies and 2 trial registry
records with reasons, identified 11 records of 10 ongoing studies,
and listed 3 studies as awaiting classification. In total, we included
73 records of 41 studies (N = 194,035) in this systematic review.
11Risk scoring for the primary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
Study design and location
Details of the methods, participants, intervention, comparison
group, and outcome measures for each of the studies in this review
are shown in the Characteristics of included studies table. We
identified 23 individual-level RCTs (N = 117,040), 17 cluster-
RCTs (N = 76,672), and 1 quasi-RCT (N = 323). The earliest
trial was reported in 1994 (British Family Heart 1994), and the
most recent was reported in 2016 (Perestelo-Perez 2016). Fifteen
trials took place in European countries outside the UK (Benner
2008; Bucher 2010; Christensen 2004; Cobos 2005; Denig 2014;
Engberg 2002; Hanon 2000; Hetlevik 1999; Jorgensen 2014;
Koelewijn-van Loon 2010; Krones 2008; Lopez-Gonzalez 2015;
Perestelo-Perez 2016; Van Steenkiste 2007; Welschen 2012); 12
trials in the USA (Bertoni 2009; Eaton 2011; Edelman 2006;
Jacobson 2006; Mann 2010; Persell 2013; Persell 2015; Sheridan
2006; Sheridan 2011; Turner 2012;Williams 2006; Zullig 2014);
7 trials in the UK (British Family Heart 1994; Hall 2003; Hanlon
1995; Holt 2010; Montgomery 2000; Montgomery 2003; Price
2011); 3 trials in Canada (Grover 2007; Lowensteyn 1998;Wister
2007); 3 trials in Australia orNewZealand (Peiris 2015; Vagholkar
2014;Webster 2010); and1 Internet-based trial that did not report
a specific country (Soureti 2011). All studies were conducted in the
outpatient setting. Participant follow-up ranged from no follow-
up in Hall 2003, Jacobson 2006, and Sheridan 2006 to 10 years
of extended follow-up in Jorgensen 2014. In total, 21 out of 41
trials reported a follow-up of one year or more.
Participants
Mean age reported in the trials ranged from 40 years in Engberg
2002 to 71 years in Montgomery 2000, and the proportion of
female participants ranged from 8% in Hanlon 1995 to 80% in
Edelman 2006. In the 20 trials that reported participants’ eth-
nicity, most (16 out of 20) included a majority of white or Eu-
ropean participants; the remaining 4 trials included a majority
of African American participants (Jacobson 2006; Mann 2010;
Persell 2015; Turner 2012). Participants in the included trials had
varying past medical histories. Ten trials included only partici-
pants with higher CVD risk (defined as diabetes mellitus or 10-
year CVD risk≥ 10%) (Benner 2008; Denig 2014; Grover 2007;
Hall 2003;Mann 2010; Perestelo-Perez 2016; Persell 2013; Persell
2015; Price 2011; Welschen 2012), and 5 of these trials included
only participants with diabetesmellitus (Denig 2014;Mann 2010;
Perestelo-Perez 2016; Price 2011; Welschen 2012). The other 31
trials included participants with all risk levels. There were 13 tri-
als that included participants with prevalent CVD, but based on
our selection criteria we included only those trials where these
participants made up < 30% of the total sample (Bertoni 2009;
British Family Heart 1994; Cobos 2005; Eaton 2011; Grover
2007; Holt 2010; Krones 2008; Montgomery 2000; Peiris 2015;
Perestelo-Perez 2016; Turner 2012; Webster 2010; Zullig 2014).
One trial included participants with human immunodeficiency
virus (HIV)whowere part of the SwissHIVCohort Study (Bucher
2010).
Interventions and comparison groups
Interventions varied across trials, which featured different CVD
risk scores, risk presentations, and co-interventions (Figure 2). The
two most common CVD risk scores used were the Framingham
CoronaryHeartDiseaseRisk Score (24 trials) and theUKProspec-
tive Diabetes Study (UKPDS) risk engine (6 trials). In these trials,
baselineCVDriskwas presented as a 5- or 10-year absolute risk of a
CVD event. Six trials used risk-adjusted cardiovascular age (called
by various names such as heart age, cardiovascular age, or vascular
age) in addition to or in lieu of the absolute CVD risk information
(Eaton 2011; Grover 2007; Lopez-Gonzalez 2015; Lowensteyn
1998; Peiris 2015; Soureti 2011). In addition to the risk mes-
sage, interventions also included: patient education material (31
trials); clinician- or patient-facing decision-support tools (27 tri-
als); nurse counselling (11 trials); academic detailing/continuing
medical education (9 trials); electronic health record integration
(10 trials); electronic or paper-based reminders (7 trials); and au-
dit and feedback (4 trials). A few trials implemented only one
of these components (Hall 2003; Hanon 2000; Lopez-Gonzalez
2015;Welschen2012), while on the opposite side of the spectrum,
there were five or more of these components (Bertoni 2009; Denig
2014; ; Koelewijn-van Loon 2010; Peiris 2015; Sheridan 2011;
Turner 2012; Vagholkar 2014; Wister 2007). In total, among the
41 studies, 28 studies incorporated health IT for some aspect of
the risk score intervention. The range of co-interventions is sum-
marised in Figure 2.
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Figure 2. Summary of CVD risk score interventions by included study.Abbreviations: CHD: coronary heart
disease; CVD: cardiovascular disease; FRS: Framingham risk score; MI: myocardial infarction; RF: risk factors,
RR: risk ratio; UKPDS: United Kingdom Prospective Diabetes Study
Comparison groups were generally characterised as ’usual care’
by study authors and did not include the systematic provision
of CVD risk scores. Some studies described the addition of: pas-
sive guideline dissemination (Bucher 2010; Mann 2010; Van
Steenkiste 2007), provision of risk factor levels alone (Edelman
2006; Jacobson 2006; Sheridan 2006), continuing medical edu-
cation for an unrelated topic (Bertoni 2009; Krones 2008), and
general health and risk factor information (Cobos 2005; Soureti
2011; Turner 2012; Webster 2010; Welschen 2012; Zullig 2014).
Comparison group descriptions are summarised in Figure 2.
Outcomes
Among the included trials, the most common primary outcome
in 10 trials addressed a clinical care process measure such as
risk factor screening, preventive treatment discussions, guide-
line adherence, or achievement of risk factor targets (Bertoni
2009; Cobos 2005; Eaton 2011; Grover 2007; Jacobson 2006;
Lowensteyn 1998; Montgomery 2000; Peiris 2015; Persell 2015;
Sheridan 2006). Other primary outcomes reported in the in-
cluded studies were multivariable CVD risk in eight trials (Benner
2008; British Family Heart 1994; Edelman 2006; Hanlon 1995;
Krones 2008; Turner 2012; Wister 2007; Zullig 2014), pa-
tient-reported outcomes in seven trials (Christensen 2004; Denig
2014; Koelewijn-van Loon 2010; Mann 2010; Montgomery
2003; Perestelo-Perez 2016; Welschen 2012), CVD risk factor
levels in six trials (Bucher 2010; Grover 2007; Hanon 2000;
Lopez-Gonzalez 2015; Persell 2013; Persell 2015), medication
prescribing rates in four trials (Hall 2003; Vagholkar 2014; Van
Steenkiste 2007; Webster 2010), and health behaviours in three
trials (Price 2011; Soureti 2011; Williams 2006). Only two trials
reported CVD events as a primary outcome, but both reported be-
ing underpowered for this endpoint after completion of the study
(Holt 2010; Jorgensen 2014).
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Study funding sources
We present detailed information on study funding sources in the
Characteristics of included studies table. Five trials reported re-
ceiving study funding exclusively from pharmaceutical compa-
nies (Benner 2008; Cobos 2005; Grover 2007; Lowensteyn 1998;
Soureti 2011). There were 19 trials that reported funding from
public and/or federal government sources (Bertoni 2009; Denig
2014; Edelman 2006; Hanlon 1995; Hetlevik 1999; Koelewijn-
van Loon 2010; Krones 2008; Montgomery 2000; Montgomery
2003; Peiris 2015; Perestelo-Perez 2016; Persell 2013; Persell 2015;
Sheridan 2011; Vagholkar 2014; Van Steenkiste 2007; Welschen
2012; Williams 2006; Wister 2007), 7 trials that reported study
funding from a combination of public and private sources (British
Family Heart 1994; Bucher 2010; Christensen 2004; Engberg
2002; Jorgensen 2014; Turner 2012; Webster 2010), and 3 trials
with study funding from internal (usually hospital) sources (Holt
2010; Jacobson 2006; Sheridan 2006). Five trials did not report
sources of study funding (Eaton 2011; Hall 2003; Hanon 2000;
Lopez-Gonzalez 2015; Mann 2010).
Excluded studies
We excluded 94 records of 77 studies after full-text review and
2 trial registry records. The most common reason for exclusion
was that a risk score was not part of the intervention (41 trials).
We excluded other studies because they provided CVD risk scores
in all treatment groups without a usual care comparator group
(16 trials), were not an RCT or quasi-RCT (10 trials), did not
study a primary prevention population (11 trials), or used clinical
vignettes and hypothetical patients (1 trial).
A complete list of excluded studies, along with the reason for
exclusion of each study, is presented in the Characteristics of
excluded studies table.
Studies awaiting classification
We identified three studies awaiting classification (Adamson 2013;
Gryn 2012; Roach 2012). Two of these studies included partici-
pants with diabetes mellitus (Adamson 2013; Roach 2012), and
one included participants with hypertension (Gryn 2012). All
three studies reported having an intervention group that received
a personalised CVD risk estimate, but the identified records were
abstracts and did not provide sufficient details to determine eli-
gibility for this systematic review. Authors of two of these studies
reported preparing manuscripts (Gryn 2012; Roach 2012). We
present additional details of these studies in the Characteristics of
studies awaiting classification table.
Ongoing studies
We identified 11 reports of 10 ongoing studies. Three of these
studies are taking place in Europe (Badenbroek 2014; Ijkema
2014; Maindal 2014), one in the USA (Sanghavi 2015), one in
Canada (NCT00694239), one in the UK (Silarova 2015), one in
Australia (Redfern 2014), and three in low- and middle-income
countries (NCT02096887; Ogedegbe 2014; Praveen 2013). Two
studies will supplement CVD risk scores with novel sources of
CVD risk information: Ijkema 2014 with coronary artery calcium
scores and Silarova 2015 with genetic risk information. Three
ongoing studies will test innovative implementation models to
provide CVD risk scores. These include: direct-to-patient health
portals within an electronic health record (Redfern 2014), non-
physician healthcare workers in resource-poor settings (Praveen
2013), and financial incentives linked to CVD risk assessment and
absolute risk reduction (Sanghavi 2015). The Characteristics of
ongoing studies table presents details of these studies.
Risk of bias in included studies
Overall and trial-specific assessment of risk of bias are shown in
Figure 3 and Figure 4. In general, there was high risk of bias across
the included studies. Due to the nature of the intervention, few
trials were able to blind participants, study personnel, or both.
Thus, in our overall risk of bias assessment, we put greater weight
on blinding of outcome assessment (detection bias) compared to
blinding of participants or study personnel (performance bias).
We concluded that only three trials had an overall low risk of bias
across most domains (Peiris 2015; Persell 2013; Persell 2015). We
summarise risk of bias assessment across each domain below, but
detailed documentation supporting risk of bias assessment for each
trial is included in the Characteristics of included studies table.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 4. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
There were 19 trials that adequately reported the methods used
for random sequence generation, and we assessed them as be-
ing at low risk of bias (Benner 2008; Bucher 2010; Cobos
2005; Denig 2014; Hanlon 1995; Jorgensen 2014; Koelewijn-van
Loon 2010; Montgomery 2000; Montgomery 2003; Peiris 2015;
Perestelo-Perez 2016; Persell 2013; Persell 2015; Price 2011;
Vagholkar 2014; Van Steenkiste 2007; Webster 2010; Welschen
2012; Wister 2007). We assessed 19 trials as being at unclear risk
of bias and 3 trials as having an inadequate method of random
sequence generation.
Sixteen trials reported adequate allocation concealment (Bucher
2010; Denig 2014; Engberg 2002; Grover 2007; Koelewijn-van
Loon 2010; Montgomery 2000; Montgomery 2003; Peiris 2015;
Persell 2013; Persell 2015; Price 2011; Sheridan 2006; Vagholkar
2014; Webster 2010; Welschen 2012; Williams 2006). Among
the remaining trials, there were 18 at unclear risk of bias and 7
trials at high risk of bias for allocation concealment.
In total, 12 trials were assessed as being at low risk of selection
bias, that is, for both random sequence generation and allocation
concealment (Bucher 2010; Denig 2014; Koelewijn-van Loon
2010;Montgomery 2000;Montgomery 2003; Peiris 2015; Persell
2013; Persell 2015; Price 2011; Vagholkar 2014; Webster 2010;
Welschen 2012).
Blinding
Due to the nature of the intervention,we assessed 38out of 41 trials
as being at high risk of bias due to an unblinded study design. The
trials with low or unclear risk of bias were Internet-based studies
where research personnel had no direct contact with participants
(Soureti 2011; Webster 2010). Therefore, we used blinding of
outcome assessors to determine overall risk of bias. Among the 41
trials, 12 trials reported adequate blinding of outcome assessors
(Bertoni 2009; Eaton 2011; Edelman 2006;Holt 2010; Jorgensen
2014; Peiris 2015; Persell 2013; Persell 2015; Price 2011; Turner
2012; Vagholkar 2014; Wister 2007). The remaining 18 trials
were at unclear risk of bias, and 11 trials were at high risk of bias
due to unblinded outcome assessors.
Incomplete outcome data
Many studies suffered from high losses to follow-up and miss-
ing data, particularly data used for calculating follow-up choles-
terol levels or risk scores. Moreover, few studies performed inten-
tion-to-treat analyses. Only 13 trials adequately addressed incom-
plete data (Bucher 2010; Eaton 2011; Grover 2007; Hall 2003;
Hanlon 1995;Holt 2010; Jorgensen 2014; Lopez-Gonzalez 2015;
Montgomery 2003; Peiris 2015; Sheridan 2011; Webster 2010;
Wister 2007). We assessed 8 trials as being at unclear risk of bias
and 20 trials as being at high risk of bias due to incomplete out-
come data.
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Selective reporting
Several of the included studies either had protocols available for
review or were prospectively registered. The risk of bias associated
with selective reporting was low in 15 trials (Benner 2008; Bertoni
2009; British Family Heart 1994; Denig 2014;Holt 2010; Krones
2008; Peiris 2015; Persell 2013; Persell 2015; Price 2011; Sheridan
2006; Sheridan 2011; Webster 2010; Welschen 2012; Williams
2006), unclear in 18 trials, and high in 8 trials.
Other potential sources of bias
Other potential sources of bias are reviewed in detail in the
Characteristics of included studies table. Common sources of po-
tential bias included: pharmaceutical funding or potential finan-
cial conflicts of interest among study authors (Benner 2008; Cobos
2005; Engberg 2002; Grover 2007; Holt 2010; Lowensteyn 1998;
Soureti 2011; Williams 2006); contamination bias (Denig 2014;
Grover 2007;Hanlon 1995;Holt 2010; Jacobson 2006; Jorgensen
2014; Persell 2015; Sheridan 2006; Sheridan 2011; Welschen
2012;Wister 2007); and poor fidelity to the intervention protocol
(Bertoni 2009; British Family Heart 1994; Denig 2014; Eaton
2011; Mann 2010).
Effects of interventions
See: Summary of findings for the main comparison CVD risk
scoring for the primary prevention of cardiovascular disease
See: Summary of findings for the main outcomes (Summary of
findings for the main comparison).
Primary outcomes
Cardiovascular disease events
We identified only three RCTs (N = 99,070) that reported the ef-
fects of providing CVD risk scores on CVD events (Bucher 2010;
Holt 2010; Jorgensen 2014). Among participants in the CVD risk
score group, there was low-quality evidence suggesting little or
no effect on CVD events compared with usual care (5.4% versus
5.3%; RR 1.01, 95% CI 0.95 to 1.08; I² = 25%; Analysis 1.1).
Notably, study authors from two of these trials reported being un-
derpowered for this endpoint because of limited recruitment of
participants over the age of 50 and low CVD event rates (Holt
2010; Jorgensen 2014). The third trial was in a cohort of people
with HIV in Switzerland (Bucher 2010). Due to the unique char-
acteristics and limited generalisability of this cohort, we reanalysed
data excluding this study; results were unchanged in direction and
magnitude (Analysis 1.2).
Cholesterol level
Effects of providing CVD risk scores on cholesterol levels were
reported for total cholesterol and LDL cholesterol. We identified
12 RCTs (N = 20,437) that reported the effects of providing CVD
risk scores on total cholesterol and were included in the meta-
analysis. There was low-quality evidence suggesting that provid-
ing CVD risk scores may slightly reduce total cholesterol levels
compared with usual care (MD −0.10 mmol/L, 95% CI −0.20
to 0.00; I² = 94%; Analysis 1.3). We also identified 10 RCTs (N =
22,122) that reported on the effects of providing CVD risk scores
on LDL cholesterol levels. There was uncertainty about the ef-
fect of providing CVD risk scores compared with usual care on
LDL cholesterol levels (MD −0.03 mmol/L, 95% CI −0.10 to
0.04; I² = 84%; low-quality evidence; Analysis 1.4); the results
were imprecise but similar in direction and magnitude to those
for total cholesterol. There was substantial heterogeneity for both
outcomes that was not explained by a single trial, so these effect
estimates should be interpreted with caution. There was no evi-
dence of publication bias by funnel plot for total cholesterol level
(Figure 5). Many of the trials identified in this review reported
on achievement of guideline-recommended cholesterol goals af-
ter provision of a CVD risk score. However, this outcome was
deemed to be unsuitable for meta-analysis due to the marked vari-
ation in cholesterol goals from different countries, guidelines, and
time periods. One pragmatic clinical trial (N = 435) did not use
systematic follow-up procedures after providing CVD risk scores
but reported that participants in the CVD risk score group had
a greater proportion of repeat LDL cholesterol levels > 30 mg/dL
lower than baseline compared with those in the usual care group
(22.5% vs. 16.1%, OR 1.59, 95% CI 1.05 to 2.41, P = 0.029;
Persell 2013).
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Figure 5. Funnel plot of comparison: 1 CVD risk score versus no CVD risk score/usual care, outcome: 1.3
Total cholesterol (mmol/L).
Blood pressure level
Trials reported the effects of providing CVD risk scores on blood
pressure levels for systolic blood pressure, diastolic blood pressure,
or both. We identified low-quality evidence suggesting that pro-
viding CVD risk scores may slightly reduce systolic blood pressure
compared with usual care (MD−2.77 mmHg, 95% CI−4.16 to
−1.38; I² = 93%; 16 trials, N = 32,954; Analysis 1.5). Similarly,
we found low-quality evidence suggesting that providing CVD
risk scores may slightly reduce diastolic blood pressure compared
with usual care (MD−1.12 mmHg, 95% CI−2.11 to−0.13; I²
= 94%; 14 trials, N = 22,378; Analysis 1.6). There was substan-
tial heterogeneity for both outcomes that was not explained by a
single trial, so readers should interpret these estimates with cau-
tion. There was no evidence of publication bias by funnel plot for
systolic blood pressure (Figure 6). Of note, there were two RCTs
that reported the effects of providing CVD risk scores on systolic
and diastolic blood pressures, but we did not pool them because of
insufficient data (Bucher 2010; Hanon 2000). Neither trial found
a difference in blood pressure level between the CVD risk score
versus usual care groups.
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Figure 6. Funnel plot of comparison: 1 CVD risk score versus no CVD risk score/usual care, outcome: 1.5
Systolic blood pressure (mmHg).
Multivariable CVD risk
In total, 17RCTs (N=29,119) reported on the effects of providing
CVD risk scores on multivariable CVD risk (a summary measure
that incorporated changes in multiple different CVD risk factor
levels simultaneously). The scale of this measure varied among
studies. Moreover, some studies compared final values between the
two treatment groups while others compared change from base-
line values. We elected to calculate standardised mean differences
(SMDs) for change from baseline values for the CVD risk score
group and the usual care comparator for our main outcomes. We
identified low-quality evidence suggesting that providing CVD
risk scores may slightly reduce multivariable CVD risk compared
with usual care (SMD−0.21, 95%CI−0.39 to−0.02; I² = 94%;
9 trials, N = 9549; Analysis 1.7). There was substantial hetero-
geneity that was not explained by a single trial, so readers should
interpret these estimates with caution. There was no evidence of
publication bias by funnel plot (Figure 7). We also meta-analysed
studies that compared final values for multivariable CVD risk es-
timates between the intervention and comparison groups and ob-
served similar findings (SMD −0.15, 95% CI −0.25 to −0.06;
Analysis 5.1).
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Figure 7. Funnel plot of comparison: 1 CVD risk score versus no CVD risk score/usual care, outcome: 1.7
Change in multivariable CVD risk.
Five trials reported the effects of the intervention on multivariable
CVD risk, but we did not pool these in the meta-analyses because
of how they reported data (British Family Heart 1994, Bucher
2010; Hetlevik 1999; Price 2011; Zullig 2014). One of these trials
demonstrated a reduction in multivariable CVD risk with the
provision of a CVD risk score (British Family Heart 1994). This
cluster-RCT randomised 12,472 men and women in 13 towns
in Britain to a nurse-led screening and counselling programme
based on Dundee score (a measure of coronary heart disease risk)
or usual care. After one year, the intervention reduced the Dundee
risk score by 16.1% (95%CI 10.9% to 21.1%) inmen and 15.7%
(95% CI 7.4% to 23.3%) in women compared with usual care.
The other four studies (N = 6626), however, did not find that
provision of a CVD risk score changed multivariable CVD risk
(Bucher 2010; Hetlevik 1999; Price 2011; Zullig 2014).
Adverse events
There were four RCTs (N = 4630) that reported on adverse events
after providing aCVDrisk score (Benner 2008;Grover 2007; Price
2011; Turner 2012). Definition of adverse events varied between
studies and included back pain, headache, cough, upper respira-
tory infection, musculoskeletal pain, and anxiety. There was low-
quality evidence suggesting that providing a CVD risk score may
reduce adverse events compared with usual care, but the results
were imprecise (1.9%versus 2.7%; RR0.72, 95%CI 0.49 to 1.04;
I² = 0%; Analysis 1.8). There were three RCTs (N = 968) that
specifically reported on the effect of the CVD risk scores on anx-
iety (Montgomery 2000; Van Steenkiste 2007; Welschen 2012).
Two measured anxiety as a continuous variable and observed that
providing CVD risk scores may have little to no effect on anxi-
ety compared with usual care (SMD −0.07, 95% CI −0.27 to
0.13; I² = 0%; 2 studies, N = 388; low-quality evidence; Analysis
1.9). We did not include Van Steenkiste 2007 in meta-analysis
due to insufficient reporting of data but observed no difference in
the proportion of anxious participants who received a CVD score
versus usual care (16% vs 16%, P value not provided). Lastly, one
trial measured psychological distress in middle-aged participants
who received a CVD risk assessment (with or without primary
care physician follow-up) compared with usual care (Christensen
2004). This trial found no difference in psychological distress at
one andfive years betweenparticipants in the two treatment groups
that received a CVD risk assessment compared with those in the
usual care group (P = 0.466 at one year and P = 0.579 at five years).
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Secondary outcomes
Medication prescriptions in higher risk individuals
New or intensified lipid-lowering medications
We identified low-quality evidence suggesting that providing
CVD risk scores may increase prescriptions for new or intensified
lipid-lowering medications in higher risk people compared with
usual care (15.7% versus 10.7%; RR 1.47, 95% CI 1.15 to 1.87;
I² = 40%; 11 trials, N = 14,175; Analysis 1.10). There was sub-
stantial heterogeneity among studies that was not explained by a
single trial, so readers should interpret these estimates with cau-
tion.
Four additional studies reported the effects of providing a CVD
risk score on lipid-lowering medication prescribing compared
with usual care, but we did not include them in the meta-anal-
ysis because they did not report sufficient data to determine
which higher-risk participants received a lipid-lowering medica-
tion (Bertoni 2009; Cobos 2005; Krones 2008; Webster 2010).
None of these studies reported a change in lipid-lowering med-
ication prescribing. In Bertoni 2009, use of a CVD risk score-
based decision support tool increased “guideline-concordant lipid-
lowering therapy” compared with passive dissemination of an un-
related guideline (9.7%, 95% CI 2.8% to 16.6%), but this was
primarily driven by a reduction in inappropriate prescribing in
lower risk individuals. Authors reported no difference in appropri-
ate lipid-loweringmedication prescribing rates (P = 0.37) (Bertoni
2009). Similarly, in Cobos 2005, a computerised decision-support
tool that provided a personalised CVD risk score decreased inap-
propriate statin prescribing (primarily in lower risk individuals)
but did not increase guideline-recommended statin prescribing
compared with usual care. In Krones 2008, the authors reported
no difference in the proportion of participants with CVD risk
>15% who were treated with preventive medications between the
CVD risk score group and the usual care comparator but formal
statistical testing was not presented. Lastly, inWebster 2010, there
was no difference in new or increased lipid-lowering medication
prescribing in a group of Australian adults randomised to a web-
based decision support tool (percent difference −1.6%, 95% CI
−3.57 to 0.57, P = 0.15), but insufficient data were available to
determine risk status of participants who received therapy.
New or intensified antihypertensive medications
We identified low-quality evidence that providingCVDrisk scores
may increase new or intensified antihypertensive medications
compared with usual care (17.2% versus 11.4%; RR 1.51, 95%
CI 1.08 to 2.11, I² = 53%; 8 studies, N = 13,255; Analysis 1.11).
There was substantial heterogeneity among studies that was not
explained by a single trial, so readers should interpret these esti-
mates with caution. We did not pool three studies reporting the
effects of providing CVD risk scores on antihypertensive medi-
cation prescribing in the meta-analysis because they did not pro-
vide sufficient information to determine which high-risk partici-
pants were prescribed antihypertensivemedications.None of these
studies reported a difference in antihypertensive medication pre-
scribing between the two groups (Jacobson 2006; Krones 2008;
Montgomery 2003).
New aspirin prescriptions
Providing CVD risk scores may increase new aspirin prescribing
compared with usual care (RR 2.71, 95% CI 1.24 to 5.91, I² =
0%; 3 studies, N = 1614; Analysis 1.12). We did not pool three
additional studies reporting the effect of providingCVDrisk scores
on aspirin prescribing in the meta-analysis because it was unclear
which participants were at higher risk (Jacobson 2006; Krones
2008), and the trials did not provide data on primary prevention
(Peiris 2015). Two of these studies reported no difference in aspirin
prescribing in the overall study population (Jacobson 2006;Krones
2008). The other study reported an increase in aspirin prescribing
among participants with prevalent CVD (17.8% vs 2.7%; RR
4.79, 95% CI 2.47 to 9.29), but this did not meet the primary
prevention focus of this review (Peiris 2015).
Medication adherence
There was uncertainty whether providing CVD risk scores had
an effect on medication adherence compared with usual care (RR
1.14, 95% CI 0.92 to 1.41, I² = 58%; 4 studies, N = 621; Analysis
1.13). One additional study (N = 150) reported “no difference” in
medication adherence rates between participants randomised to a
statin decision support tool but did not provide specific estimates
or statistical testing (Mann 2010).
Health behaviours
Smoking
Providing a CVD risk score may increase smoking cessation com-
pared with usual care (RR 1.38, 95% CI 1.13 to 1.69, I² = 0%;
7 studies, N = 5346; Analysis 1.14). There were nine additional
studies that reported on the effects of providing CVD risk scores
on the prevalence of smoking rates, and results were mixed. Five
of these studies reported reductions in smoking prevalence in the
CVD risk score group compared with the usual care group (British
Family Heart 1994; Jorgensen 2014; Koelewijn-van Loon 2010;
Lopez-Gonzalez 2015; Van Steenkiste 2007), whereas four studies
reported no change in smoking prevalence in the CVD risk score
group compared with usual care (Denig 2014; Hetlevik 1999;
Price 2011; Zullig 2014). In the only study to biochemically verify
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smoking status, there was no difference in urine cotinine for par-
ticipants who received a CVD risk score compared with usual care
(SMD −0.53, 95% CI −1.23 to 0.17, P = 0.136; Price 2011).
Exercise
There were eight RCTs (N = 8391) that reported the effects of
providing CVD risk scores on physical activity (Edelman 2006;
Hanlon 1995; Koelewijn-van Loon 2010; Lopez-Gonzalez 2015;
Price 2011; Van Steenkiste 2007; Webster 2010; Wister 2007).
Physical activity outcomes varied by studies and included: self-
reported increase in physical activity, number of days exercising >
30 minutes, and proportion meeting physical activity guidelines.
Two studies (N = 2595) measured self-reported increase in physi-
cal activity, and demonstrated no evidence that providing a CVD
risk score had an effect on this outcome compared with usual care
(RR 0.98, 95% CI 0.90 to 1.06, I² = 0%; Analysis 1.15). The re-
maining 6 RCTs reported mixed results on physical activity. One
RCT of 154 participants reported an increase in the number of
days with physical activity > 30 minutes (3.7 days in intervention
versus 2.4 days in control; P = 0.002; Edelman 2006). Similarly,
Lopez-Gonzalez 2015 reported an increase in self-reported exer-
cise sessions per week in participants receiving a Framingham risk
message compared with usual care: 3.48 sessions (95% CI 3.35 to
3.62) in the Framingham risk message group versus 3.60 sessions
(95% CI 3.47 to 3.73) in the usual care group. In Van Steenkiste
2007, authors reported an increase in within-group physical activ-
ity among participants receiving a CVD risk score compared with
usual care, but there were marked baseline imbalances between
the two treatment groups and follow-up data were missing from
>50% of participants. In contrast, there was no change in physical
activity in the CVD risk score group compared with usual care in
two RCTs involving 930 participants (Koelewijn-van Loon 2010;
Wister 2007). Only one RCT (N = 198) used an objective mea-
sure of physical activity with an accelerometer and showed no dif-
ference in total accelerometer counts between those in the CVD
risk score group and those in the usual care group (SMD 0.086,
95% CI −0.202 to 0.374, P = 0.559; Price 2011).
Diet
There were six RCTs (N = 5375) that reported information on
the effects of providing CVD risk scores on diet (Hanlon 1995;
Koelewijn-van Loon 2010; Price 2011; Soureti 2011; Webster
2010; Wister 2007). Measures of diet were highly variable with
little overlap, so we did not perform quantitative meta-analysis.
Results varied among studies. Two studies reported improvements
in heart-healthy diets after providing a CVD risk score (Hanlon
1995; Wister 2007). In Hanlon 1995, self-reported increase in
fruit and vegetable consumption (24.3% versus 11.6%, P < 0.001)
and self-reported reduction in fat consumption (30.0% versus
9.4%, P < 0.001) was greater in the CVD risk score group com-
pared with usual care (Hanlon 1995). Similarly, in Wister 2007
nutritional level (as measured by a 5-point ordinal scale based on
the number of recommended food groups met per day)was higher
in the CVD risk score group compared with the usual care group
(0.30, 95%CI 0.13 to 0.47 versus−0.05, 95% CI−0.22 to 0.12;
p <0.01; units not provided). In contrast, four studies reported
no difference in healthy dietary patterns between the two groups
(Koelewijn-van Loon 2010; Price 2011; Soureti 2011; Webster
2010).
Decisional conflict
We identified evidence suggesting that providing a CVD risk score
may reduce decisional conflict compared with usual care (SMD
−0.29, 95% CI −0.57 to−0.01, I² = 79%; 4 studies, N = 1261;
Analysis 1.16). The effect estimate had substantial heterogene-
ity that was explained by Montgomery 2003, the study with the
largest magnitude reduction in decisional conflict. The direction
of the effect was similar, but the magnitude was attenuated when
excluding this trial from the analysis (SMD−0.16, 95%CI−0.28
to −0.04, I² = 0%; 3 studies, N = 1049 participants).
Health-related quality of life
One trial (N = 308) reported on the effect of providing CVD risk
scores on health-related quality of life, measured by the Dutch
Euro quality of life (EQ5D-NL) scale. There was no evidence to
suggest that providing CVD risk scores compared with usual care
had an effect on quality of life in this one study (effect size−0.006,
95% CI −0.035 to 0.023, I² = 0%; Denig 2014).
Costs
One trial conducted in Spain reported the effects of providing
CVD risk scores on direct costs (Cobos 2005). Providing a CVD
risk score to a clinician decreased overall lipid-lowering medica-
tion prescribing rates by decreasing prescriptions in low-risk indi-
viduals. The adjusted mean treatment cost per patient was EUR
237 in the usual care group versus EUR 178 in the intervention
group, for a difference of EUR 59 (95% CI 34, 83; P < 0.001), a
savings of 25% in treatment costs. Similarly, the adjusted means
of the total costs per patient were EUR 283 in the usual care group
versus EUR223 in the intervention group, for a difference of EUR
60 (95% CI 33, 86; P = 0.001), a total savings of 21%. A reduc-
tion in lipid-lowering medication prescribing rates among low-
risk participants was also seen in a quality improvement trial em-
ploying a personal digital assistant (PDA) that calculated 10-year
coronary heart disease risk (Bertoni 2009); however, investigators
performed no formal cost-effectiveness analysis. Likewise, British
Family Heart 1994 did not perform a formal cost-effectiveness
analysis, but based on the observed risk factor changes and the
projected reduction in coronary events, the authors suggested that
the modest improvements did not support broader implementa-
tion of the intervention.
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Subgroup and sensitivity analyses
Weperformed a subgroup analysis evaluating the effects of provid-
ing CVD risk scores on CVD risk factor levels (total cholesterol,
LDL-cholesterol, systolic blood pressure, diastolic blood pressure,
and multivariable CVD risk) by use of clinical decision-support
tools to provide CVD risk scores. Results were similar in mag-
nitude and direction, but substantial heterogeneity remained for
all analyses (Analysis 2.1; Analysis 2.2; Analysis 2.3; Analysis 2.4;
Analysis 2.5).
Due to the substantial heterogeneity observed for CVD risk fac-
tor levels, we also performed post hoc subgroup analyses evalu-
ating the effects of providing CVD risk scores by use of health
IT and by trials that exclusively enrolled participants with higher
risk (defined as 10-year CVD risk ≥ 10% or a high-risk condi-
tion such as diabetes mellitus). For subgroup analyses by use of
health IT, results were similar in magnitude and direction, but
substantial heterogeneity remained for all analyses (Analysis 3.1;
Analysis 3.2; Analysis 3.3; Analysis 3.4; Analysis 3.5). In contrast,
heterogeneity for the effects of providing CVD risk scores on total
cholesterol and LDL cholesterol was attenuated when including
trials that exclusively enrolled higher-risk participants (MD−0.13
mmol/L, 95% CI−0.22 to−0.03, I² = 34%; 3 studies, N = 4105
for total cholesterol, Analysis 4.1; and MD −0.07 mmol/L, 95%
CI −0.11 to −0.03, I² = 0%; 3 studies, N = 14,219 for LDL
cholesterol, Analysis 4.2). This attenuation of heterogeneity was
not seen for systolic blood pressure (Analysis 4.3), diastolic blood
pressure (Analysis 4.4), or multivariable CVD risk (Analysis 4.5),
which may reflect the greater emphasis on risk-based treatment in
cholesterol guidelines compared with blood pressure guidelines.
We did not identify sufficient data to perform subgroup analyses
by sex or trial design (RCT versus quasi-RCT). Additionally, after
reading study protocols, it was often unclear whether CVD risk
scores were provided directly to patients or to clinicians because
frequently CVD risk scores were provided to both within the con-
text of a clinical encounter.We did not perform sensitivity analyses
because we assessed all studies as being at unclear or high risk of
bias.
D I S C U S S I O N
Summary of main results
The trials identified in this systematic review provide low-quality
evidence that current strategies for providing CVD risk scores in
primary prevention may have little to no effect on CVD events
compared with usual care. However, only three studies reported
this outcome, and all had limitations. Compared with usual care,
providing CVD risk scores may reduce CVD risk factors like
cholesterol, blood pressure and multivariable CVD risk by a small
amount andmay reduce adverse events, but results were imprecise.
There was substantial heterogeneity for many analyses, particu-
larly when analysing change in risk factor levels. This was likely
a result of: diverse risk levels of the participants recruited for the
studies; the multifaceted and varying nature of the interventions
tested; different baseline medication treatment rates; and the dif-
ferent outcomes collected.Given this heterogeneity, readers should
interpret results with caution.
Providing CVD risk scores may increase prescriptions for new or
intensified lipid-lowering medications, new or intensified antihy-
pertensive medications, and new aspirin therapy in higher-risk
people. Further, providing CVD risk scores may increase smoking
cessation and may reduce decisional conflict compared with usual
care. However, providing CVD risk scores may have little to no
effect on medication adherence or health-related quality of life.
Measurement of exercise and diet was highly variable among the
included studies, and the effects of providing CVD risk scores on
these outcomes were mixed. Data on costs were also limited but
suggest a reduction in healthcare costs after providing CVD risks
scores. Full reporting of effect sizes and quality of evidence ratings
for main outcomes are listed in Summary of findings for the main
comparison.
Overall completeness and applicability of
evidence
This review provides the most contemporary appraisal of the
evidence to date. We identified 73 records of 41 studies (N =
193,614), 8 ongoing studies, and 3 studies awaiting classification.
This compares with only four trials (N = 4648) identified in two
previous systematic reviews addressing a similar objective and us-
ing Cochrane methodology (Brindle 2006; Beswick 2008). We
employed broad selection criteria that led to the inclusion of a
wide range of trials with different designs, risk levels among partic-
ipants, and choices of outcomes. CVD risk score interventions also
ranged from simple CVD risk score presentations to multifaceted
interventions that incorporated different risk messages, clinical
decision support tools, electronic reminders, patient activation
material, audit and feedback, and nurse-led counselling sessions.
These inclusive selection criteria led to substantial heterogeneity
in many of our pooled estimates. However, they also enhance the
external validity of our findings due to the varied settings, pop-
ulations, and interventions studied in the trials. Although many
CVD prevention guidelines recommend the use of multivariable
CVD risk scores to guide primary prevention treatment strategies
(Anderson 2013; NCEP 2002; NICE 2014; Piepoli 2016; Stone
2014;WHO 2007), we identified multiple evidence gaps to guide
the application of CVD risk scores in clinical practice. Trials gen-
erally had a short-term focus, had methodological limitations par-
ticularly in the domains of attrition bias and detection bias, and
were underpowered for clinical endpoints. Given the multifacto-
rial nature of many of the CVD risk score interventions, it is also
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unclear which component of the intervention was most effective
at improving CVD prevention. Thus, there is uncertainty about
optimal implementation of CVDrisk scores in practice to improve
cardiovascular health outcomes.
Quality of the evidence
Using the GRADE framework, we rated the quality of evidence
guiding the clinical application of CVD risk scores in primary
CVD prevention as low overall. Quality assessments were gen-
erally downgraded due to: study limitations across multiple risk
of bias domains; inconsistency of results due to the substantial
unexplained heterogeneity in pooled estimates; and imprecision.
Specifically, we rated the quality of evidence for the effects of pro-
viding CVD risk scores on CVD events as low, downgrading due
to study limitations and imprecision. We rated the quality of ev-
idence for the effects of providing CVD risk scores on CVD risk
factor levels (total cholesterol, systolic blood pressure, and multi-
variable CVD risk) as low, downgrading due to study limitations
and inconsistency. We rated the quality of evidence for the effects
of providing CVD risk scores on adverse events as low, downgrad-
ing due to study limitations and imprecision. We rated the quality
of evidence for the effects of providing CVD risk scores on new or
intensified lipid-lowering medications and antihypertensive med-
ications as low, downgrading due to study limitations and incon-
sistency.
Potential biases in the review process
Our review has several strengths. First, we followed a pre-speci-
fied, published protocol to guide our systematic review and noted
any deviations from this protocol. Second, we conducted a com-
prehensive, transparent search strategy that was guided by an in-
formation specialist (MAB) and that identified published reports,
conference abstracts, and clinical trial registers. Third, we included
only RCTs or quasi-RCTs that used a systematic method of allo-
cation to the CVD risk score intervention. Fourth, we performed
all title screening, data extraction, and risk of bias assessments in
duplicate to minimise bias. Fifth, we used the GRADE framework
to rate the quality of evidence and factored this quality assessment
to guide our conclusions regarding the effects of providing CVD
risk scores.
The principal limitation of this review is the quality of the avail-
able data. Nearly all trials (38 out of 41) had high or unclear risk of
bias across multiple domains. Moreover, most trials were powered
for process outcomes rather than clinical outcomes, were designed
for short duration, did not use systematic follow-up procedures,
and delivered CVD risk messages at a single time point only. Trials
also varied in terms of design, risk levels of participants, complex-
ity of CVD risk score interventions, content of risk messages, and
choice of outcomes. This heterogeneity is demonstrated in the re-
sults of our meta-analysis and should temper confidence in our
reported effect estimates. This inconsistency is also reflected in our
GRADE quality assessments. Our selection criteria of trials with
all or ≥70% primary prevention participants and where only the
intervention group received a multivariable CVD risk score led to
the exclusion of several well-known trials that included a majority
of participants with established CVD (Cleveringa 2008; Ketola
2001;Weymiller 2007). Other prominent but excluded trials pro-
vided aCVDrisk score to both treatment groups (Keyserling 2014;
Kullo 2016). Nevertheless, we feel that our inclusive definition of
a CVD risk score intervention and the methods we used to select
and evaluate the evidence outweigh these limitations.
Agreements and disagreements with other
studies or reviews
Our results are consistent with prior systematic reviews performed
on this topic. Two previous systematic reviews performed with
Cochrane methodology identified no strong evidence that CVD
risk scores improved health outcomes (Beswick 2008; Brindle
2006). However, both reviews searched literature through 2004
and only included interventions that provided a CVD risk score to
clinicians. Therefore, they identified only four studies (N = 4648).
In contrast, our search was performed through March 2016 and
included CVD risk score assessment provided directly to patients
or performed at the health system level. Consequently, we iden-
tified a greater number of trials and were able to provide greater
detail about the effects of CVD risk scores on a variety of interme-
diate outcomes and health behaviours. Other systematic reviews
have also highlighted that CVD risk scores can increase patients’
intent to start therapy and physicians’ prescribing of cardiovascular
medications with no evidence of harm (Sheridan 2008; Sheridan
2010). However, these reviews did not systematically collect or
report effects of CVD risk scores on individual risk factor levels
or cardiovascular outcomes.
Our results complement the findings of a recently published non-
Cochrane systematic review that evaluated the effect of providing
a CVD risk score on clinical outcomes (Usher-Smith 2015). This
review identified 17 trials (N =19,036) and reported a small reduc-
tion inmodelledCVD risk (−0.39%, 95%CI−0.71 to−0.07); a
trend toward lower mean total or LDL cholesterol (−0.11 mmol/
L, 95% CI−0.23 to 0.01); an increase in lipid-lowering and anti-
hypertensive medication prescribing in high-risk participants (RR
2.11, 95% CI 1.27 to 3.49 and RR 2.38, 95% CI 1.11 to 5.10,
respectively); and mixed effects on smoking cessation, physical
activity, and alcohol consumption. Notably, this review did not
identify evidence that providing CVD risk scores had an effect on
blood pressure level (systolic blood pressure: −0.82 mmHg, 95%
CI −2.70 to 1.05; diastolic blood pressure: −0.48 mmHg, 95%
CI−1.41 to 0.44). This review, however, has notable limitations.
For example, it included non-randomised, before-after studies at
high risk of selection bias. Additionally, the authors did not use a
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systematic framework, such as GRADE, to assess the quality of ev-
idence or guide recommendations. Lastly, the authors used restric-
tive inclusion criteria that led to the exclusion of many contempo-
rary trials that incorporated CVD risk score interventions within
complex, multifaceted interventions. Our review addresses many
of these limitations by including only RCTs or quasi-RCTs, using
GRADE to assess the quality of evidence, and including trials with
multifaceted interventions such as Peiris 2015, where provision of
a CVD risk score was just one component of a larger implementa-
tion model. Thus, our review may provide a more comprehensive
and generalisable assessment of the current state of the science.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Due to the low-quality evidence available, we are unable to draw
firm conclusions about the clinical effectiveness of providingCVD
risk scores in primaryCVDprevention. ProvidingCVDrisk scores
may increase lipid-lowering and blood pressure-lowering medica-
tion prescribing in higher risk people and may have a small effect
on reducing cardiovascular risk factor levels; however, there is in-
sufficient high-quality evidence to determine whether this trans-
lates into improved CVD outcomes. For clinical outcomes, not
only was there low-quality evidence, but only three studies re-
ported this endpoint. Much uncertainty remains about the op-
timal implementation of CVD risk scores in clinical practice to
improve cardiovascular health outcomes.
Implications for research
In spite of the widespread promulgation of CVD risk scores in
prevention guidelines, there is low-quality evidence and several
gaps in evidence for guiding implementation in practice. Given
the low event rates in primary prevention, it may not be feasible or
practical to conduct a study with a large enough size and duration
to determine the effects of providing CVD risk scores on CVD
outcomes. Future studies should clearly identify how well the in-
tended CVD risk score application was implemented in practice
and evaluate its effectiveness in studies powered to identify reduc-
tions in causal risk factor levels. Moreover, studies should identify
the optimal content and format of CVD risk messages that moti-
vate behaviour change in physicians and patients, assess the impact
of providing CVD risk information longitudinally over time, and
look beyond initiation of evidence-based risk-reducing therapies
to address uptake and long-term adherence to these therapies to
achieve risk factor changes and eventual improvements in health
outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Benner 2008
Methods Cluster-randomised trial, parallel group (1:1)
Participants Patients from outpatient clinics in 9 European countries
Unit of randomisation: primary care clinic
Inclusion criteria: 45-64 years of age with a history of hypertension, systolic blood
pressure≥ 140 mmHg (or≥ 130 mmHg if renal disease), and a 10-year risk of coronary
heart disease (CHD) ≥ 10%
Exclusion criteria: individuals with a history of CHD, diabetes mellitus, fasting plasma
glucose > 6.9 mmol/L, or practices that routinely used risk calculators
101 clinics randomised: n = 51 intervention, n = 50 usual care; 1 clinic excluded prior
to participant recruitment
1103 participants randomised: n = 565 intervention, n = 538 usual care
Mean (SD) age: 56.8 (5.1) years, 14% women, 96% white; no diabetes mellitus
Interventions Intervention group:
• Physicians calculated participants 10-year predicted CHD risk using a hand-held
electronic device and advised participants according to a risk communication
programme;
• participants were provided with a ’Heart Health’ report including absolute and
relative risk information and bar charts
• nurse-led education sessions by phone to discuss behaviour modifications every 4
weeks (weeks 6, 12, 18).
Comparison group: usual care (risk factor assessment but 10-year CHD risk not pro-
vided)
Outcomes Primary outcome: Framingham 10-year CHD risk at 6 months
Secondary outcomes: changes in blood pressure and cholesterol levels; attainment of
blood pressure andATP-III LDL-C goals; knowledge; attitude; behaviour; adverse effects
Number of clinics analysed: n = 50 intervention, n = 50 usual care
Number of participants analysed for safety: n = 563 intervention, n = 533 usual care
Number of participants analysed for efficacy: n = 524 intervention, n = 461 usual care
Follow-up: 6 months
Study funding sources “This study was sponsored by Pfizer Inc, who were involved in the study design, data
collection, data analysis, manuscript preparation and publication decisions.”
Notes Endpoints analysed using mixed effects models to account for clustering
Did not meet recruitment target. 91 participants (n = 30 intervention, n = 61 usual care)
were excluded from efficacy analyses due to failure of hand-held electronic devices
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Benner 2008 (Continued)
Random sequence generation (selection
bias)
Low risk Computer based algorithm to assign study
sites to allocation
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Physicians unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Risk factors in follow-up were measured by
the unblinded physicians
Incomplete outcome data (attrition bias)
All outcomes
High risk > 10% excluded due to device failure or loss
to follow-up. Disproportionate loss to fol-
low-up in usual care and these individuals
were excluded from analyses. ITT analysis
not performed
Selective reporting (reporting bias) Low risk All outcomes from protocol were reported
Other bias High risk Pharmaceutical funding and several inves-
tigators had ties to industry
Bertoni 2009
Methods Cluster-randomised trial, parallel group (1:1)
Participants 66 primary care practices in North Carolina randomised (n = 32 intervention, n =
34 comparison). 5 practices withdrew before intervention started (3 intervention, 2
comparison)
Medical records abstracted from 5057 participants at baseline (n = 2841 intervention, n
= 2216 comparison)
Inclusion criteria: self-described primary care practices, staffed by internal medicine or
family medicine providers, 3 h driving radius of research site in North Carolina
Exclusion criteria: direct affiliation to medical school or residency programme, practices
providing subspecialty care, sites outside of North Carolina
Mean age of participants: 46 years, 57% women, 62% non-Hispanic white, 9% African
American; 7% established CVD, 9% diabetes mellitus
Interventions Both groups received guideline dissemination, patient education materials, continuing
medical education, feedback based on baseline chart audit, and 4 visits for intervention-
specific academic detailing
Intervention group:
• Hand-held computerised decision support tool (personal digital assistant) with
ATP-III treatment recommendations
• Personalised risk information printed for participants
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Bertoni 2009 (Continued)
Comparison group: no decision support, dissemination of JNC-7 guidelines, blood
pressure measurement devices provided to participants
Outcomes Primary outcome: proportion of participants treated appropriately to lipid-lowering
treatment 4 months after intervention
Secondary outcomes: proportion of participants with appropriate lipid-lowering treat-
ment, inappropriate lipid-lowering treatment, and lipid screening
61 practices analysed (n = 29 intervention; n = 32 comparison)
Medical records abstracted from 3821 participants at follow-up (n = 2010 intervention,
n = 1811 comparison)
Follow-up: 1 year
Study funding sources Funded by that National Heart, Lung, and Blood Institute, USA
Notes Endpoints analysed using generalised estimating equations to account for clustering
Analyses compared overall prescribing rates in randomly selected participants before and
after the intervention but did not follow individual participants
Analyses
Trial reported a net improvement in appropriate management but this was due to a re-
duction in inappropriate lipid-lowering treatment compared with the comparison group
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported by authors
“Randomization was stratified by practice
type and size and blocked”
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported by authors
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “The intervention was not blinded.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Abstractors were not informed regarding
the practice’s intervention arm.”
Incomplete outcome data (attrition bias)
All outcomes
High risk 2 practices withdrew after randomisation
and data were not collected
Selective reporting (reporting bias) Low risk All outcomes reported in clinical trial reg-
istration were reported
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Bertoni 2009 (Continued)
Other bias Unclear risk 46% of practices stopped using the clinical
decision support tool
British Family Heart 1994
Methods Cluster-randomised trial with internal and external comparators
Participants Men and women from 14 towns in the UK with 2 matched-practices within each town
Unit of randomisation: general medical practice
Inclusion criteria: all men aged 40-59 years and their partners regardless of age
Exclusion criteria: not specified
The trial consisted of 2 comparison groups, an internal comparison and an external
comparison. Regions were first randomised to the study or usual care (defined as the
external comparison group). Within the study region, general medical practices were
then randomised to the nurse-led screening and the CVD risk score intervention or usual
care (defined as the internal comparison)
Total randomised: 28 practices (n = 14 intervention, n = 14 comparison). Authors did
not specify how many practices were in the internal comparison group and how many
were in the external comparison group
Total participants (n = 12,924): intervention, 2011 men and 1425 women; internal
comparison, 2174 men and 1402 women; external comparison, 3519 men and 2393
women
Mean (SD) age: 51.5 (5.7) years for men and 49.1 (6.8) years for women; 42% women;
5.1% of men and 1.6% of women reported prior coronary heart disease; 1.8% of men
and 0.5% of women reported diabetes mellitus
Interventions Intervention group: nurse-led cardiovascular risk screening and lifestyle intervention:
• Communication of risk decile by Dundee risk score
• Counselling on diet, weight, smoking, exercise, and alcohol
• Frequency of follow-up determined by Dundee risk score
Comparison group: usual care without nurse-screening, lifestyle counselling, or com-
munication of Dundee risk score (Note: for analyses, we used comparisons between the
intervention group and the internal control group as this was the authors’ primary out-
come)
Outcomes Primary outcome: change in Dundee risk score
Secondary outcome: distribution and means of cardiovascular risk factors (systolic blood
pressure, diastolic blood pressure, total cholesterol, smoking prevalence); proportion of
participants with risk factor levels above prespecified cut-points
Number analysed in follow-up: 26 practices (13 intervention, 13 comparison)
Participants analysed at 1-year follow-up: total, n = 12,472; intervention, 1767 men and
1217 women; internal comparison, 2174 men and 1402 women; external comparison,
3519 men and 2393 women
Follow-up: 1 year
Study funding sources Public and private sources. “The study was funded by the Family Heart Association with
an educational grant fromMerck Sharp and Dohme, the family health service authorities
and Fife Health Board, Boehringer Mannheim UK, Wessex Regional Health Authority,
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British Family Heart 1994 (Continued)
the Health Education Authority, the Scottish Home and Health Department, and the
Department of Health.”
Notes Endpoints analysed using random effects models to account for clustering
Data reported separately for men and women by the authors but combined for meta-
analyses in this review
Protocol deviation identified by 1 nurse in an intervention practice. An executive com-
mittee decided (without sight of data) to discard all data from this intervention practice
and therefore to disregard all data from the comparison practice
Authors did not perform a formal cost-effectiveness analysis but the overall predicted
risk reduction of 12% from the intervention was not felt to be cost-effective
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “All men aged 40-59 years in each inter-
vention and comparison practice were ran-
domly ordered at the same time within five
year age groups . . . [and] randomly divided
into two groups: intervention and an inter-
nal comparison group”
Allocation concealment (selection bias) High risk “[W]ithin each age group their households
were approached in order”
Participants were also recruited after indi-
vidual practices were randomised
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of outcome assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
High risk 14% lost to follow-up in intervention
group; those who did not return were more
likely to be smokers and have higher risk
factor levels
Selective reporting (reporting bias) Low risk All outcomes from protocol reported
Other bias High risk Protocol deviations by 1 nurse in interven-
tion group. Executive committee decided
to discard data from the entire practice and
the comparator practice. No baseline mea-
surements in comparison groups
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Bucher 2010
Methods Cluster-randomised trial, parallel group (1:1)
Participants Physicians in the Swiss HIV Cohort Study (SHCS) in Switzerland caring for HIV-
infected participants
Unit of randomisation: physician
Inclusion criteria: all physicianswhowere part of the SCHSwere eligible. Eligible patients
were those registered with the SHCS, not pregnant, aged ≥ 18 years, continuous ART
for 90 days prior to baseline and with complete data on CHD risk factors at baseline
Exclusion criteria: no additional criteria from above
165 physicians randomised at baseline (n = 80 intervention, n = 85 comparison)
117 physicians included (n = 57 intervention, n = 60 comparison) - 45 physicians were
excluded because they did not have any participants with risk factor assessment and 3
physicians did not have any eligible participants
4097 participants eligible at baseline (n = 2097 intervention, n = 2000 comparison)
Mean age (IQR): 44 (39-51) , 30%women, 5%diabetesmellitus, 26%with Framingham
risk score (FRS) ≥ 10%
Interventions Intervention group: risk profile generated by the data centre for each participant ran-
domised to the intervention group; profile consisted of 10-year CHD risk as calculated
by FRS. Study nurses added the FRS risk profile to the patient chart. Each risk profile
also included individualised targets for LDL cholesterol, systolic/diastolic blood pressure
Comparison group: booklet of evidence-based guidelines for management of CHD risk
factors. Guidelines also gave directions on how to approach and motivate lifestyle mod-
ifications and how to calculate CHD risk from a website
Outcomes Primary outcome: total cholesterol
Secondary outcomes: systolic and diastolic blood pressure, Framingham risk score
Follow-up: 12-18 months
3362 participants analysed at follow-up (n = 1680 intervention, n = 1682 comparison)
Study funding sources Public and private sources. “This trial was funded by a grant from the Swiss National
Science Foundation for nested cohort projects . . . and an unrestricted educational grant
from Bristol-Myers Squibb, Baar, Switzerland.”
Notes Primary and secondary outcomes analysed using generalised estimating equations to
account for clustering
Analyses reporting the effect of the intervention on medication prescribing and CVD
events (not mentioned in methods, or in trial registration)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomized groupswere assigned accord-
ing to a computerized list for each strata
generated by a biostatistician not otherwise
involved in the trial.”
Allocation concealment (selection bias) Low risk See above
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Bucher 2010 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “This was an open intervention trial, that
is, physicians knew whether they received
the intervention or not but were not told
what outcomes would be measured.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method used for outcome assessment not
provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk 80% of participants had a final assessment
with data recorded for the primary out-
come; ITT analysis performed
Selective reporting (reporting bias) High risk Trial prospectively
registered (NCT00264394). Primary and
secondary outcomes reported but medica-
tion prescribing outcome not prespecified
Other bias Unclear risk Analyses for primary and secondary out-
comes accounted for clustering but un-
clear if medication prescribing outcome ac-
counted for clustering
Christensen 2004
Methods Randomised controlled, parallel group (1:1:1) trial
Participants 1507 middle-aged (30-49 years) participants registered in general practice clinics in the
district of Ebeltoft, Denmark
Inclusion criteria: aged 30-49 years (by 1 January 1991); registered with a local general
practitioner (GP) in Ebeltoft, Denmark
Exclusion criteria: none reported
Baseline characteristics not provided, 11% were high CVD risk
Interventions Participants were randomised into a control group and 2 intervention groups
Intervention group 1: health screening +written feedback fromGP+optional discussions
with GP (n = 502)
Intervention group 2: health screening + written feedback from GP + scheduled 45-min
discussion with GP annually (n = 504)
Control group: usual care (n = 501)
Among those randomised to intervention group 1, 89% (449/502) received a health
screening. Among those randomised to intervention group 2, 90% (456/504) received
health screening and 88% (443/504) received GP visit. In total, 90% of those in the 2
intervention groups received a cardiovascular risk score
Health screening was performed by laboratory assistants and consisted of cardiovascular
risk calculation and categorisation into low, moderate, elevated, or high. Intervention
groups were combined for analyses by the authors because there were no differences
between the 2 groups. Results were compared to usual care participants who did not
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Christensen 2004 (Continued)
receive a CVD risk score
Outcomes Psychological distress, measured by GHQ-12 - measured anxiety/insomnia, depression,
social impairment/hypochondria, and social dysfunction
Measured at baseline, 1 year, and 5 years
Authors report 84.1% follow-up at 1 year and 79.2% follow-up at 5 years but few other
details on the number of participants analysed in follow-up
Study funding sources Study funded by a combination of Danish public organisations and private industry (i.
e. Novo Nordisk, Bayer Denmark, Roche)
Notes Few trial details provided. No details on baseline characteristics. Psychological distress
measured 1 and 5 years after participants received their CVD risk score
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of outcome assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
High risk 20% missing data for GHQ-12 at 1 year;
25% missing data for GHQ-12 at 5 year;
ITT analysis reported but not performed
Selective reporting (reporting bias) Unclear risk Protocol document not available
Other bias High risk Unlikely that measurement of psycholog-
ical distress at 1 and 5 years after a CVD
risk score intervention is meaningful
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Cobos 2005
Methods Cluster-randomised trial, parallel group (1:1)
Participants People with hypercholesterolemia recruited from primary care health practices in Cat-
alonia region, Spain
Unit of randomisation: primary care health practices
Inclusion criteria: total cholesterol level > 200 mg/dL
Exclusion criteria: triglycerides > 400 mg/dL or participating in another study within
the medical centre
44 primary care health practices randomised (n = 22 intervention, n = 22 comparison).
2 practices withdrew before participants recruited
2191 participants recruited after selection criteria (n = 1046 intervention, n = 1145
comparison)
Mean age: 60 years, 57% women, 16% with diabetes mellitus, and 12% with CHD; ~
50% of participants were previously treated with lipid-lowering drugs
Interventions Intervention group:
• Practices provided patient education material promoting a health cardiovascular
lifestyle
• Physicians were asked to use a clinical decision support software module that
calculated 10-year CHD risk and provided treatment recommendations from within
the electronic health record
Control group: usual care with health promotion pamphlets but no calculation of CHD
risk
Outcomes ITT analysis performed on the 2191 participants recruited (described above). Per-pro-
tocol analyses also presented in the manuscript
Primary outcomes: proportion of participants meeting LDL goals (for CHD, 10-year
CHD risk ≥ 20%, and 10-year CHD risk < 20%); total direct costs
Secondary outcomes: final lipid profile; healthcare resource consumption incurred during
the study
Mean follow-up: 12 months
Study funding sources “Study supported by the Department of Outcomes Research & Disease Management,
Novartis Farmaceutica SA, Spain”
Notes Endpoints analysed using generalised estimating equations to account for clustering
Only 71% of physicians in the intervention group used the decision support tool
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization table was prepared by
the statistician, using blocks of four prac-
tices.”
Allocation concealment (selection bias) High risk Randomisation performed using blocks of
4 practices
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Cobos 2005 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of personnel or participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method for outcome assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk > 20% missing lipid levels in follow-up;
ITT analysis used but no imputation of
missing values
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Study supported by Novartis and 1 author
had industry ties. Approximately 71% of
physicians in the intervention group did
not use the decision support tool
Denig 2014
Methods Randomised controlled trial, 2 × 2 factorial
Participants Participants with type 2 diabetesmellitus aged < 65 yearsmanaged in primary care setting
Inclusion criteria: no additional criteria reported
Exclusion criteria: people with myocardial infarction (MI) in preceding year, stroke,
heart failure, angina, or terminal illness
344 participants randomised at baseline (n = 225 intervention, n = 119 for usual care
group)
Mean (SD) age: 61.7 (8.5), 44% women, > 90% white, 100% diabetes mellitus; high-
rate of baseline treatment (76% treated with statin)
Interventions Intervention group: decision aid for people with diabetes mellitus that provided indi-
vidually-tailored risk information and treatment options for multiple cardiovascular risk
factors; the decision-aid was offered to participants before a regular diabetes mellitus
check-up and to healthcare provider during the consultation
Comparison group: usual care
For this systematic review, groups randomised to the decision aid, which provided a
CVD risk score, were compared to those in the usual care group (who did not receive a
decision aid)
Outcomes Primary outcome: diabetes empowerment scale
Secondary outcome: changes in drug prescription in those with high HbA1c, systolic
blood pressure, or LDL; self-efficacy; satisfaction; negative emotions; and general health
status (EQ-5D); smoking status
306 participants analysed for the study’s primary outcome (n = 199 intervention, n =
107 comparison). Not explicitly stated how many were analysed for secondary outcomes
obtained from the electronic health record
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Denig 2014 (Continued)
Follow-up: 6 months before and after intervention
Study funding sources Funded by Netherlands Organization for Health Research and Development
Notes 4 different formats of the decision aid were tested in exploratory analyses but outcomes
for participants allocated to any decision aid were combined by the study authors in this
manuscript and was similarly done for this systematic review
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A stratified computer generated allocation
sequence was used.”
Allocation concealment (selection bias) Low risk “We used a predefined computer algorithm
with a blockwise scheme to conceal the allo-
cationprocess from the healthcare provider.
”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk High-risk for patient-reported outcomes
Low-risk for clinical outcomes (automatic
data extraction from database)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 31 participants excluded (22 intervention
vs 9 control); excluded from analysis
Selective reporting (reporting bias) Low risk All outcomes from protocol reported
Other bias High risk Randomisation occurred within a practice,
increasing the risk for contamination. De-
cision aid was accessed for 88% (198/225)
of intervention participants but only 46%
(103/225) of intervention participants re-
ceived all basic elements of the intervention
Eaton 2011
Methods Cluster-randomised trial, parallel group (1:1)
Participants Patients from 30 primary care practices in southeastern New England, USA
Inclusion criteria: no additional criteria reported
Exclusion criteria: no additional criteria reported in text but PRISMA flow diagram in
the paper notes that participants were excluded if they were pregnant, died, or left the
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practice during the 1 year follow-up
30 practices randomised (n = 15 intervention, n = 15 comparison)
4105 participants after exclusion criteria (n = 2100 intervention, n = 2000 comparison)
Mean (SD) age: 54.0 years (1.1) in intervention group and 52.3 (1.1) in control group;
29% women; 96% white; 20% CHD; 10% diabetes mellitus
Interventions Both groups received a 1-h academic detailing session where ATP-III guidelines were
discussed and pocket guidelines were given
Intervention group:
• Patient education toolkit
• Computer kiosk with patient activation software
• Personal digital assistant-based decision support tool for clinician
• 4 booster academic detailing sessions
Comparison group: personal digital assistant without decision support
Outcomes Primary outcome: proportion of participants screened and treated per 2001 guidelines
Follow-up: 1 year
30 practices analysed (n = 15 intervention, n = 15 comparison)
4105 participants analysed (n = 2100 intervention, n = 2000 comparison)
Study funding sources Not reported
Notes Endpoints analysed using generalised linear mixed models to account for clustering
Only 39% had a Heart Age calculated by clinicians. In post hoc analyses, physicians with
above-median use of the decision support tool were more likely to have their participants
meet LDL goals (OR 1.23, 95% CI 1.04 to 1.06)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Chart outcome abstractors blinded to
physician and practice
Incomplete outcome data (attrition bias)
All outcomes
Low risk No practices lost to follow-up and ITT
analysis performed for primary outcome
Selective reporting (reporting bias) Unclear risk Protocol document unavailable
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Eaton 2011 (Continued)
Other bias High risk Low uptake of both patient activation tool
among patients and decision support tool
among physicians
Edelman 2006
Methods Randomised controlled trial, parallel group (1:1)
Participants Adults ≥ 45 years without prevalent CVD
Inclusion criteria:≥ 1 cardiovascular risk factors (diabetesmellitus,HTN, dyslipidaemia,
smoking, or elevated BMI)
Exclusion criteria: history of MI, stroke, heart failure, terminal illness, pregnant women
154 adults enrolled and randomised (n = 77 intervention, n = 77 comparison)
Mean (SD) age: 52.2 years (5.2) in intervention group, 53.4 years (4.8) in control group;
81% women, 76% white, 20% African American, 16% diabetes mellitus
Interventions Intervention group:
• Personalised risk education
• Personalised health plan delivered by health coach
• Individual coaching sessions biweekly by phone
• Group sessions weekly for the first 4 months, bi-weekly for months 5-9, and then
at conclusion
Comparison group: usual care, mailed health assessment (blood test values but CVD
risk score not provided)
Outcomes Primary outcome: Framingham risk score
Secondary outcome: BMI, waist circumference, blood pressure, fasting lipid profile,
smoking status, exercise frequency, readiness to increase exercise
Follow-up: baseline, 5 months, and 10 months
Study funding sources Center for Medicare and Medicaid Services, Veterans Affairs Health Services Research
& Development career development award
Notes Resource intensive intervention from health coaches with multiple follow-up meetings
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
High risk Participants and personnel not blinded
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Edelman 2006 (Continued)
All outcomes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “A research assistant blinded to treatment
arm assignmentmeasured the data required
to calculate FRS at baseline, 5 months, and
10 months.”
Incomplete outcome data (attrition bias)
All outcomes
High risk > 20% loss to follow-up
Selective reporting (reporting bias) Unclear risk Protocol document not available for review
Other bias Low risk Other sources of bias not identified
Engberg 2002
Methods Randomised controlled trial, parallel group (1:1:1)
Participants Men and women aged 30-49 years from primary care clinics in Ebeltoft, Denmark
Inclusion criteria: additional criteria not reported
Exclusion criteria: none reported
1507 participants randomised (n = 504 health screening + physician discussion, n = 502
health screening only, n = 501 comparison/usual care)
Mean age: 40.5 years, 51% women, 100% Danish
Interventions Intervention groups: 2 health screenings or 2 health screenings + 45 min follow-up
consultation with general practitioner to discuss health-related lifestyle goals
Comparison group: usual care
For the analyses in this review, the “health screening + physician discussion” and “health
screening only” groups were combined since both groups received a personalised CVD
risk score
Outcomes Primary outcome not specified; Danish CVD risk score, BMI, cholesterol level, systolic
blood pressure, and diastolic blood pressure reported
1093 participants analysed at 5 years (n = 346 health screening + physician discussion,
n = 378 health screening only, n = 369 usual care)
Follow-up: 1 year and 5 years
Study funding sources Funded by County Health Insurance office and other private/public sponsors, including
Novo Nordisk, ASTRA-Denmark, Bayer, and Roche
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Engberg 2002 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Low risk “An employee of Aarhus County who was
not otherwise involved in the study carried
out the randomization.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Participants were informed by their gen-
eral practitioner about which intervention
they would be offered.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear risk of bias for cardiovascular risk
factors. High-risk of bias for patient-re-
ported outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk 25-30% loss to follow-up in all 3 treatment
groups by 5 years. No imputation of miss-
ing values
Selective reporting (reporting bias) Unclear risk Primary and secondary outcomes unclear
in protocol document
Other bias Unclear risk Partial funding frompharmaceutical indus-
try. Authors speculate on potential risk of
contamination between participants in dif-
ferent treatment groups but attempted to
mitigate this risk by allocating cohabitating
couples into the same intervention group
Grover 2007
Methods Randomised controlled trial, parallel group (1:1)
Participants Patients in primary care clinics across 10 provinces in Canada
Inclusion criteria:
• CVD, DM, or 10-year CHD risk > 30% and TC:HDL ratio > 4
• 10-year CHD risk 20-30% and TC:HDL ratio > 5
• 10-year CHD risk 10-20% and TC:HDL ratio > 6
Exclusion criteria: hypersensitivity to statins, risk of pregnancy, breastfeeding, active liver
disease or liver enzyme abnormalities, elevated creatine kinase, elevated triglycerides (>
939 mg/dL), history of pancreatitis, significant renal insufficiency
3053 participants enrolled and randomised (n = 1510 intervention, n = 1543 compari-
son)
Mean age: 56 years, 32% women, 50% diabetes mellitus, 23% CVD
Interventions Intervention group: physicians and participants provided with coronary risk profile con-
sisting of a 8-year CHD risk estimate, cardiovascular age, and age gap; repeat profile
provided at 3 months to demonstrate response to therapy and amount of risk reduction
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Grover 2007 (Continued)
Comparison group: usual care
Outcomes Primary outcomes: change in LDL-C level, change in TC/HDL ratio, percentage of
participants reaching national lipid targets
Secondary outcomes: change in nonlipid risk factors, global 10-year risk
3053 participants analysed for efficacy outcomes (n = 1510 intervention, n = 1543
comparison)
Follow-up: 1 year
Study funding sources Funded by Pfizer Canada and multiple investigators with pharmaceutical industry ties
Notes Protocol violation noted for 121 participants (n = 56 intervention, n = 65 comparison)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Low risk “Randomizationwas completed at a central
coordinating centre”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method for outcome assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12% loss to follow-up which was similar in
the 2 groups; ITT analysis performed
Selective reporting (reporting bias) Unclear risk Protocol document not available for review
Other bias High risk Pharmaceutical funding
Potential for contamination bias since
randomisation occurred within physician
practice (investigators attempted to evalu-
ate for this with sensitivity analyses)
Protocol violation noted for 4% of partici-
pants (n = 121)
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Hall 2003
Methods Quasi-randomised controlled trial, parallel group (1:1)
Participants Participants aged 35-75 years, with type 2 diabetes mellitus and no history of CVD or
renal disease attending a specialised diabetes mellitus clinic in the UK
Inclusion criteria: not reported
Exclusion criteria: not reported
323 participants recruited (n = 162 intervention, n = 161 comparison)
Mean age of participants not reported; 48% women; 100% diabetes mellitus
Interventions The New Zealand cardiovascular risk score was calculated for all participants
Intervention group: CVD risk score was documented on the front of the participant’s
chart before visit
Comparison group: no risk score documentation
Outcomes Primary outcome: not specified
Outcomes reported: changes in diabetes mellitus treatment, changes in antihypertensive
treatment, referral to dietician, risk score mentioned in letter to GP
Follow-up: none
Study funding sources Funding source not reported by authors
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “We allocated patients alternately to exper-
imental and control groups.”
Allocation concealment (selection bias) High risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method for outcome assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants included in study were
analysed
Selective reporting (reporting bias) Unclear risk No protocol available for review
Other bias High risk Small study bias
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Hanlon 1995
Methods Randomised controlled trial, parallel group (1:1:1:1:1)
Participants 1371 employees from 2 Glasgow factories randomised to 5 groups (n = 293 group 1, n
= 297 group 2, n = 285 group 3, n = 263 group 4, n = 233 group 5)
Inclusion criteria: additional criteria not reported
Exclusion criteria: night-shift workers and workers participating in another cholesterol
treatment study
58% of sample were 40-59 years of age, 9% women
Interventions 4 intervention groups:
• Group 1: health education
• Group 2: health education and feedback on cholesterol concentration
• Group 3: health education and feedback on risk score
• Group 4: health education with feedback on cholesterol concentration and risk
score
1 comparison group (internal control): group 5 no health intervention
This review reports results for the comparison of group 4 and group 5
Outcomes Outcomes reported: change in Dundee score; plasma cholesterol concentration; diastolic
blood pressure, BMI; self-reported behaviours
1157 employees analysed at 5 months (n = 247 group 1, n = 250 group 2, n = 241 group
3, n = 219 group 4, n = 200 group 5)
1107 employees analysed at 12 months (n = 240 group 1, n = 237 group 2, n = 226
group 3, n = 211 group 4, n = 193 group 5)
Follow-up: baseline, 5 months, and 12 months
Study funding sources Scottish Chief Scientist Office
Notes Authors also compared the effects of the intervention to an external control site that
was not randomised. These comparisons were reported in the manuscript but are not
presented in this review
Outcomes for changes in risk factors and health behaviours only reported at 5 months
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “[S]ubjects were allocated, by means of
computer generated randomisation, to one
of five groups.”
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of outcome assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis performed
Selective reporting (reporting bias) High risk Protocol not available and no trial registra-
tion. 12 month outcomes not reported
Other bias High risk Potential for contamination bias.
“We recognised that subjects in group 5
(internal control) were open to influences
from colleagues because the messages given
to other participants were being freely dis-
cussed in the workplace.”
Hanon 2000
Methods Randomised controlled trial, parallel group (1:1)
Participants 1526 hypertensive participants (aged 18-75 years) with uncontrolled treated hyperten-
sion (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg).
Number randomised per group not reported
Inclusion criteria: same criteria as above
Exclusion criteria: pregnancy, diabetes mellitus, severe hypertension, renal or pulmonary
disease, psychiatric disease, secondary hypertension
Baseline age (SD): 60 years (10); 46% women
Interventions All groups were treated with a therapeutic strategy that consisted of fosinopril 20 mg/
day for 8 weeks with the possible increase to fosinopril + hydrochlorothiazide at 4 weeks.
Participants randomised to the intervention group had their 10-year Framingham risk
information provided to their treating physician
Outcomes Primary and secondary outcomes not specified. Outcomes reported include: agreement
between calculated risk and estimated risk by general practitioner, blood pressure at week
8
1273 participants analysed but number per group not reported
Follow-up: 8 weeks
Study funding sources Not reported. 1 author affiliated with a pharmaceutical company
Notes Study published in French
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Hanon 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation stated but method for ran-
dom sequence generation not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
High risk 1527 randomised but only 1273 analysed;
no reasons provided for loss to follow-up;
no imputation
Selective reporting (reporting bias) High risk Outcomes not prespecified and study not
registered
Other bias Unclear risk Few study details provided in text
Hetlevik 1999
Methods Cluster-randomised controlled trial, parallel group (1:1)
Participants People with hypertension from29primary care health centres in Sor andNord-Trondelag
counties in Norway
Unit of randomisation: health centre
Number recruited: 29 health centres and 2239 participants total (n = 17 health centres
with 984 participants in the intervention group; n = 12 health centres with 1255 par-
ticipants in the comparison group)
Mean age: 64 years, 58% women, 100% Norwegian
Interventions Intervention group:
• Computerised clinical decision support software with risk scores and guideline-
based treatment recommendations
• Educational seminars
• Audit and feedback
Comparison group: usual care
Outcomes Outcomesmeasured: last registered cholesterol, bloodpressure, weight (or BMI), number
of cigarettes
Risk score calculated only if enough information available during the search period
Number analysed at 18 month follow-up: n = 887 intervention, n = 1127 comparison
Number analysed after 3 month extension (21 month follow-up): n = 879 intervention,
n = 1119 comparison
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Hetlevik 1999 (Continued)
Follow-up: 18 months initially, trial extended 3 months due to missing data
Study funding sources Norwegian Medical Association with contribution from the foundation promoting gen-
eral practice in Sor-Trondelag
Notes Issues with intervention fidelity: “After 18 months the CDSS had been used, partly or
totally, in the treatment of 104 patient in the intervention group.”
Trial extended by 3 months because of inadequate collection of data at 18 months
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel not blinded, and not clear that
participants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes abstracted by primary investiga-
tor who was not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk > 90% of participants in both groups were
missing data to calculate 10-year CHD risk
at 18 months. The trial was extended by 3
months which decreased this amount to ~
50%
Selective reporting (reporting bias) Unclear risk No protocol available for review
Other bias High risk Trial extended by 3 months due to miss-
ing data. Clinicians provided lists of miss-
ing participant information and were asked
to resolve this. Poor intervention fidelity
(CDSS was used partially or totally in the
treatment of only 104 participants in the
intervention group)
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Holt 2010
Methods Randomised controlled trial, parallel group (1:1)
Participants People aged 50 years and older from primary care practices in West Midlands, UK
running the EMIS (Egton Medical Information Systems) LV software
Total number randomised: 38,417 (n = 18,912 intervention, n = 19,235 comparison)
Interventions Intervention group: receives electronic alert messages identifying participants at high-
risk for CVD, those whose risk factor data is incomplete, and those who may have un-
diagnosed diabetes mellitus. Health record searched and updated every 24 h. Treatment
recommendations not provided. Alerts can be ignored by clinicians
Comparison group: usual care. Computer software acquires data from the electronic
health record but does not generate an electronic alert for the clinician
Outcomes Primary outcome: difference in annual incidence rate of CVD events (composite of
CHD, stroke/TIA, myocardial infarction, sudden cardiac death)
Secondary outcomes include differences in the proportion of: high-risk participants
identified, participants with missing data, participants with undefined diabetes mellitus
status
Number analysed at follow-up: 36,092 (n=18,021 intervention, n = 18,071 comparison)
Follow-up: 2 years
Study funding sources Department of Health PhD Studentship from Warwick Medical School
Notes User was not obliged to respond to the alert
“Recruitment into the study had to be closed before the required number of patients
over 50 years could be achieved, due to resource constraints.”
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “The e-Nudge software automatically ran-
domised registered patients within each
practice to intervention and control arms,
depending on whether the last digit of the
10-digit NHS number was odd or even.”
Allocation concealment (selection bias) High risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Physicians were kept unaware of odd/even
rule for allocationbut an alertwould appear
each time a patient record was opened
Personnel not blinded; unclear if partici-
pants were blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcomes assessed by electronic abstrac-
tion from medical record
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Holt 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1practicewithdrew from study at 6months
but overall < 10% missing data
Selective reporting (reporting bias) Low risk Authors clearly report changes to the proto-
col and outcomes reported match the pro-
tocol and trial registration
Other bias High risk Risk of contamination bias because ran-
domisation was at the individual level, and
the same physician may have taken care
of participants randomised to intervention
and control groups
Senior author is the medical director of
the software company that provided the e-
Nudge software
Underpowered for primary outcome
Jacobson 2006
Methods Randomised controlled trial, parallel group (1:1)
Participants People with LDL-C > 100 mg/dL , no history of CHD or vascular disease, and not
currently receiving lipid-lowering therapy
Inclusion criteria: additional criteria not reported
Exclusion criteria: people older than 74 years, LDL-C < 100 mg/dL, charts missing risk
factor information used to calculate 10-year CHD risk
Total number of participants randomised: 368 (n = 186 intervention, n = 182 compar-
ison)
Mean (SD) age: 58 (9), 72% women, 92% African American, 6% white, 23% diabetes
mellitus
Interventions Intervention group: charts appended to include 10-year absolute CHD risk, ATP-II risk
category, and potential treatment options
Comparison group: charts appended with ATP-II LDL-C targets and consensus targets
for blood pressure, BMI, and haemoglobin A1c. No risk information included
Both groups received a 1-h academic detailing session to review the importance of risk
assessment in cholesterol management
Outcomes Primary outcome: proportion of high-risk participants who were recommended a statin
Secondary outcomes: proportion of moderate-risk participants who were recommended
a statin; proportion of entire cohort receiving lifestyle counselling, intensified blood
pressure management, or documentation of risk in chart
Total number of participants analysed: 351 (n = 182 intervention, n = 169 comparison)
Study funding sources Emory University Medical Care Foundation
Notes Authors report possible protocol violations and randomisation errors
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Jacobson 2006 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Method of random sequence generation
not reported. “Randomization errors” re-
ported by authors
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of personnel; unclear if partic-
ipants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of outcome assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
High risk Differential loss to follow-up (greater in
control group); ITTanalysis not performed
Selective reporting (reporting bias) Unclear risk No protocol available for review
Other bias High risk Risk of contamination bias as same physi-
cian may have taken care of participants
randomised to intervention and control
groups
Jorgensen 2014
Methods Randomised controlled trial, parallel group (1:1)
Participants Danish residents aged 30-60 years from 11 municipalities in suburban Copenhagen,
Denmark
61,301 people originally randomised within the study but 59,993 people met the inclu-
sion criteria at baseline for this analysis
Total randomised: 59,993 (n = 11,708 intervention, n = 48,285 comparison)
Mean age: not reported, 50% women, 88% Danish
Interventions Intervention group: invited for screening, risk assessment, and lifestyle counselling up
to 4 times over a 5-year period; high-risk individuals were offered additional lifestyle
counselling on smoking cessation, diet, and physical activity
Comparison group: not invited for screening; formal risk assessment not provided
Outcomes Primary outcome: incident ischaemic heart disease
Secondary outcome: incident stroke, incident combined ischaemic heart disease and
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Jorgensen 2014 (Continued)
stroke, mortality, and attendance rates
Total analysed in follow-up: 59,616 (n = 11,629 intervention, n = 47,987 comparison)
Follow-up: 10 years
Study funding sources Public, private, and industry sources: Danish Research Councils, Health Foundation,
Danish Centre for Evaluation andHealth Technology Assessment, Copenhagen County,
Danish Heart Foundation, Ministry of Health and Prevention, Association of Danish
Pharmacies, Augustinus Foundation, Novo Nordisk, Velux Foundation, Becket Foun-
dation, and Ib Henriksens Foundation
Notes Trial powered for 70% participation rate in the intervention group but only 52% of
people in the intervention group accepted the invitation and were examined at baseline
Data for risk factor levels not available given the pragmatic study design
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The 61 301 people were randomised by
computer generated random numbers with
different randomisation ratios in the differ-
ent age and sex groups …”
*Note for this analysis, 59,313 people met
the baseline inclusion criteria
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel and participants not blinded to
intervention but “neither the control group
nor their doctor knew that they formed a
control group.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Use of data from central registers further
blinded the assessment of endpoints in re-
lation to randomisation group.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 1% loss to follow-up of event data
Selective reporting (reporting bias) High risk Cardiovascular outcomeswere not prespec-
ified in the original trial protocol
Other bias High risk Potential for contamination bias because
randomisation was at the participant level
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Koelewijn-van Loon 2010
Methods Cluster-randomised controlled trial, parallel group (1:1)
Participants Adults from 25 practices with blood pressure ≥ 140 mmHg or already being treated for
high blood pressure, total cholesterol ≥ 6.5 mmol/L or already being treated for high
cholesterol, smoking (men ≥ 50 years, women ≥ 55 years), diabetes mellitus, family
history of CVD and visible obesity
Unit of randomisation: primary care practice
Exclusion criteria: existing CVD, familial hypercholesterolaemia
Total randomised: 25 practices with 615 participants (13 practices with 322 participants
in the intervention group, 12 practices with 293 participants in the comparison group)
Mean age: 57 years, 55% women, 14% diabetes mellitus
Interventions Intervention group: received individual 10-year CVD risk assessment, risk communica-
tion via decision aid, motivational interviewing by nurses regarding lifestyle modifica-
tions
Comparison group: usual care consistent with Dutch guidelines
Outcomes Primary outcome: questionnaires to assess fruits and vegetables intake, fat intake, physical
exercise, smoking, alcohol consumption; self-reported adherence to medical treatment;
cardiovascular risk factor levels
Secondary outcomes: perception of own health behaviour, attitude towards behaviour
change, self-efficacy, risk perception, anxiety, satisfaction
Total analysed at follow-up: 24 practices with 526 participants (13 practices with 264
participants in the intervention group, 11 practices with 258 participants in the com-
parison group)
Follow-up: baseline, 12 weeks, and 52 weeks
Study funding sources The Netherlands Organization for Health Research and Development
Notes Study includes patient-reported outcomes only
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “An independent statistician performed a
central block randomization”
Allocation concealment (selection bias) Low risk Treatment allocation performed centrally
by an independent statistician
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Because of the training, nurses could not
be blinded. To minimize potential bias, pa-
tients were informed about the aim of the
study, but not about being part of an inter-
vention or control group.”
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Koelewijn-van Loon 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of outcome assessment was not re-
ported for all outcomes, but several out-
comes were self-report questionnaires
Incomplete outcome data (attrition bias)
All outcomes
High risk Participants with missing data were ex-
cluded; ITT analysis not performed
Selective reporting (reporting bias) High risk Protocol and trial registration reports risk
factor levels (cholesterol, blood pressure,
and 10-year CVD risk) as outcomes that
would be collected. Protocol also discusses
economic analysis but these data are not
provided in the published report
Other bias Low risk Other sources of bias not identified
Krones 2008
Methods Cluster-randomised controlled trial, parallel group (1:1)
Participants Adults with measured cholesterol level from 162 primary care practices in Hessen, Ger-
many; recruited from 14 continuing medical education (CME) groups
Unit of randomisation: CME group
Inclusion criteria: additional criteria not reported
Exclusion criteria: CME groups excluded if they participated in previous quality im-
provement projects
Total randomised at baseline: 14 CME groups (N = 1132)
Intervention group: 7 CME groups with 44 practices (n = 550)
Comparison group: 7 CME groups with 47 practices (n = 582)
Mean age: 59 years, 56%women, 97%German nationality, 18% diabetes mellitus, 20%
CVD
Interventions Intervention group: 2 CME sessions to learn shared decision-making communication
strategies, guideline booklet, paper-based risk calculator, and individual risk summary
sheet for each participant
Comparison group: CME unrelated to CVD prevention
Outcomes Primary outcomes: relative change in global risk at 6 months, patient participant scale
Secondary outcomes: GP prescription behaviour, CV risk status after 6 months
Total analysed at follow-up:
Intervention group: 7 CME groups with 40 practices (n = 460)
Comparison group: 7 CME groups with 41 practices (n = 466)
Follow-up: baseline, after consultation, at 6 months
Study funding sources The study was funded by the German FederalMinistry of Education and Research, grant
No. 01GK0401
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Krones 2008 (Continued)
Notes Baseline imbalances with more diabetics and more participants with prior CVD events
in the comparison group
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) High risk Physicians recruited participants after clus-
ter-randomisation
“physicians were asked to approach all con-
secutive patients who had their cholesterol
levelsmeasured during a period of 4 weeks”
Baseline imbalances between the 2 groups
for diabetes mellitus, secondary preven-
tion, and desire to participate in decision-
making
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Participating family doctors could not be
blinded because of the intervention. Pa-
tients were informed that different kinds of
risk communication and decision support
would be assessed; they were unaware of
their physicians’ group allocation, however.
”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Family doctors provided data on risk fac-
tors to calculate a CVD risk score for each
patient at baseline and at follow-up.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 18% loss to follow-up. Imputed miss-
ing values for individuals missing a single
value to calculate 10-year CVD risk. Large
amount of missing data for shared deci-
sion-making questionnaire (but this out-
come was not included in this systematic
review)
Selective reporting (reporting bias) Low risk All outcomes reported in trial registration
were reported
Other bias Low risk Other sources of bias not identified
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Lopez-Gonzalez 2015
Methods Randomised controlled trial, parallel group (1:1:1)
Participants Public sector workers from Spain recruited from an annual work health assessment
Inclusion criteria: additional criteria not reported
Exclusion criteria: unable to understand medical advice, lacking permanent work con-
tract, failed to attend the 2 scheduled visits - separated by 1 year
Total randomised 3153 participants: (n = 1051 intervention group receiving 10-year
Framingham risk score, n = 1045 intervention group receiving heart age, n = 1057
comparison group with conventional medical advice)
Mean age: 46 (7.1) years, 52% women
Interventions Intervention groups:
• Group 1: Framingham 10-year risk score re-calibrated to Spanish population +
conventional medical advice
• Group 2: heart age + conventional medical advice. Groups 1 and 2 were
combined for these analyses since both of these groups received a CVD risk score. Risk
estimates were provided by research assistants trained in risk communication
Comparison group: conventional medical advice without provision of a CVD risk score
Outcomes Outcomes reported: BMI, fasting lipids (total cholesterol, triglycerides, HDL, glucose)
, blood pressure, self-reported smoking, self-reported physical activity. Results for inter-
vention groups 1 and 2 were combined for the analyses reported in this systematic review
Number analysed at follow-up 2844 participants: (n = 955 in group 1, n = 914 in group
2, n = 975 in comparison group)
Follow-up: 1 year
Study funding sources Not reported by authors
Notes Few details provided within the study about themeans used for calculating and providing
the CVD risk score
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Using a computerized random number
generator, the 3153 participants were ran-
domly allocated to one of the three study
groups”
However, marked differences in baseline
characteristics raises questions about the
adequacy of randomisation
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “[S]ingle blind design”
67Risk scoring for the primary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lopez-Gonzalez 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of outcome assessment unclear
Incomplete outcome data (attrition bias)
All outcomes
Low risk 10% loss to follow-up
Selective reporting (reporting bias) Unclear risk No protocol available for review
Other bias Unclear risk Risk calculator developed by Unilever. Un-
clear if this model was validated
Lowensteyn 1998
Methods Cluster-randomised controlled trial, parallel group (2:1)
Participants Adults age 30-74 years without CVD, recruited from 253 physician practices in Quebec,
Canada
Unit of randomisation: continuing medical education (CME) meeting
Inclusion and exclusion criteria: additional criteria not reported
Total randomised at baseline: 24 CME meetings with 253 physicians and 958 enrolled
participants
Intervention group: 16CMEmeetings with 170 physicians and 782 enrolled participants
Comparison group: 8 CME meetings with 83 comparison group physicians and 176
enrolled participants
Mean age 51 years, 35% women
Interventions Intervention group: physicians received coronary risk profile (8-year CHD risk and car-
diovascular age) for their participants within 10 working days after the baseline partici-
pant assessment
Comparison group: usual care, received coronary risk profile at completion of study
(after outcomes collected)
Outcomes Primary outcome: likelihood of high-risk vs low-risk participants being seen at 3-month
follow-up
Secondary outcome: CVD risk factor levels, 8-year CHD risk
Total analysed at follow-up: 291 participants (n = 202 intervention and n = 89 compar-
ison)
Follow-up: 3 months
Study funding sources Grant-in-aid from Merck Frosst Canada, Inc
Notes Authors of the study had a financial stake in the computer risk model used for risk
prediction
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Lowensteyn 1998 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not re-
ported by authors, but participants “se-
lected” by physicians after randomisation
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of outcome assessment unclear but
likely clinicians who were not blinded
Incomplete outcome data (attrition bias)
All outcomes
High risk High loss to follow-up rate. Approximately
70% of participants (667/958) were not re-
assessed at follow-up and not included in
analyses. Differential loss to follow-up in
intervention group
Selective reporting (reporting bias) Unclear risk No protocol available for review
Other bias High risk Study funded by Merck. 4 authors had fi-
nancial stake in the prediction tool that was
developed
Mann 2010
Methods Randomised controlled trial, parallel group (1:1)
Participants Adult primary care patients with a diagnosis of diabetes mellitus; English- or Spanish-
speaking from urban New York
Exclusion criteria: additional criteria not reported
Total randomised at baseline 150 participants (n = 80 intervention, n = 70 comparison)
Mean age: 58 years (SD 11.5), women 73%, 89% Black or Latino, 100% diabetes
mellitus
Interventions The intervention consisted of a provider-led discussion of the participant’s risk using the
Statin Choice tool which provided a 10-year underlying risk category (average ≤ 15%,
elevated = 15%-30%, or high > 30%), a revised risk with statin therapy, and risks of
statin treatment
Comparison group: printed material from the American Diabetes Association on how
to reduce cholesterol through dietary modifications
Outcomes Primary outcomes not specified
Outcomes assessed from surveys: statin knowledge, decision
Total analysed at follow-up - not specified by authors
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Mann 2010 (Continued)
Study funding sources Not reported by authors
Notes There was limited use of the Statin Choice decision support tool by the 46 providers
(mean use 1.7 times)
Adherence outcome poorly reported: “At 3 and 6 months, 70% and 80% of the partici-
pants reported good adherence to statins with no difference between groups.” No further
details provided
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded to
intervention group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-reported outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias High risk Limited use of decision support tool in trial
Montgomery 2000
Methods Cluster-randomised controlled trial, parallel group (1:1:1)
Participants Adults aged 60-79 years with high blood pressure from 27 general practices from UK
Unit of randomisation: general practice
Exclusion criteria: non-ambulatory patients, life-threatening illness, recentmajor surgery
Total randomised at baseline: 27 general practices with 715 participants (n = 269 com-
puterised decision support + risk chart, n = 264 risk chart, n = 182 usual care)
Mean age: 71 years, 54% women, 11% diabetes mellitus, 11% history of MI or stroke
Interventions Intervention groups:
• Group 1: computer-based clinical decision support + CVD risk chart
• Group 2: CVD risk chart.
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Montgomery 2000 (Continued)
In the “CVD risk chart” group, CVD risk information was manually extracted by nurses
and included in the medical record
Comparison group: usual care
Outcomes Primary outcome: percentage of participants in each group with 5-year CVD risk ≥
10%
Secondary outcomes: systolic and diastolic blood pressure, CVD drug prescription
Total analysed at 12 months follow-up 531 participants (n = 202 computerised decision
support + risk chart, n = 199 risk chart, n = 1 usual care)
Follow-up: 12 months
Study funding sources NHSWales Office of Research and Development, grant number RC016, NHS Research
and Development Primary Care Career Scientist Award
Notes For the analyses in this systematic review, participants randomised to both intervention
groups were combined (both these groups received CVD risk scores) and were compared
with usual care (did not receive systematic provision of a CVD risk score)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was performed with a ta-
ble of random numbers by a researcher not
involved in the study and who was blind to
the identity of the practices.”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Because of the nature of the study, neither
the doctors andnurses nor the patientswere
blind to their study group.”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were unblinded clinic
staff
Incomplete outcome data (attrition bias)
All outcomes
High risk 41% of participants had missing choles-
terol data
Selective reporting (reporting bias) Unclear risk Protocol not available for review
Other bias Low risk Other sources of bias not identified
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Montgomery 2003
Methods Randomised controlled trial, factorial design (2 × 2)
Participants Adults aged 32-80 years with newly diagnosed hypertension from South Western UK
Exclusion criteria: severe hypertension requiring immediate treatment, secondary hyper-
tension, hypertension associated with pregnancy, dementia
Total randomised: n = 217 participants (n = 51 to decision aid + video/leaflet, n = 52
decision aid only, n = 55 video/leaflet only, n = 59 usual care)
Mean age: 59 years, 49% women
Interventions Intervention group: factorial design with decision support tool ± instructional video and
leaflet about cardiovascular risk factors
Comparison group: usual care
Participants randomised to the decision support tool received a CVD risk score
Outcomes Primary outcome: decisional conflict scale
Secondary outcomes: subscales of decision conflict scale related to uncertainty and de-
cision quality; intention to start treatment; anxiety; knowledge; treatment decision
Total analysed at follow-up for primary outcome: n = 212 (n = 50 decision aid + video/
leaflet, n = 50 decision aid only, n = 54 video/leaflet only, n = 58 usual care)
Total analysed at 3-month follow-up for secondary outcomes: n = 199 (n = 48 decision
aid + video/leaflet, n = 48 decision aid only, n = 51 video/leaflet only, n = 52 usual care)
Follow-up: 3 months for initial study
3-year extended follow-up reported in a subsequent study published by Emmert et al.
2005
Total analysed at 3 years follow-up: n = 188 (n = 87 decision aid, n = 101 no decision
aid)
Study funding sources Medical ResearchCouncil, National Health Service Primary Care Career Scientist Award
Notes For the analyses in this systematic review, all participants randomised to the decision
support tool, which provided a CVD risk score, were combined and compared with
participants not randomised to the decision support tool
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The allocation schedule was computer-
generated by an individual not involved in
the study and executed by one of the au-
thors (AM), to whom the allocation was
concealed in advance by the nature of the
minimisation procedure.”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Given the nature of the interventions,
there was no masking of participants or the
researcher administering the interventions
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Montgomery 2003 (Continued)
(AM).”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Likewise, blinding was not possible for
outcome assessment, as this was conducted
principally through self-completion ques-
tionnaires.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk < 10% loss to follow-up; ITT analysis per-
formed
Selective reporting (reporting bias) Unclear risk Protocol document not available
Other bias Low risk Other sources of bias not identified
Peiris 2015
Methods Cluster-randomised controlled trial, parallel group (1:1)
Participants Patients from primary care practices in Sydney, Australia and New Zealand who had
attended the service 3 or more times in a 24 month period and at least once in a 6 month
period
Unit of randomisation: primary care practice
Specific inclusion and exclusion criteria not reported
Total randomised at baseline: 61 primary care practices with 38,725 participants (n =
31 practices with 19,385 participants in intervention group; n = 30 practices with 19,
340 participants in comparison group)
Total “high-risk” participants randomised at baseline: 10,308 participants (n = 5392
intervention group, n = 4916 comparison group)
Mean age: 61 years, 58% women, 17% diabetes mellitus, 13% CVD
Interventions Intervention group: clinical decision support software, audit and feedback tools, guide-
line dissemination and staff training. Clinical decision support software presented 5-year
CVD risk information and heart age
Comparison group: usual care
Outcomes Primary outcome: proportion of participants who received “appropriate” screening of
CVD risk factors by end of study; proportion of high-risk participants receiving recom-
mended medication prescription
Secondary outcomes: CV risk factor levels, incident CVD events, escalation of drug
prescriptions in high-risk people
Total analysed at follow-up: 60 primary care practices (n = 30 intervention group, n =
30 comparison group). 1 practice withdrew from the intervention group shortly after
randomisation, but this did not affect number of total participants
Total ’high-risk’ participants analysed at follow-up: 10,181 participants (n = 5335 inter-
vention group, n = 4846 comparison group)
Median follow-up: 17 months
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Peiris 2015 (Continued)
Study funding sources The National Health and Medical Research Council of Australia and the New South
Wales Department of Health
Notes Authors report higher than anticipated intracluster coefficients in their analyses
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Permuted block randomisation was cen-
trally performed using a web-based form.”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Participating services did not make any
special provisions to advertise the trial and
their allocation status to patients; however,
it would be reasonable to assume that when
the tools were used during a consultation,
patients may have been aware of the inter-
vention.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “[O]utcome analyses were conducted
blinded to randomised allocation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis used
Selective reporting (reporting bias) Low risk All outcomes from protocol and trial regis-
tration were reported
Other bias Unclear risk Marked baseline imbalances between the
groups that were not statistically significant
due to larger than expected intracluster co-
efficients (ICC)
Perestelo-Perez 2016
Methods Cluster-randomised trial, parallel group (1:1)
Participants Patients from primary care centres in Tenerife, Spain
Unit of randomisation: clinician
Study aim: to assess the efficacy of the statin choice decision aid compared to usual
primary care in Spanish participants with type 2 diabetes mellitus
Inclusion criteria: 18 years of age or older, type 2 diabetes mellitus, Spanish language-
speaking, and no cognitive or sensorial impairments
Exclusion criteria: no additional criteria listed
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Perestelo-Perez 2016 (Continued)
Total randomised at baseline: 29 physicians with 168 participants (n = 15 physicians
with 86 participants in intervention group, n = 14 physicians with 82 participants in the
comparison group)
Mean age (SD): intervention 63.9 years (9.7) and control 59.6 years (12.3); sex: inter-
vention 41% women, control 34% women; 100% diabetes mellitus; 10-year risk cat-
egory: intervention 37.6% high risk, control 25.3% high risk; ischaemic heart disease:
intervention 24%, control 18%
Interventions Intervention group: statin choice decision aid about the use of statins. The decision aid
consisted of a 3-page pamphlet listing: CVD risk factors, 10-year CVD risk based on the
UKPDS risk engine presented in pictographs with and without statins, list of adverse
effects of statins and their incidence
Comparison group: usual care
Outcomes Primary and secondary outcomes not specified
Outcomes reported: statin knowledge, risk perception, decisional conflict scale (DCS)
, satisfaction with decision-making, problem areas in diabetes questionnaire, self-report
of statin taking, self-report of adherence at 3 months (Morisky), consultation time by
physician
Follow-up: immediately after encounter and at 3 months
Total analysed at 3 months follow-up: 131 participants (n = 67 intervention, n = 64
comparison)
Study funding sources Spanish Ministry of Health, Social Services and Equality (grant number: EC10-005)
Notes Analyses of outcomes accounted for clustering, but no power calculations performed.
Significant baseline differences between intervention and control groups. At 3 months,
20%of participantswere lost to follow-up (but 42%missing data for adherence outcome)
. ITT analysis not performed
Study funded by SpanishMinistry ofHealth, Social Services andEquality (grant number:
EC10-005)
No conflicts of interest reported
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Physicians who consented to participate
were randomised to intervention or usual
care by means of a computer-generated list.
”
Allocation concealment (selection bias) High risk Participants were recruited to the trial by
clinicians and this occurred after clinicians
were randomised
Significant baseline difference between the
2 treatment groups suggests high risk of se-
lection bias. Participants in the interven-
tion group were significantly older, had
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Perestelo-Perez 2016 (Continued)
more hypertension, andweremore likely to
be prescribed statins at baseline than par-
ticipants in the control group
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and clinicians not blinded to
intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported by authors but all outcomes
were measured by participant self-report
Incomplete outcome data (attrition bias)
All outcomes
High risk 34/168 (20%) participants were lost to fol-
low-up. Adherence data were missing for
71/168 (42%) participants. ITT analysis
not performed
Selective reporting (reporting bias) High risk Per clinical trial registration, the primary
outcome was adherence at 3 months as
measured by Morisky scale, chart abstrac-
tion, and pharmacy records. This was not
reported as a primary outcome by the au-
thors and the latter 2 methods were not
used to measure adherence
Several secondary outcomes not reported:
haemoglobin A1c, lipid profile, health-re-
lated quality of life, consultation time
Other bias High risk Small study bias
Persell 2013
Methods Cluster-randomised controlled trial, parallel group (1:1)
Participants Participants aged 40-79 years from 29 physician panels with a Framingham risk score
of at least 5%, LDL cholesterol level above guideline threshold for drug treatment, and
not prescribed a lipid-lowering medication
Exclusion criteria: coronary heart disease, heart failure, stroke, diabetes mellitus, periph-
eral vascular disease
Total randomised at baseline: 29 physicians with 435 participants (n = 14 physicians
and 218 participants in the intervention group, n = 15 physicians and 217 participants
in the comparison group)
Mean age 60.7 years, 23% women, mean Framingham Risk score (SD): 14.2 (6.7) in
intervention group and 13.8 (6.3) in comparison group
Interventions Intervention group: patients of physicians randomised to the intervention group were
mailed individualised CVD risk messages that described benefits of using a statin (and
controlling hypertension or quitting smoking when relevant)
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Persell 2013 (Continued)
Comparison group: usual care
Outcomes Primary outcome: occurrence of a LDL-cholesterol level that was at least 30mg/dL lower
than prior
Secondary outcome: lipid-lowering drug prescription, aspirin prescription, change in
systolic and diastolic blood pressure, difference in number of antihypertensive medica-
tions prescribed, documentation of quitting smoking
Follow-up: 9 months; but extended to 18 months post hoc
Total analysed in follow-up: same as above
Study funding sources Agency for Healthcare Research and Quality, USA
Notes Primary endpoint at 9 months not met in the original protocol but analyses included a
18-month post hoc analysis that did achieve the primary endpoint
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed using a
random number generator (SAS 9.2, SAS
Institute Inc., Cary, NC) by a researcher
who was not aware of the physicians’ order
in the blocks. Allocation to intervention or
control groups was not revealed until after
randomization was completed.”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All outcomes were assessed by applying
the outcome criteria to patient data auto-
matically collected from EHRs using auto-
mated searches. No human judgment was
involved in outcome assessments.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ITT analysis performed
All included participants analysed but only
38% of intervention and 34% of control
had LDL testing which biases result to null
Selective reporting (reporting bias) Low risk All outcomes from trial registration were
reported
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Persell 2013 (Continued)
Other bias Unclear risk Initial trial follow-up planned for 9
months; extended to 18 months post hoc
Persell 2015
Methods Randomised controlled trial, parallel group (1:1)
Participants 646 men 35 years or older and women 45 years or older, without CVD or diabetes
mellitus, and with a 10-year risk of CHD > 10% in 11 federally qualified health centres
in the USA
Exclusion criteria: diagnosed vascular disease, diabetes mellitus, primary language other
than English or Spanish, primary care clinician discretion
Mean age 60 years, 11% women, 50% African American, 33% non-Hispanic white,
13% Hispanic
Interventions Intervention group: the intervention group received telephone and mailed outreach with
individualisedCVDrisk information and uncontrolled risk factors provided by lay health
workers
Comparison group: usual care
Outcomes Primary outcome: discussion about drug treatment for cholesterol at 6 months, follow-
up LDL-cholesterol level > 30 mg/dL lower than baseline value
Secondary outcome: statin prescription at 6 months, repeat LDL-cholesterol test at 1
year
Follow-up: 1 year
Study funding sources Agency for Healthcare Research and Quality, USA
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “ANorthwestern investigator (SP)whowas
not aware of patients’ identities, stratified
eligible patients by CHC network then
randomly assigned patients in a 1:1 ratio
within each stratum using a random num-
ber generator in SAS9.3 statistical software.
”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded to intervention
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Persell 2015 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Northwestern investigators reviewed these
charts and were blinded to study group as-
signments.”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Pragmatic trial design. Outcomes obtained
as a part of routine care. Only 36% of par-
ticipants had a repeat LDL cholesterol test
after 1 year
Selective reporting (reporting bias) Low risk All outcomes from clinical trial registration
reported. Post hoc outcomes and analyses
delineated in manuscript
Other bias Unclear risk Potential for contamination bias since ran-
domisation occurred at the level of partici-
pant
Price 2011
Methods Randomised controlled trial, 2 × 2 factorial design
Participants Adults at increasedCVDrisk (10-year Framingham risk≥ 20%) recruited from4 general
practices in Oxfordshire, UK
Exclusion criteria: prevalent cardiovascular disease (MI, stroke, TIA, prior revascularisa-
tion), physical disability or condition reducing the ability to walk
Total randomised at baseline 194 (n = 99 to personalised 10-year CVD risk estimate, n
= 95 to risk factor levels only)
Mean age: 62 years, 33% women, 98% white, 19% diabetes mellitus
Interventions Participants were randomised in a 2 × 2 factorial design to receive: either a personalised
10-year cardiovascular disease risk estimate from a decision support tool or were told
their blood pressure, total cholesterol, and fasting glucose values and if they were elevated
per guidelines. Participants were simultaneously randomised to receive or not receive a
brief lifestyle intervention by slideshow targeting physical activity, diet, and smoking
Results presented for decision support tool compared with no decision support
Outcomes Primary outcome: physical activity at 1 month, cardiovascular risk factor levels at 1
month
Secondary outcomes: BMI, cholesterol levels, fasting glucose, anxiety, quality of life, self-
regulation, worry about heart attack risk, intention to increase physical activity, recall of
risk information
Total analysed at follow-up 185 (n = 94 in personalised 10-year CVD risk group, n = 91
in risk factor levels only group)
Follow-up: 1 month
Study funding sources Diabetes Trials Unit Fellowship, Insulin Dependent Diabetes Trust
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Price 2011 (Continued)
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computerized randomization was used to
allocate participants and was performed in-
ternally.”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded.
“One research fellow remained unblinded
in order to deliver the intervention.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Research nurses who inputted data were
blind to intervention allocation.”
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT analysis but “valid baseline and follow-
up accelerometer data were only available
for 125 participants (64%)”
Selective reporting (reporting bias) Low risk Outcomes reported as outlined in the pro-
tocol document
Other bias Low risk Other sources of bias not identified
Sheridan 2006
Methods Randomised controlled trial, parallel group (1:1)
Participants Men and women aged 35-75 years without CVD in North Carolina, USA
Exclusion criteria: prior history of CVD, serious chronic medical condition that would
limit their candidacy for screening (i.e. chronic renal failure, cirrhosis of the liver, HIV,
current non-skin cancer), people who had participated in a previous quality improvement
initiative
Total randomised 87 adults (n = 49 to intervention group, n = 38 to comparison group)
Mean age 53 years, 59% women, 73% white, 23% African American, 8% diabetes
mellitus
Interventions Intervention group: participants provided with most-recent risk factor information and
instructed to review a computerised decision support tool prior to clinic visit. The
decision support tool provided individualised CHD risk, the pros and cons of pertinent
risk-reducing therapies, and the amount of risk reduction achievable after 1 or more
therapeutic interventions
Comparison group: provided a list of their cardiovascular risk factors
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Sheridan 2006 (Continued)
Outcomes Primary outcome: discussion with provider about CHD risk reduction, plans for CHD
risk reduction
Secondary outcomes: knowledge about CHD prevention, perception of CHD risk, in-
terest in participating in decision-making, accuracy of risk perception, self-perceived
barriers to risk reduction
Total analysed 75 adults (n = 41 in intervention group, n = 34 in comparison group)
Study funding sources Internal funding from Department of Medicine at University of North Carolina
Notes 2 authors received consulting and licensing fees from Bayer, Inc. 1 author received
honoraria and consulting fees from Merck, Pfizer, and Glaxo Smith Kline
Small pilot study
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”We used a computerized random number
generator to randomize patients to receive
either the Heart to Heart decision aid or
a list of their CHD risk factors that they
could present to their doctor.“
Baseline imbalances in key parameters such
as CHD risk factors, baseline CHD risk,
and interest in prevention strategies
Allocation concealment (selection bias) Low risk ”Intervention assignments were sealed in
security envelopes until after subjects
agreed to participate in the study. The re-
search assistant then broke the seal to de-
termine intervention assignment.“
Blinding of participants and personnel
(performance bias)
All outcomes
High risk ”We blinded patients to the purpose of our
study by telling them only that they were
participating in a study about “prevention
of CHD.” Doctors were not blinded and
saw patients in both the decision aid and
control group
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of outcome assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 12 participants excluded postrandomisa-
tion (8 because they did not meet eligibility
criteria); ITT analysis not performed
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Sheridan 2006 (Continued)
Selective reporting (reporting bias) Low risk All outcomes from trial registration were
reported
Other bias High risk Small study bias with key baseline imbal-
ances in spite of randomisation
Possible contamination bias as same doc-
tors saw participants who were in interven-
tion and control groups
Sheridan 2011
Methods Randomised controlled trial, parallel group (1:1)
Participants Men and women aged 40-79 years with no history of CVD or diabetes mellitus, at
moderate or high-risk based on Framingham risk score
Exclusion criteria: serious medical condition that limited life expectancy to less than 5
years, first clinic visit, no cholesterol level checked in 18 months, extreme risk factor
levels (systolic blood pressure > 180 mmHg or total cholesterol > 300 mg/dL)
Total randomised at baseline: 160 participants (n = 81 to intervention group, n = 79 to
comparison group)
Mean age: 63 years, 28% women, 86% white, 10% African American
Interventions Intervention group:
• web-based, computerised decision support tool to promote initiation of effective
CHD prevention strategies prior to clinic visit that included provision of personalised
CVD risk estimate
• series of automated mailed tailored messages to promote adherence to
medications at 2, 4, and 6 weeks
Comparison group: usual care
Outcomes Primary outcome: feasibility of subject recruitment, intervention delivery, and measure-
ment of study outcomes
Secondary outcomes: self-reported adherence, global CHD risk, blood pressure, serum
total and HDL cholesterol levels, smoking status, aspirin use, intent to start CHD
reducing medication, self-efficacy for CHD risk reduction
Total analysed: 154 participants (n = 77 intervention group, n = 77 comparison group)
Follow-up: 3 months
Study funding sources NationalHeart, Lung, andBlood Institute, USA;National Cancer Institute, USA; Amer-
ican Heart Association
Notes Feasibility study, no power calculation
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Sheridan 2011 (Continued)
Random sequence generation (selection
bias)
Unclear risk Method for sequence generation not re-
ported. Baseline imbalances between inter-
vention and control noted
Allocation concealment (selection bias) Unclear risk “Patients were randomised by study staff
who accessed an online randomised sched-
ule.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Physicians were not blinded and saw pa-
tients in both the intervention and control
group.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method of outcome assessment not re-
ported
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The study lost 6 patient participants dur-
ing follow-up, resulting in a 96% follow up
rate.”
Selective reporting (reporting bias) Low risk All outcomes reported in trial registration
reported
Other bias High risk “[P]hysicians saw patients in both the in-
tervention and control groups, which may
have resulted in contamination between
study groups.”
Soureti 2011
Methods Randomised controlled trial, parallel group (1:1:1:1)
Participants Men and women age 30-60 years with obesity (BMI ≥ 29 kg/m²)
Exclusion criteria: diagnosis of a heart condition or cancer, being pregnant
Total randomised at baseline 781 participants (n = 197 to CVD risk message, n = 194
to CVD risk message + automated health planning tool, n = 195 to health planning tool
alone, n = 195 to educational information (control)
Mean age: 47 years. Few baseline characteristics presented
Interventions Participants randomised to 1 of 3 intervention groups: a CVD risk message, CVD risk
message + automated health planning tool, health planning tool alone
Comparison group: educational information about diet low in saturated fats without
CVD risk message or planning tool
For this systematic review, data for participants in the 2 CVD risk message groups were
combined and compared with participants in the 2 groups that did not receive a CVD
risk message (n = 392 intervention group, n = 389 comparison group)
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Soureti 2011 (Continued)
Outcomes Primary outcome: saturated fat intake as measured by self-reported food-frequency ques-
tionnaire, 2-item scale to evaluate consumption of low-fat foods
Secondary outcomes: CVD risk perception, intention to reduce saturated fat intake, self-
efficacy, planning and outcome expectancies
Total analysed in follow-up 581 participants (n = 141 in CVD risk message group, n
= 137 in CVD risk message + automated health planning tool, n = 141 in automated
health planning tool alone, n = 141 in educational information (control)
For this systematic review, n = 278 in CVD risk groups, n = 282 in comparison groups
Follow-up: 5 weeks
Study funding sources Unilever funded and created the Heart Age score tested in the study
Notes Internet-based trial with a large amount of missing data
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method of blinding not reported
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes were patient-reported
Incomplete outcome data (attrition bias)
All outcomes
High risk > 20% loss to follow-up; ITT analysis not
performed
Selective reporting (reporting bias) High risk Trial registered retrospectively
Other bias High risk Trial funded by Unilever and multiple au-
thors were employees of Unilever. Heart
Age Calculator software was also propri-
etary of Unilever
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Turner 2012
Methods Randomised controlled trial, parallel group (1:1)
Participants African American adults aged 40-75 years with uncontrolled hypertension
Exclusion criteria: individualswith >40%missed or cancelled clinic appointments during
the past 3 years
Total randomised: 280 participants (n = 136 intervention group, n = 144 comparison
group)
Mean age: 62 years, 65%women, 100% African Americans, 54% diabetes mellitus, 18%
with CAD or equivalent
Interventions Intervention group:
• 3 monthly calls from trained peer coach with well-controlled hypertension
• 2 visits on alternate months with health educator to review a personalised 4-year
heart disease calculator and slide shows about heart disease risks
Comparison group: received written material, brochures, and cookbook from American
Heart Association addressing healthy lifestyle
Outcomes Primary outcome: change in 4-year CHD risk at 6 months
Secondary outcomes: 5 mmHg or greater reduction in SBP at 6months; absolute change
in blood pressure
Total analysed for primary outcome: 212 participants (n = 96 intervention group, n =
118 comparison group)
Follow-up: 6 months
Study funding sources Robert Wood Johnson Foundation and the staff of the Finding Answers, Disparities
Research for Change Program; unrestricted
Notes Intervention targeted to individuals with uncontrolled hypertension but mean blood
pressure was 140.5/81.2 mmHg
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “[R]andomised at a 1:1 ratio using random
computer-generated assignments”
Allocation concealment (selection bias) Unclear risk Method of allocation concealment not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “[S]ingle-blinded study;” “All providers
were blinded to the study arm.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The 6-month endpoint blood pressure
was performed by blinded office medical
assistants”
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Turner 2012 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk Greater missing data in the intervention
group
“After 6 months, 94 (69%) intervention
subjects and 118 (82%) control subjects
had 4-year CHD risk assessed”
Selective reporting (reporting bias) Unclear risk Trial registration retrospectively; all out-
comes from trial registration reported
Other bias Unclear risk Unrestricted supplementary funding from
Pfizer, Inc
Vagholkar 2014
Methods Cluster-randomised trial, parallel group (1:1)
Participants People aged 45-69 years without CVD, recruited from 34 general practices in urban
Sydney, Australia
Unit of randomisation: practice
Exclusion criteria: insufficient English skills, cognitively impaired, Aboriginal or Torres
Strait Islander, diagnosed or treated CVD
Total randomised: 34 clusters of 1074 participants (n = 18 practices with 567 participants
in the intervention group, n = 16 practice with 507 participants in the comparison group)
Mean age: 56 years, 58% women, 56% Anglo-Celtic, 12% diabetes mellitus
Interventions Intervention group: physicians received training on the importance of absolute risk as-
sessment and use of a CVD risk calculator; participants received a 20-30 min consulta-
tion that involved calculating cardiovascular risk and providing appropriate management
based on risk level and current guidelines
Comparison group: general health check
Outcomes Primary outcome: antihypertensive medication prescription, lipid-lowering medication
prescription at 12 months
Secondary outcomes: changes in blood pressure and blood lipids; self-reported smoking;
self-reported physical activity levels; diet consumption
Total analysed: 34 clusters of 906 participants (n = 18 practices with 475 participants in
the intervention group; n = 15 practices with 431 participants in the comparison group)
Follow-up: 12 months
Study funding sources National Health and Medical Research Council of Australia
Notes Only 685/1074 (64%) had values available for risk assessment
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Vagholkar 2014 (Continued)
Random sequence generation (selection
bias)
Low risk “A person (U.J.) independent of the inter-
vention and data collection conducted the
allocation using a computer randomization
program.”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel not blinded to intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Research staff collecting practice datawere
blinded to group allocation, as were pa-
tients.”
Incomplete outcome data (attrition bias)
All outcomes
High risk Large amount of missing data. Only 64%
of participants had values available for risk
assessment
Selective reporting (reporting bias) High risk Several outcomes (such as health-related
quality of life) mentioned in trial registry
and protocol were not reported in this re-
port
Other bias Low risk Other sources of bias not identified
Van Steenkiste 2007
Methods Cluster-randomised controlled trial, parallel group (1:1)
Participants People aged 40-75 years without CVD recruited from 45 primary care clinicians
Unit of randomisation: primary care clinician
Additional inclusion and exclusion criteria not reported
Total randomised: 45 primary care clinicians with 623 participants (n = 19 primary care
clinicians with 332 participants in intervention group, n = 26 primary care clinicians
with 291 participants in the comparison group
Mean age: 54 years, 55% women, 100% Dutch, 20% diabetes mellitus
Interventions Intervention group: primary care clinicians trained to use cardiovascular risk in guidelines
and in the use of a clinical decision support tool (paper booklet) provided to participants
prior to clinic visit (2 clinic visits separated by 2 weeks)
Comparison group: educational materials about the guidelines on paper
Outcomes Primary outcome not specified. Outcomes reported: appropriate risk classification, ap-
propriate assessment, appropriate smoking advice, appropriate dietary advice
Secondary outcomes: anxiety, appropriateness of perceived risk, self-reported lifestyle
changes (smoking in past 7 d, phys activity > 2 h, EtOH use, BMI > 30), self-efficacy
regarding lifestyle changes
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Van Steenkiste 2007 (Continued)
Total analysed at 0 weeks: 490 participants (n = 276 intervention group, n = 200 com-
parison group)
Total analysed at 26 weeks: 427 participants (n = 227 intervention group, n = 200
comparison group)
Follow-up: 26 weeks
Study funding sources The Netherlands Organization for Health Research and Development
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer was used for the stratified ran-
domization, which was at practice level to
prevent contamination of the intervention
within group practices.”
Allocation concealment (selection bias) High risk Participant recruitment occurred after clus-
ter-randomisation which increases the risk
of selection bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes assessed by physicians who were
not blinded to intervention
Incomplete outcome data (attrition bias)
All outcomes
High risk > 20% loss to follow-up; ITT analysis not
performed
Selective reporting (reporting bias) Unclear risk Protocol not available for review
Other bias Low risk Other sources of bias not identified
Webster 2010
Methods Randomised controlled trial, parallel group (1:1)
Participants Adult Australian residents with access to the Internet, trial recruitment strategies geared
toward individuals with self-reported hypercholesterolemia
Total randomised: 2099 participants (n = 1062 participants intervention group, n =
1037 participants comparison group)
Mean age: 56 years, 55% women, 12% diabetes mellitus, 9% CHD
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Webster 2010 (Continued)
Interventions Intervention group: individuals assigned to intervention received immediate, fully au-
tomated, personally tailored cholesterol treatment advice based on current Australian
guidelines regarding the need for starting or increasing statin therapy or non-drug inter-
vention strategies
Comparison group: provided with general information about cholesterol management
Outcomes Primary outcome: number of participants reporting starting or increasing lipid-lowering
medication
Secondary outcomes: number of participants who self-reported: a cholesterol level, doc-
tor visit, start of a healthy diet, start of an exercise programme, weight-loss, smoking
cessation, blood pressure check-up
Total analysed: same as above (ITT)
Follow-up: 8 weeks
Study funding sources MBF Australia, Pfizer, National Health and Medical Research Council of Australia Pro-
gram Grant (Grant ID: 571281)
Notes Internet-based study, no human contact
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomizationwas done automatically in
real time by a central computerized service
run by the investigators at The George In-
stitute for International Health.”
Allocation concealment (selection bias) Low risk See above
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Participants were not informed of the pre-
cise randomised comparison being made
and were simply told that they were par-
ticipating in a trial that sought to ‘find out
if advice about cholesterol provided on the
Internet can improve your cholesterolman-
agement.”’
“Investigators were blinded to the alloca-
tion of all individuals throughout the trial.
”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes self-reported by participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk 93% follow-up, ITT analysis performed
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Webster 2010 (Continued)
Selective reporting (reporting bias) Low risk All prespecified outcomes reported
Other bias High risk Outcomes subject to recall bias
Welschen 2012
Methods Randomised controlled trial, parallel group (1:1)
Participants Type-2 diabetics under the age of 75 years newly referred to the Diabetes Care System
West-Friesland, a managed care system in the Netherlands
Exclusion criteria: unable to read/write Dutch, history of stroke/TIA
Total randomised: 262 participants (n = 132 intervention group, n = 130 comparison
group)
Mean age 59 years, 44% women, 100% diabetes mellitus
Interventions Intervention group: received: risk communication intervention from trained diabetes
nurses and dieticians in addition to usual care. Risk communication consisted of: general
explanation about risks of diabetes mellitus, presentation of 10-year absolute CVD risk,
visual/graphical presentation of absolute and relative risk, and explanation of treatment
benefits using a ’positive’ frame
Comparison group: received usual care provided by the diabetes nurses and dieticians of
the Diabetes Care System which consisted of general information about having diabetes
mellitus and education about treatment options and lifestyle modifications
Outcomes Primary outcome: appropriateness of risk perception.
Secondary outcomes: anxiety, generalised worry, illness perception, attitude, intention
to change behaviour, satisfaction with communication
Total analysed: 204 participants (n = 102 intervention group, n = 102 comparison group)
Follow-up: 12 weeks
Study funding sources Dutch Diabetes Research Foundation Grant 2007.13.004
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “All participating patients gave written in-
formed consent and were randomised into
an intervention and a control group by
means of a list drawn up by a computer-
ized randomisation program (version 1.0.
0; Random Allocation Software).”
Allocation concealment (selection bias) Low risk “The manager of the DCS [Diabetes Care
System], who is not involved in the pa-
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Welschen 2012 (Continued)
tients’ care, allocates the patient to one of
the two groups on the basis of the randomi-
sation list.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded to
intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes derived from self-report ques-
tionnaires
Incomplete outcome data (attrition bias)
All outcomes
High risk > 20% loss to follow-up; ITT analysis not
performed
Selective reporting (reporting bias) Low risk All pre-specified outcomes from protocol
were reported
Other bias High risk Potential for contamination because the
same diabetes nurses and dieticians deliv-
ered the risk communication intervention
and usual care
Williams 2006
Methods Randomised controlled trial, parallel group (7:3)
Participants Inclusion criteria: adult smokers who smoked > 5 cigarettes/day
Exclusion criteria: history of psychotic illness, unable to read/speak English, minimum
life expectancy of 18 months
Total randomised: 1006 participants (n = 714 intervention group, n = 292 comparison
group)
Mean age: 46 years, 64% women, 82% white
Interventions Intervention group: multifaceted intervention
• Encouraged to meet at least 4 times with a counsellor (in-person or by phone)
• Encouraged to meet twice with a dietician if LDL cholesterol was elevated
• Provided with a choice of a study physician or 1 of their own to prescribe
medications
Counselors were trained to support participants in making clear and autonomous choices
and goal-setting
Comparison group: received booklets on smoking cessation and healthy diet; also en-
couraged to enrol in a smoking cessation programme and to meet with their physician
Outcomes Primary outcome: 12-month prolonged tobacco abstinence
Secondary outcomes: change in percent calories from fat, LDL-C from baseline to 18
months
Total analysed: same as above (ITT analysis)
Follow-up: 18 months
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Williams 2006 (Continued)
Study funding sources National Institute of Mental Health, USA; National Cancer Institute, USA
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported
Allocation concealment (selection bias) Low risk “The results of a stratified permu-
tated blocked randomization were placed
in numbered double-sealed security en-
velopes.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded to
treatment assignment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Self-reported outcomes
Incomplete outcome data (attrition bias)
All outcomes
High risk 28% loss to follow-up at 18 months; ITT
analysis reported by authors but analyses
appear to be completers analysis for LDL
Selective reporting (reporting bias) Low risk Prespecified outcomes all reported
Other bias Unclear risk Received funding from pharmaceutical in-
dustry
Wister 2007
Methods Randomised controlled trial, parallel group (1:1)
Participants Participants age 45-64 years from the Fraser Health region in British Columbia, Canada
Exclusion criteria: no additional criteria specified
Number of primary prevention participants randomised: 315 participants (n = 157
intervention group, n = 158 comparison group)
Mean age: 56 years, 58% women
Interventions Intervention group: participants and their primary care doctor received a ’report card’
showing the person’s CVD risk profile; also participants received Telehealth lifestyle
counselling by 2 kinesiologists trained in motivational interviewing every 6 months for
approximately 30 min per session
Comparison group: usual care
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Wister 2007 (Continued)
Outcomes Primary outcome: Framingham risk score
Total analysed: same as above (ITT analysis)
Follow-up: 1 year
Study funding sources Canadian Institutes of Health Research, Community Alliance for Health Research Pro-
gram, project 43267
Notes This study included participants eligible for either primary or secondary prevention but
randomised and analysed these 2 groups separately. For this systematic review, we report
on the 315 participants in the primary prevention group
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The study statistician then randomly as-
signed the participants to the intervention
or control study arm according to com-
puter-generated random numbers.”
Allocation concealment (selection bias) Unclear risk “The research coordinator received the as-
signment codes in envelopes, which were
concealed from all members of the research
team and were not opened by the coordi-
nator until the point of randomization.”
Not reported if sealed or opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel not blinded to intervention but
“all data were collected without patients’
knowledge of group allocation.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The outcome assessors were blinded to
group allocation …”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No major loss to follow-up. ITT analysis
with multiple imputation of missing data
performed
Selective reporting (reporting bias) Unclear risk No protocol document available for review
Other bias Unclear risk Potential for contamination bias but sensi-
tivity analysis removing analysis of all par-
ticipants who shared a physician did not
result in change in point estimates
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Zullig 2014
Methods Randomised controlled trial, parallel group (1:1)
Participants Adults with CVD or a CVD-risk equivalent condition, at least 1 modifiable risk factor
(e.g. hypertension or active smoking)
Exclusion criteria: patients with metastatic cancer, dementia, psychosis, or end-stage
renal disease; no Internet access; nursing care; unable to read English; heart transplant;
hospitalised for a cardiac-related illness in the previous 3 months
Total randomised: 96 participants (n = 47 intervention group. n = 49 comparison group)
Mean age: 63 years, 68% women, 62% white, 32% African American, 29% diabetes
mellitus
Interventions Intervention group: participants were presented a web-based decision support tool that
calculated their CVD risk based on the Framingham risk score and in subsequent on-
line encounters could select modules with evidence-based recommendations regarding
healthy lifestyle behaviours (medication adherence, diet, risk factor knowledge, smoking
cessation)
Comparison group: usual care, received general printed educational CVD information
Outcomes Outcomes reported: mean differences in 10-year Framingham risk score, BMI, smoking
status, systolic blood pressure, and self-reported medication adherence
Total analysed: not reported
Follow-up: 3 months
Study funding sources Informed Medical Decisions Foundation, grant number 0170-1
Notes -
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of random sequence generation
not reported but authors report baseline
differences between participants, so this
may be high risk of bias
Allocation concealment (selection bias) Unclear risk “Randomization assignments were placed
in sealed, consecutively numbered en-
velopes.”
Not reported if envelopes were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded to the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Unclear who assessed 3 month follow-up
visit outcomes. Medication use was self-re-
ported
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Zullig 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Outcome data were not clearly reported in-
cluding number of participants contribut-
ing to data
Selective reporting (reporting bias) Unclear risk Protocol document not available
Other bias Unclear risk Small study bias
ATP: Adult Treatment Panel, of the National Cholesterol Education Program; BMI: body mass index; CAD: coronary artery disease;
CDSS: computerised clinical decision support; CHD: coronary heart disease; CME: continuing medical education; CVD: cardio-
vascular disease; FRS: Framingham risk score; GHQ: general health questionnaire; HTN: hypertension; ITT: intention-to-treat;
LDL: low-density lipoprotein; MI: myocardial infarction; SBP: systolic blood pressure; TIA: transient ischaemic attack.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ajay 2014 Risk score not part of the intervention
Allen 2011 Risk score not part of the intervention
Avis 1989 Risk score not part of the intervention (health risk appraisal)
Baruth 2011 Risk score not part of the intervention
Berra 2007 Risk score not part of the intervention
Bjarnason-Wehrens 2013 Risk score not part of the intervention
Black 2014 Risk score not part of the intervention
Botija-Yague 2007 Risk score not part of the intervention
Branda 2013 Risk intervention used in both groups
Brett 2012 Risk score used in both groups
Bruckert 2008 Risk score not part of the intervention
Carrington 2012 Risk score not part of the intervention
CARRS 2012 Risk score not part of the intervention
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(Continued)
Carter 2009 Risk score not part of the intervention
Carter 2015 Not primary prevention
Chow 2009 Risk score not part of the intervention
Claes 2007 Risk score used in both groups
Cleveringa 2008 Not primary prevention
Cochrane 2012 Risk score not part of the intervention
Colwell 2011 Risk score not part of the intervention
Daniels 2012 Risk score not part of the intervention
Deales 2014 Risk score not part of the intervention
Dresser 2009 Risk score not part of the intervention
Edwards 2006 Clinical vignettes/hypothetical patients
El Fakiri 2008 Risk score not part of the intervention
Evans 2010 Risk score used in both groups
Fabregas 2014 Risk score not part of the intervention
Fretheim 2006 Risk score not part of the intervention
Freund 2015 Not RCT or quasi-RCT
Gill 2009 Risk score not part of the intervention
Gomez-Marcos 2006 Risk score not part of the intervention
Green 2014 Risk score used in both groups
Harmsen 2014 Risk score used in both groups
Holbrook 2011 Risk score not part of the intervention
Hormigo-Pozo 2009 Risk score not part of the intervention
Huntink 2013 Risk score not part of the intervention
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(Continued)
Ishani 2011 Risk score not part of the intervention
Jacobs 2011 Risk score used in both groups
Jennings 2006 Risk score not part of the intervention
Jones 2009 Not primary prevention
Kaczorowski 2011 Risk score not part of the intervention
Ketola 2001 Not primary prevention
Keyserling 2014 Risk score used in both groups
Kullo 2016 Risk score used in both groups
Laan 2012 Not RCT or quasi-RCT
Lalonde 2004 Not RCT or quasi-RCT
Lalonde 2006 Risk score used in both groups
Lauritzen 2008 Risk score not part of the intervention
Liddy 2015 Risk score not part of the intervention
Lindholm 1995 Risk score not part of the intervention
Ma 2009 Risk score not part of the intervention
Mendis 2010 Risk score not part of the intervention
Mills 2010 Risk score not part of the intervention
Mortsiefer 2015 Risk score not part of the intervention
NCT01134458 Not primary prevention
NCT01979471 Not primary prevention
Nebieridze 2011 Risk score used in both groups
Paterson 2002 Not RCT or quasi-RCT
Pignone 2004 Not RCT or quasi-RCT
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(Continued)
Powers 2011 Not primary prevention
Qureshi 2012 Risk score used in both groups
Reid 1995 Risk score not part of the intervention
Rodriguez-Salceda 2010 Risk score used in both groups
Selvaraj 2012 Risk score not part of the intervention
Sheridan 2012 Risk score used in both groups
Skinner 2011 Risk score not part of the intervention
Smith 2008 Risk score not part of the intervention
Soureti 2010 Risk score used in both groups
Stewart 2012 Risk score not part of the intervention
Thomsen 2001 Not RCT or quasi-RCT
Vaidya 2012 Not RCT or quasi-RCT
Van Breukelen-van der Stoep 2014 Not RCT or quasi-RCT
Van den Brekel-Dijkstra 2016 Not RCT or quasi-RCT
Van Limpt 2011 Not primary prevention
Waldron 2010 Risk score used in both groups
Weymiller 2007 Not primary prevention
Zamora 2013 Not primary prevention
Zamora 2015 Not primary prevention
Zhu 2013 Not RCT or quasi-RCT
RCT: randomised controlled trial.
98Risk scoring for the primary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of studies awaiting assessment [ordered by study ID]
Adamson 2013
Methods Randomised controlled trial, parallel group (1:1)
Participants 31 participants attending a specialist diabetes clinic appointment at the Oxford Centre for Diabetes
Mean age: 51 years, 55% women, 100% diabetes mellitus
Interventions Intervention group: received a facilitated discussion based on 10-year coronary heart disease and stroke risk estimate
generated by the UKPDS Risk engine
Control group: received routine discussion of CVD risk factors
Outcomes Participant satisfaction, measured by questionnaire and semi-structured interviews
Notes Abstract only, full report not published
Gryn 2012
Methods Randomised controlled trial, parallel group (1:1)
Participants 78 individuals with hypertension aged 30-84 years
Exclusion criteria: no prior MI, stroke, heart failure, or pregnancy
Mean age 62 years, 55% women, 17% diabetes mellitus
Interventions Intervention group: received information on their personalised estimated risk of heart disease and stroke and education
about the utility of effective blood pressure management in decreasing their risk estimate
Control group: usual care
Outcomes Primary outcome: adherence at baseline, 3, 6, and 12 months measured by pill counting and electronic pill bottles
Secondary outcomes: blood pressure, self-perception of cardiovascular and stroke risk, perceived benefit of treatment
Notes Published abstract and scientific poster reviewed. Manuscript still in preparation
Roach 2012
Methods Randomised controlled trial, parallel group (1:1)
Participants 144 type-2 diabetics from 4 urban primary care clinics
Interventions Intervention group: randomised to a Spanish-language, tablet computer-basedCVDrisk communication intervention
incorporating the individual’s unique 10-year CVD risk information
Comparison group: usual care
Outcomes CVD risk discussion during clinic visit, medication change
Notes Published abstract reviewed. Manuscript in preparation
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CVD: cardiovascular disease; MI: myocardial infarction; UKPDS: United Kingdom Prospective Diabetes Study.
Characteristics of ongoing studies [ordered by study ID]
Badenbroek 2014
Trial name or title The INTEGRATE study
Methods Stepped-wedge randomised controlled trial
Participants All eligible patients 45-70 years of age from 40 general practices in the Netherlands with electronic medical
records
Interventions The intervention is the Personalized Prevention Approach for CardioMetabolic Risk (PPA CMR). An online
risk estimation tool based on the FINDRISK score is used to screen for participants with increased CVD risk.
Participants with a FINDRISK score above risk threshold are offered additional measurements by their GP.
In clinic, a GP uses SCORE to assess 10-year CVD risk and then provides participants with increased risk
with tailored lifestyle advice and/or medication
Control group: wailting list control; do not receive risk score nor lifestyle advice; recieve intervention at 1
year
Outcomes Primary outcomes: number of newly detected participants with CVD; change in individual risk factors (smok-
ing, physical inactivity, obesity, unhealthy diet, blood pressure, cholesterol levels); expected new participants
with CVD and mortality at 5, 10, 20 years; cost-effectiveness; non-participation and compliance
Secondary outcomes: difference in primary outcome at 5 years; willingness to change lifestyle; change in
health status
Starting date 1 April 2014
Contact information Professor N. J. de Wit Julius Health Centre UMC Utrecht Huispost Str. 6.131 PO Box 85500 3508 GA
Utrecht Netherlands N.J.deWit@umcutrecht.nl
Notes www.integrateproject.nl
NTR4277, the Netherlands National Trial Register
Ijkema 2014
Trial name or title Risk Or Benefit IN Screening for CArdiovascular disease (ROBINSCA) study
Methods Population-based randomised screening trial, parallel group (1:1:1)
Participants 39,000 participants at increased risk for CVD
Interventions Comparison of 3 cardiovascular screening strategies: classic risk screening based on the Systematic COronary
Risk Evaluation (SCORE) model; screening for coronary artery calcium using computed tomography; usual
care
All groups will receive written general lifestyle advice. Individuals at increased risk for CVD based on classic
risk assessment or coronary calcium will be referred to general practitioner for lifestyle advice or medical
therapy
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Ijkema 2014 (Continued)
Outcomes Primary outcome: cumulative 5-year fatal and non-fatal coronary heart disease
Secondary outcomes: sensitivity of the screening tests, favorable and unfavorable effects of screening, cost-
effectiveness
Starting date First quarter 2014
Contact information H.J. de Koning, Department of Public Health, Erasmus MC, University Medical Center Rotterdam, PO Box
2040, 3000 CA Rotterdam, The Netherlands
h.dekoning@erasmusmc.nl.
Notes www.robinsca.nl
Maindal 2014
Trial name or title The CORE-trial: a pragmatic randomized controlled trial in primary care investigating effectiveness and cost-
effectiveness of the Check Your Health Preventive Programme offered population-wide to 30-49 years
Methods Pragmatic household-cluster-randomised trial
Participants 10,505 participants aged 30-49 years from 35 practices within central Denmark
Interventions The intervention consists of a preventive health check that consists of a health examination and individual
risk profile (Heart-SCORE model) during a single office visit. Follow-up visits are stratified by risk profile to
a health promoting consultation, behavioural programme, or no follow-up
Comparison group: standard prevention and treatment strategy
Outcomes Primary outcomes: 10-year risk of fatal CVD, physical activity (self-report and cardiorespiratory fitness),
health-related quality of life, functional capacity (affiliation to the labour market and sick leave > 3 weeks)
Secondary outcomes: cost-effectiveness as measured by life-years gained, direct costs, and total health cost
Starting date May 2013; anticipated completion April 2017
Contact information Annelli Sandbæk, PhD Professor, Department of Public Health, University of Aarhus;
annelli.sandbaek@alm.au.dk
Helle T Maindal, PhD, Associate Professor, Department of Public Health, University of Aarhus;
htm@ph.au.dk
Notes ClinicalTrials.gov ID: NCT02028195
NCT00694239
Trial name or title Risk Assessment and Treat Compliance in Hypertension Education Trial (RATCHET)
Methods Randomised controlled trial, parallel group (1:1)
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NCT00694239 (Continued)
Participants Adults aged 30-84 years
Inclusion criteria: essential hypertension (new diagnosis or established diagnosis) meeting criteria for phar-
macologic therapy as defined by current guidelines
Exclusion criteria: lack of written informed consent, previous myocardial infarction, previous stroke, con-
gestive heart failure, stage 3 or greater chronic kidney disease, pregnancy, use of medication bubble/blister
package
Interventions Intervention group: knowledge of cardiovascular risk assessment plus standard care
Control group: standard/usual care
Outcomes Primary outcome: medication compliance
Secondary outcomes: patient perception of cardiovascular risk, pilot feasibility study, blood pressure, choles-
terol level, Framingham risk score
Follow-up: 1 year
Starting date May 2007
Contact information George Dresser
University of Western Ontario, Canada
LHSC Victoria Hospital, Rm E6-302
519.685.8500 ext.33342
George.Dresser@lhsc.on.ca
Notes Anticipated completion date March 2011 but no results posted yet
NCT02096887
Trial name or title Effect of Patient Education on Compliance and Cardiovascular Risk Parameters (FAILAKA)
Methods Cluster-randomised controlled trial, parallel group (1:1)
Participants Adults aged 30-70 years
Inclusion criteria:
1. Participants with 1 or more CVD risk factors will be consecutively enrolled, smokers and obese
participants should have an additional risk factors
2. The risk factors are based on Framingham risk score calculator and include smoking, high blood
pressure, high blood cholesterol, diabetes mellitus and being overweight or obese
3. All participants must be adults (30-70 years of age) who give informed consent
4. All participants should be of Kuwaity nationality, literate and fluent in either Arabic or English
5. Participants are likely to be available for a 1 year follow-up
Exclusion criteria:
1. People with mental disability or severe psychiatric disorder who are unable to provide informed
consent or participate in educational activities
2. People with severe visual or hearing disability that will prevent participation in the educational activity
3. People < 30 years or > 70 years of age
4. Illiterate people
5. Non-Kuwaiti nationals
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NCT02096887 (Continued)
6. People who are not permanently resident in Kuwait
7. People who refuse to provide the informed consent
Interventions Intervention group: participants attending clinics randomised to structured patient education will receive
education targeting their risk factors and receive information about evidence-based targets. Physician in
education clinics will also calculate Framingham risk score and provide a booklet entitled, ’Know your
numbers’
Control group: usual care
Outcomes Primary outcome: cardiovascular risk factor control (HbA1c, blood pressure, LDL-cholesterol, body mass
index, and smoking cessation)
Medication compliance: assessed by Morisky scale
Starting date June 2014
Contact information Dr. Samia Almusallam
Director of the Family Medicine residency programme
Kuwait Institute for Medical Specialization
Notes Anticipated completion date January 2016 but no results posted
Ogedegbe 2014
Trial name or title Task shifting and blood pressure control in Ghana: a cluster-randomized trial
Methods Cluster-randomised trial, parallel group (1:1) assignment
Participants 640 participants with uncomplicated hypertension (BP 140-179/90-99 mmHg and absence of target organ
damage) from 32 community health centres and district hospitals in Ghana
Interventions The intervention consists of WHO Package CV risk assessment, patient education, initiation and titration
of antihypertensive medications, behavioural counselling, and assessment of barriers to adherence
Comparison group: usual care
Outcomes Primary outcome: mean change in systolic blood pressure from baseline to 12 months
Secondary outcomes: proportion of participants with adequate systolic blood pressure control at 12 months;
levels of physical activity; percent change in weight; and dietary intake of fruits and vegetables at 12 months
Starting date May 2013; completion date March 2017
Contact information Gbenga Ogedegbe, MD, MS, MPH, Center for Healthful Behavior Change, Division of Health & Behavior,
Department of Population Health, New York University School of Medicine, 550 1st Avenue, New York, NY
10016
Olugbenga.ogedegbe@nyumc.org
Notes ClinicalTrials.gov ID: NCT01802372
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Praveen 2013
Trial name or title Systematic Appraisal Referral and Treatment of CVD risk in rural India (SMARTHealth India)
Methods Stepped wedge cluster-randomised trial
Participants 15,000 adults age 40 years and older at high cardiovascular disease risk from 18 primary health centres and
54 villages in rural Andhra Pradesh
Interventions Intervention group: a mobile device-based clinical decision support system for non-physician healthcare
workers and primary care doctors to assess and manage CVD risk, provide lifestyle advice, and manage risk
factors according to Indian national guidelines
Comparison group: usual care
Outcomes The primary study outcome is the difference in the proportion of people meeting guideline-recommended
blood pressure targets in the intervention period vs the control period
Secondary outcomes include mean reduction in blood pressure levels; change in cardiovascular disease risk
factors (BMI, smoking, healthy eating habits, physical activity, self-reported use of BP and other cardiovascular
medicines, quality of life), and CVD event rates (hospitalisation data)
Starting date Fourth quarter of 2013; randomisation planned to continue until first quarter of 2016
Contact information Devarsetty Praveen, the George Institute for Global Health, Hyderabad, India, dpraveen@georgeinstitute.
org.in
Notes -
Redfern 2014
Trial name or title Consumer Navigation of Electronic Cardiovascular Tools (CONNECT) study
Methods Randomised controlled trial, parallel group (1:1)
Participants 2000 regular adult health service attendees at Australian general practice or Aboriginal CommunityControlled
Health Services
Interventions Intervention group: will be able to securely access a consumer portal to view participant data uploaded from
the clinic record, use interactive tools to view their personal CVD risk and explore relative risk reductions from
various CVD management strategies, access healthy lifestyle reminders and motivational message prompts,
and connect with peers to set healthy lifestyle goals
Comparison group: usual care
Outcomes Primary outcome: proportion of participants meeting the Australian guideline BP and lipid targets.
Secondary outcomes: proportionmeeting guideline-recommendedBP and LDL-cholesterol targets separately,
difference in mean systolic and diastolic blood pressure, difference in mean cholesterol levels, difference in
mean BMI, difference in health literacy scores, difference in cardiovascular and renal events, physical activity
levels, smoking, fruits/vegetable intake, adherence to cardioprotective medications, health-related quality of
life
Starting date October 2014; still recruiting
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Redfern 2014 (Continued)
Contact information Professor Julie Redfern, the George Institute for Global Health, Level 10, King George V Building, Missenden
Road, Camperdown NSW 2050, Australia
jredfern@georgeinstitute.org.au
Notes Australian New Zealand Clinical Trials Registry number: ACTRN12613000715774
Sanghavi 2015
Trial name or title Million hearts: cardiovascular disease risk reduction model
Methods Cluster-randomised trial (1:1) parallel group
Participants 720 general medical practices, Medicare fee-for-service beneficiaries aged 18-79 years of age without history
of myocardial infarction or stroke
Interventions Intervention group: practices will be asked to screen all eligible Medicare beneficiaries for their 10-year risk of
a heart attack or stroke using the American College of Cardiology/American Heart Association (ACC/AHA)
10-year Atherosclerotic Cardiovascular Disease (ASCVD) pooled cohort risk calculator. For participants at
the highest risk (10-year ASCVD risk > 30%), providers will receive a monthly per beneficiary Cardiovascular
Care Management payment to reduce their practice-wide absolute risk
Control group: practices will be asked to report only clinical data (such as age, cholesterol level, and other
information) on their attributed Medicare Beneficiaries at years 1, 2, 3, and 5 of the model. Control group
practices will be paid a USD 20 per-beneficiary payment (based on the estimated costs of preparing and
transmitting the required data) for each reporting cycle
Outcomes Population-wide reduction in 10-year composite risk and population-wide reduction in composite incidence
of myocardial infarction and stroke. Trial is powered for latter outcome based on Medicare fee-for-service
claims data
Starting date January 2016 reported. Trial has not started yet.
Contact information Darshak M Sanghavi, MD, Centers for Medicare and Medicaid Services, Prevention and Population Health
Models Group, 7500 Security Blvd, Baltimore, MD 21244
darshak.sanghavi@cms.hhs.gov
Notes Trial conducted by Center for Medicare and Medicaid Innovation
Silarova 2015
Trial name or title Information and Risk Modification Trial (INFORM)
Methods Randomised controlled trial, parallel group (1:1:1:1)
Participants 932 men and women blood donors with no previous history of CVD aged 40-94 years in England
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Silarova 2015 (Continued)
Interventions 4 groups:
• Group 1: lifestyle advice only
• Group 2: lifestyle advice + 10-year CHD risk based on phenotypic characteristics
• Group 3: lifestyle advice + 10-year CHD risk based on phenotypic and genetic characteristics
• Group 4: no intervention/usual care
Outcomes Primary outcome: change in objectively measured physical activity
Secondary outcomes: objectively measured dietary behaviours, CVD risk factors, medication and healthcare
usage, perceived risk, cognitive evaluation of provision of CHD risk scores, psychological outcomes
Starting date January 2015
Contact information Professor Simon Griffin, Cambridge Institute of Public Health, University of Cambridge School of Clinical
Medicine
Forvie Site, Cambridge Biomedical Campus, Cambridge CB2 0SR, United Kingdom
sjg49@medschl.cam.ac.uk
Notes Participants who took part in the INTERVAL study (www.intervalstudy.org.uk, ISRCTN24760606) and
completed their 2-year questionnaire participate in the INFORM study
CVD: cardiovascular disease.
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D A T A A N D A N A L Y S E S
Comparison 1. CVD risk score versus no CVD risk score/usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CVD events 3 99070 Risk Ratio (IV, Fixed, 95% CI) 1.01 [0.95, 1.08]
2 CVD events, excluding Bucher
2010
2 95708 Risk Ratio (IV, Fixed, 95% CI) 1.01 [0.94, 1.08]
3 Total cholesterol 12 20437 Mean Difference (IV, Random, 95% CI) -0.10 [-0.20, 0.00]
4 Low-density lipoprotein
cholesterol
10 22122 Mean Difference (IV, Random, 95% CI) -0.03 [-0.10, 0.04]
5 Systolic blood pressure 16 32954 Mean Difference (IV, Random, 95% CI) -2.77 [-4.16, -1.38]
6 Diastolic blood pressure 14 22378 Mean Difference (IV, Random, 95% CI) -1.12 [-2.11, -0.13]
7 Change in multivariable CVD
risk
9 9549 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.39, -0.02]
8 Adverse events (investigator
defined)
4 4630 Risk Ratio (IV, Fixed, 95% CI) 0.72 [0.49, 1.04]
9 Anxiety 2 388 Std. Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.27, 0.13]
10 New/intensified lipid-lowering
medication
11 14175 Risk Ratio (Random, 95% CI) 1.47 [1.15, 1.87]
11 New/intensified
antihypertensive medication
8 13255 Risk Ratio (Random, 95% CI) 1.51 [1.08, 2.11]
12 New aspirin 3 1614 Risk Ratio (Fixed, 95% CI) 2.71 [1.24, 5.91]
13 Medication adherence 4 621 Risk Ratio (IV, Random, 95% CI) 1.14 [0.92, 1.40]
14 Smoking cessation 7 5346 Risk Ratio (Fixed, 95% CI) 1.38 [1.13, 1.69]
15 Exercise 2 2595 Risk Ratio (IV, Fixed, 95% CI) 0.98 [0.90, 1.06]
16 Decisional conflict 4 1261 Std. Mean Difference (IV, Random, 95% CI) -0.29 [-0.57, -0.01]
Comparison 2. CVD risk score versus no CVD risk score/usual care by decision support use
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total cholesterol by decision
support use
12 20437 Mean Difference (IV, Random, 95% CI) -0.10 [-0.20, 0.00]
1.1 Decision support use 8 9444 Mean Difference (IV, Random, 95% CI) -0.09 [-0.20, 0.01]
1.2 No decision support use 4 10993 Mean Difference (IV, Random, 95% CI) -0.11 [-0.27, 0.06]
2 Low-density lipoprotein
cholesterol by decision support
10 22122 Mean Difference (IV, Random, 95% CI) -0.03 [-0.10, 0.04]
2.1 Decision support use 9 21739 Mean Difference (IV, Random, 95% CI) -0.02 [-0.10, 0.06]
2.2 No decision support use 1 383 Mean Difference (IV, Random, 95% CI) -0.11 [-0.25, 0.03]
3 Systolic blood pressure by
decision support use
16 32954 Mean Difference (IV, Random, 95% CI) -2.77 [-4.16, -1.38]
3.1 Decision support use 13 22457 Mean Difference (IV, Random, 95% CI) -2.17 [-3.52, -0.82]
3.2 No decision support use 3 10497 Mean Difference (IV, Random, 95% CI) -4.57 [-6.89, -2.25]
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4 Diastolic blood pressure by
decision support use
14 22378 Mean Difference (IV, Random, 95% CI) -1.12 [-2.11, -0.13]
4.1 Decision support use 10 11385 Mean Difference (IV, Random, 95% CI) -0.76 [-1.29, -0.23]
4.2 No decision support use 4 10993 Mean Difference (IV, Random, 95% CI) -2.09 [-3.33, -0.85]
5 Change in multivariable CVD
risk by decision support
9 9549 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.39, -0.02]
5.1 Decision support use 7 6209 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.27, -0.07]
5.2 No decision support use 2 3340 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.98, 0.46]
Comparison 3. CVD risk score versus no CVD risk score/usual care by health IT use
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total cholesterol by health IT
use
12 20437 Mean Difference (IV, Random, 95% CI) -0.10 [-0.20, 0.00]
1.1 Health IT use 8 9444 Mean Difference (IV, Random, 95% CI) -0.09 [-0.20, 0.01]
1.2 No health IT use 4 10993 Mean Difference (IV, Random, 95% CI) -0.11 [-0.27, 0.06]
2 Low-density lipoprotein
cholesterol by health IT use
10 22122 Mean Difference (IV, Random, 95% CI) -0.03 [-0.10, 0.04]
2.1 Health IT use 9 21739 Mean Difference (IV, Random, 95% CI) -0.02 [-0.10, 0.06]
2.2 No health IT use 1 383 Mean Difference (IV, Random, 95% CI) -0.11 [-0.25, 0.03]
3 Systolic blood pressure by health
IT use
16 32954 Mean Difference (IV, Random, 95% CI) -2.77 [-4.16, -1.38]
3.1 Health IT use 13 22457 Mean Difference (IV, Random, 95% CI) -2.17 [-3.52, -0.82]
3.2 No health IT use 3 10497 Mean Difference (IV, Random, 95% CI) -4.57 [-6.89, -2.25]
4 Diastolic blood pressure by
health IT use
14 22378 Mean Difference (IV, Random, 95% CI) -1.12 [-2.11, -0.13]
4.1 Health IT use 10 11385 Mean Difference (IV, Random, 95% CI) -0.76 [-1.29, -0.23]
4.2 No health IT use 4 10993 Mean Difference (IV, Random, 95% CI) -2.09 [-3.33, -0.85]
5 Change in multivariable CVD
risk by health IT use
9 9549 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.39, -0.02]
5.1 Health IT use 6 5387 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.26, -0.12]
5.2 No health IT use 3 4162 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-0.69, 0.39]
Comparison 4. CVD risk score versus no CVD risk score/usual care by risk status of participants
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total cholesterol by risk status 12 20437 Mean Difference (IV, Random, 95% CI) -0.10 [-0.20, 0.00]
1.1 High-risk participants
only
3 4105 Mean Difference (IV, Random, 95% CI) -0.13 [-0.22, -0.03]
1.2 Participants of all risk
levels
9 16332 Mean Difference (IV, Random, 95% CI) -0.10 [-0.23, 0.03]
2 Low-density lipoprotein
cholesterol by risk status
10 22122 Mean Difference (IV, Random, 95% CI) -0.03 [-0.10, 0.04]
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2.1 High-risk participants
only
3 14219 Mean Difference (IV, Random, 95% CI) -0.07 [-0.11, -0.03]
2.2 Participants of all risk
levels
7 7903 Mean Difference (IV, Random, 95% CI) -0.01 [-0.11, 0.09]
3 Systolic blood pressure by risk
status
16 32954 Mean Difference (IV, Random, 95% CI) -2.77 [-4.16, -1.38]
3.1 High-risk participants
only
5 18375 Mean Difference (IV, Random, 95% CI) -2.22 [-4.04, -0.40]
3.2 Participants of all risk
levels
11 14579 Mean Difference (IV, Random, 95% CI) -2.96 [-4.68, -1.24]
4 Diastolic blood pressure by risk
status
14 22378 Mean Difference (IV, Random, 95% CI) -1.12 [-2.11, -0.13]
4.1 High-risk participants
only
3 4091 Mean Difference (IV, Random, 95% CI) -0.90 [-2.42, 0.63]
4.2 Participants of all risk
levels
11 18287 Mean Difference (IV, Random, 95% CI) -1.20 [-2.26, -0.14]
5 Change in multivariable CVD
risk by risk status
9 9549 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.39, -0.02]
5.1 High-risk participants
only
2 4038 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-0.21, -0.09]
5.2 Participants of all risk
levels
7 5511 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.49, 0.05]
Comparison 5. Multivariable CVD risk
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Multivariable CVD risk 5 1921 Std. Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.25, -0.06]
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Analysis 1.1. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 1 CVD events.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 1 CVD events
Study or subgroup [CVD risk score] No CVD risk score Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Bucher 2010 (1) 9/1680 4/1682 0.3 % 2.25 [ 0.70, 7.30 ]
Holt 2010 454/18021 476/18071 26.1 % 0.96 [ 0.84, 1.09 ]
Jorgensen 2014 782/11629 3143/47987 73.6 % 1.03 [ 0.95, 1.11 ]
Total (95% CI) 31330 67740 100.0 % 1.01 [ 0.95, 1.08 ]
Total events: 1245 ([CVD risk score]), 3623 (No CVD risk score)
Heterogeneity: Chi2 = 2.68, df = 2 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.31 (P = 0.76)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
[CVD risk score] [No CVD risk score]
(1) This study included patients with HIV, so findings may not be generalizable to the general population.
Analysis 1.2. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 2 CVD events,
excluding Bucher 2010.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 2 CVD events, excluding Bucher 2010
Study or subgroup CVD risk score No CVD risk score Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Holt 2010 454/18021 476/18071 26.2 % 0.96 [ 0.84, 1.09 ]
Jorgensen 2014 782/11629 3143/47987 73.8 % 1.03 [ 0.95, 1.11 ]
Total (95% CI) 29650 66058 100.0 % 1.01 [ 0.94, 1.08 ]
Total events: 1236 (CVD risk score), 3619 (No CVD risk score)
Heterogeneity: Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.81)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
[CVD risk score] [No CVD risk score]
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Analysis 1.3. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 3 Total
cholesterol.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 3 Total cholesterol
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L]IV,Random,95% CI IV,Random,95% CI
Benner 2008 524 5.4 (1) 461 5.6 (1) 8.9 % -0.20 [ -0.33, -0.07 ]
British Family Heart 1994 2984 5.54 (1.35) 3576 5.67 (1.33) 9.9 % -0.13 [ -0.20, -0.06 ]
Cobos 2005 1046 6.05 (0.86) 1145 5.97 (0.86) 9.8 % 0.08 [ 0.01, 0.15 ]
Engberg 2002 724 5.54 (1.03) 369 5.68 (1.06) 8.8 % -0.14 [ -0.27, -0.01 ]
Grover 2007 (1) 1510 -1.51 (0.88) 1543 -1.41 (0.92) 9.9 % -0.10 [ -0.16, -0.04 ]
Hanlon 1995 (2) 263 0.16 (0.57) 233 0.03 (0.55) 9.4 % 0.13 [ 0.03, 0.23 ]
Hetlevik 1999 581 6.64 (1.2) 768 6.57 (1.3) 8.7 % 0.07 [ -0.06, 0.20 ]
Lopez-Gonzalez 2015 (3) 1869 -0.13 (0.23) 975 0.14 (0.24) 10.2 % -0.27 [ -0.29, -0.25 ]
Lowensteyn 1998 (4) 202 -0.49 (0.99) 89 -0.09 (0.87) 6.9 % -0.40 [ -0.63, -0.17 ]
Sheridan 2011 33 5.25 (1.18) 34 5.07 (1.18) 2.5 % 0.18 [ -0.39, 0.75 ]
Webster 2010 600 5.45 (1.21) 593 5.51 (1.23) 8.7 % -0.06 [ -0.20, 0.08 ]
Wister 2007 (5) 157 -0.41 (1.14) 158 -0.14 (1.14) 6.4 % -0.27 [ -0.52, -0.02 ]
Total (95% CI) 10493 9944 100.0 % -0.10 [ -0.20, 0.00 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 193.00, df = 11 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
[CVD risk score] [No CVD risk score]
(1) Change from baseline.
(2) Change from baseline.
(3) Change from baseline.
(4) Change from baseline.
(5) Change from baseline.
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Analysis 1.4. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 4 Low-density
lipoprotein cholesterol.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 4 Low-density lipoprotein cholesterol
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L]IV,Random,95% CI IV,Random,95% CI
Benner 2008 524 3.4 (0.9) 461 3.5 (1) 10.4 % -0.10 [ -0.22, 0.02 ]
Cobos 2005 1046 3.86 (0.83) 1145 3.79 (0.83) 12.8 % 0.07 [ 0.00, 0.14 ]
Eaton 2011 1780 2.96 (0.82) 1683 2.92 (0.8) 13.4 % 0.04 [ -0.01, 0.09 ]
Edelman 2006 56 3.13 (1.22) 66 3.44 (1.22) 2.4 % -0.31 [ -0.74, 0.12 ]
Grover 2007 (1) 1510 -1.32 (0.76) 1543 -1.24 (0.77) 13.4 % -0.08 [ -0.13, -0.03 ]
Lowensteyn 1998 (2) 202 -0.4 (0.87) 89 -0.01 (0.8) 6.8 % -0.39 [ -0.59, -0.19 ]
Peiris 2015 (3) 5335 -0.14 (1.8) 4846 -0.09 (1.8) 12.7 % -0.05 [ -0.12, 0.02 ]
Vagholkar 2014 413 3.2 (0.8) 417 3 (0.8) 10.9 % 0.20 [ 0.09, 0.31 ]
Webster 2010 317 3.38 (1.13) 306 3.31 (1.06) 8.0 % 0.07 [ -0.10, 0.24 ]
Williams 2006 174 3.74 (0.71) 209 3.85 (0.71) 9.3 % -0.11 [ -0.25, 0.03 ]
Total (95% CI) 11357 10765 100.0 % -0.03 [ -0.10, 0.04 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 50.25, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
[CVD risk score] [No CVD score]
(1) Change from baseline.
(2) Change from baseline.
(3) Low-density lipoprotein cholesterol data only reported for the ”high-risk” subgroup. Change from baseline.
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Analysis 1.5. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 5 Systolic blood
pressure.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 5 Systolic blood pressure
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
Benner 2008 524 138 (14) 461 144 (14) 7.4 % -6.00 [ -7.75, -4.25 ]
British Family Heart 1994 2984 128.2 (24.5) 3576 135.3 (24.6) 7.9 % -7.10 [ -8.29, -5.91 ]
Eaton 2011 2104 123.6 (14.4) 1999 124.1 (13.8) 8.1 % -0.50 [ -1.36, 0.36 ]
Engberg 2002 724 130.9 (18.2) 369 132.6 (19.9) 6.7 % -1.70 [ -4.12, 0.72 ]
Grover 2007 (1) 1510 -6.3 (13.5) 1543 -5.3 (13.2) 8.1 % -1.00 [ -1.95, -0.05 ]
Hetlevik 1999 816 156.8 (19.4) 1023 155.6 (19) 7.4 % 1.20 [ -0.57, 2.97 ]
Lopez-Gonzalez 2015 (2) 1869 -3.3 (5.1) 975 1 (3.6) 8.4 % -4.30 [ -4.62, -3.98 ]
Lowensteyn 1998 (3) 202 -2 (14.2) 89 -1.2 (14.1) 5.4 % -0.80 [ -4.32, 2.72 ]
Montgomery 2000 401 153 (18) 130 159 (22) 4.8 % -6.00 [ -10.17, -1.83 ]
Montgomery 2003 87 149 (14) 101 147 (15) 4.8 % 2.00 [ -2.15, 6.15 ]
Peiris 2015 (4) 5335 -2.3 (30.9) 4846 -1.5 (30.9) 7.9 % -0.80 [ -2.00, 0.40 ]
Sheridan 2011 26 139.3 (13.2) 27 146.6 (13.2) 2.6 % -7.30 [ -14.41, -0.19 ]
Turner 2012 116 131.8 (14.7) 131 140 (18.1) 4.9 % -8.20 [ -12.29, -4.11 ]
Vagholkar 2014 313 126.4 (14.5) 262 129 (13.3) 6.8 % -2.60 [ -4.87, -0.33 ]
Wister 2007 (5) 157 -7.5 (15.7) 158 -3.6 (15.9) 5.5 % -3.90 [ -7.39, -0.41 ]
Zullig 2014 47 125.1 (14.7) 49 124.6 (14.7) 3.4 % 0.50 [ -5.38, 6.38 ]
Total (95% CI) 17215 15739 100.0 % -2.77 [ -4.16, -1.38 ]
Heterogeneity: Tau2 = 5.99; Chi2 = 207.12, df = 15 (P<0.00001); I2 =93%
Test for overall effect: Z = 3.91 (P = 0.000092)
Test for subgroup differences: Not applicable
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(1) Change from baseline.
(2) Change from baseline.
(3) Change from baseline.
(4) Systolic blood pressure data only reported for the ”high-risk” subgroup within this study. Change from baseline.
(5) Change from baseline.
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Analysis 1.6. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 6 Diastolic blood
pressure.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 6 Diastolic blood pressure
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
Benner 2008 524 85 (8.4) 461 87 (9.7) 8.2 % -2.00 [ -3.14, -0.86 ]
British Family Heart 1994 2984 81.4 (10.8) 3576 84.5 (10.8) 9.0 % -3.10 [ -3.62, -2.58 ]
Eaton 2011 2103 75.8 (9) 1999 76.7 (8.2) 9.0 % -0.90 [ -1.43, -0.37 ]
Engberg 2002 724 79.8 (10.5) 369 81 (11.7) 7.8 % -1.20 [ -2.62, 0.22 ]
Grover 2007 (1) 1510 -3.8 (7.9) 1543 -3.6 (7.7) 9.0 % -0.20 [ -0.75, 0.35 ]
Hanlon 1995 (2) 263 1.2 (7.6) 233 0.9 (7.3) 8.0 % 0.30 [ -1.01, 1.61 ]
Hetlevik 1999 816 88.8 (9.7) 1023 89.8 (8.9) 8.6 % -1.00 [ -1.86, -0.14 ]
Lopez-Gonzalez 2015 (3) 1869 -2.3 (4) 975 1.3 (2.9) 9.2 % -3.60 [ -3.86, -3.34 ]
Lowensteyn 1998 (4) 202 -0.9 (8.1) 89 0.1 (9.8) 6.1 % -1.00 [ -3.32, 1.32 ]
Montgomery 2000 401 85.5 (9.5) 130 84 (11) 6.5 % 1.50 [ -0.61, 3.61 ]
Montgomery 2003 87 85 (8) 101 85 (10) 5.7 % 0.0 [ -2.57, 2.57 ]
Sheridan 2011 26 80.4 (8.2) 27 80.2 (8.2) 3.3 % 0.20 [ -4.22, 4.62 ]
Turner 2012 116 76.4 (9.4) 131 78.6 (10.4) 5.9 % -2.20 [ -4.67, 0.27 ]
Zullig 2014 47 73.4 (10) 49 73.5 (10) 3.7 % -0.10 [ -4.10, 3.90 ]
Total (95% CI) 11672 10706 100.0 % -1.12 [ -2.11, -0.13 ]
Heterogeneity: Tau2 = 2.77; Chi2 = 232.17, df = 13 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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(1) Change from baseline.
(2) Change from baseline.
(3) Change from baseline.
(4) Change from baseline.
114Risk scoring for the primary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.7. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 7 Change in
multivariable CVD risk.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 7 Change in multivariable CVD risk
Study or subgroup CVD risk score No CVD risk score
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Benner 2008 524 -6.3 (7) 461 -4.9 (6.6) 11.7 % -0.21 [ -0.33, -0.08 ]
Grover 2007 1510 -5.9 (4.5) 1543 -5.3 (4.3) 12.2 % -0.14 [ -0.21, -0.07 ]
Hanlon 1995 263 0.53 (1.59) 233 0.34 (1.81) 11.1 % 0.11 [ -0.06, 0.29 ]
Krones 2008 415 -3 (4.61) 407 -3.33 (4.61) 11.6 % 0.07 [ -0.07, 0.21 ]
Lopez-Gonzalez 2015 1869 -0.27 (0.84) 975 0.24 (0.78) 12.1 % -0.62 [ -0.70, -0.54 ]
Lowensteyn 1998 202 -1.8 (4.7) 89 -0.3 (5.3) 10.1 % -0.31 [ -0.56, -0.06 ]
Montgomery 2000 401 0.09 (5.27) 130 0.77 (4.22) 10.9 % -0.13 [ -0.33, 0.06 ]
Turner 2012 94 -0.51 (2) 118 0.31 (3) 9.8 % -0.31 [ -0.59, -0.04 ]
Wister 2007 157 -3.07 (5.52) 158 -1.1 (5.54) 10.5 % -0.36 [ -0.58, -0.13 ]
Total (95% CI) 5435 4114 100.0 % -0.21 [ -0.39, -0.02 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 134.90, df = 8 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 1.8. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 8 Adverse events
(investigator defined).
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 8 Adverse events (investigator defined)
Study or subgroup CVD risk score No CVD risk score Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Benner 2008 11/565 15/538 23.4 % 0.70 [ 0.32, 1.51 ]
Grover 2007 20/1510 28/1543 42.6 % 0.73 [ 0.41, 1.29 ]
Price 2011 13/99 18/95 32.2 % 0.69 [ 0.36, 1.33 ]
Turner 2012 1/136 1/144 1.8 % 1.06 [ 0.07, 16.76 ]
Total (95% CI) 2310 2320 100.0 % 0.72 [ 0.49, 1.04 ]
Total events: 45 (CVD risk score), 62 (No CVD risk score)
Heterogeneity: Chi2 = 0.10, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.077)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
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Analysis 1.9. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 9 Anxiety.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 9 Anxiety
Study or subgroup CVD risk score No CVD risk score
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Montgomery 2003 87 34.8 (10.3) 97 36.8 (13.8) 47.3 % -0.16 [ -0.45, 0.13 ]
Welschen 2012 102 34.1 (11.2) 102 33.9 (11.7) 52.7 % 0.02 [ -0.26, 0.29 ]
Total (95% CI) 189 199 100.0 % -0.07 [ -0.27, 0.13 ]
Heterogeneity: Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
[CVD risk score] [No CVD risk score]
117Risk scoring for the primary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 10
New/intensified lipid-lowering medication.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 10 New/intensified lipid-lowering medication
Study or subgroup CVD risk score No CVD risk score log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Benner 2008 524 461 0.0072 (0.1519) 18.6 % 1.01 [ 0.75, 1.36 ]
Bucher 2010 436 425 0.137 (0.3228) 9.4 % 1.15 [ 0.61, 2.16 ]
Denig 2014 88 44 0.7885 (0.4597) 5.7 % 2.20 [ 0.89, 5.42 ]
Hall 2003 162 161 0.3505 (0.3302) 9.1 % 1.42 [ 0.74, 2.71 ]
Jacobson 2006 93 92 0.312 (0.2459) 12.8 % 1.37 [ 0.84, 2.21 ]
Mann 2010 80 70 0.9651 (0.6463) 3.2 % 2.63 [ 0.74, 9.32 ]
Peiris 2015 5335 4846 1.1694 (0.3053) 10.1 % 3.22 [ 1.77, 5.86 ]
Persell 2013 218 217 0.6905 (0.3255) 9.3 % 1.99 [ 1.05, 3.78 ]
Persell 2015 328 318 0.2241 (0.2144) 14.6 % 1.25 [ 0.82, 1.90 ]
Price 2011 99 95 -0.2772 (0.6868) 2.9 % 0.76 [ 0.20, 2.91 ]
Vagholkar 2014 38 45 0.3514 (0.564) 4.1 % 1.42 [ 0.47, 4.29 ]
Total (95% CI) 7401 6774 100.0 % 1.47 [ 1.15, 1.87 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 16.57, df = 10 (P = 0.08); I2 =40%
Test for overall effect: Z = 3.09 (P = 0.0020)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
[No CVD risk score] [CVD risk score]
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Analysis 1.11. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 11
New/intensified antihypertensive medication.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 11 New/intensified antihypertensive medication
Study or subgroup CVD risk score No CVD risk score log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Bucher 2010 436 425 0.039 (0.3529) 12.9 % 1.04 [ 0.52, 2.08 ]
Denig 2014 107 48 -0.0479 (0.392) 11.4 % 0.95 [ 0.44, 2.06 ]
Grover 2007 629 668 0.235 (0.0851) 26.9 % 1.26 [ 1.07, 1.49 ]
Hall 2003 162 161 0.4187 (0.2914) 15.7 % 1.52 [ 0.86, 2.69 ]
Peiris 2015 5335 4846 1.1694 (0.3053) 15.0 % 3.22 [ 1.77, 5.86 ]
Persell 2013 76 85 0.9761 (0.5748) 6.7 % 2.65 [ 0.86, 8.19 ]
Price 2011 99 95 2.7924 (1.4482) 1.3 % 16.32 [ 0.96, 278.89 ]
Vagholkar 2014 38 45 0.0513 (0.4331) 10.1 % 1.05 [ 0.45, 2.46 ]
Total (95% CI) 6882 6373 100.0 % 1.51 [ 1.08, 2.11 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 14.87, df = 7 (P = 0.04); I2 =53%
Test for overall effect: Z = 2.41 (P = 0.016)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
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Analysis 1.12. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 12 New aspirin.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 12 New aspirin
Study or subgroup CVD risk score No CVD risk score log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Benner 2008 524 461 1.1247 (0.5633) 50.1 % 3.08 [ 1.02, 9.29 ]
Persell 2013 218 217 0.7583 (0.6051) 43.4 % 2.13 [ 0.65, 6.99 ]
Price 2011 99 95 1.5887 (1.5559) 6.6 % 4.90 [ 0.23, 103.36 ]
Total (95% CI) 841 773 100.0 % 2.71 [ 1.24, 5.91 ]
Heterogeneity: Chi2 = 0.35, df = 2 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 13 Medication
adherence.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 13 Medication adherence
Study or subgroup CVD risk score No CVD risk score Risk Ratio Weight Risk Ratio
n/N n/N IV,Random,95% CI IV,Random,95% CI
Perestelo-Perez 2016 51/55 36/42 37.4 % 1.08 [ 0.94, 1.25 ]
Sheridan 2011 45/76 25/73 18.7 % 1.73 [ 1.20, 2.50 ]
Turner 2012 70/136 69/144 28.7 % 1.07 [ 0.85, 1.36 ]
Zullig 2014 20/47 24/48 15.1 % 0.85 [ 0.55, 1.32 ]
Total (95% CI) 314 307 100.0 % 1.14 [ 0.92, 1.40 ]
Total events: 186 (CVD risk score), 154 (No CVD risk score)
Heterogeneity: Tau2 = 0.02; Chi2 = 7.17, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 1.21 (P = 0.23)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
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Analysis 1.14. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 14 Smoking
cessation.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 14 Smoking cessation
Study or subgroup CVD risk score No CVD risk score log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Benner 2008 524 461 0.3137 (0.1119) 85.0 % 1.37 [ 1.10, 1.70 ]
Hanlon 1995 263 233 -0.1226 (0.8215) 1.6 % 0.88 [ 0.18, 4.43 ]
Lowensteyn 1998 202 89 -0.4219 (0.9219) 1.3 % 0.66 [ 0.11, 3.99 ]
Sheridan 2011 77 77 1.1116 (1.6409) 0.4 % 3.04 [ 0.12, 75.77 ]
Webster 2010 1062 1037 -0.024 (0.4734) 4.7 % 0.98 [ 0.39, 2.47 ]
Williams 2006 714 292 0.9442 (0.4009) 6.6 % 2.57 [ 1.17, 5.64 ]
Wister 2007 157 158 -1.0986 (1.6369) 0.4 % 0.33 [ 0.01, 8.25 ]
Total (95% CI) 2999 2347 100.0 % 1.38 [ 1.13, 1.69 ]
Heterogeneity: Chi2 = 4.88, df = 6 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 3.11 (P = 0.0019)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.15. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 15 Exercise.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 15 Exercise
Study or subgroup CVD risk score No CVD risk score Risk Ratio Weight Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
Hanlon 1995 208/263 191/233 89.7 % 0.96 [ 0.88, 1.05 ]
Webster 2010 112/1062 100/1037 10.3 % 1.09 [ 0.85, 1.41 ]
Total (95% CI) 1325 1270 100.0 % 0.98 [ 0.90, 1.06 ]
Total events: 320 (CVD risk score), 291 (No CVD risk score)
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
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Analysis 1.16. Comparison 1 CVD risk score versus no CVD risk score/usual care, Outcome 16 Decisional
conflict.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 1 CVD risk score versus no CVD risk score/usual care
Outcome: 16 Decisional conflict
Study or subgroup CVD risk score No CVD risk score
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Krones 2008 372 14.7 (20) 372 18.1 (20) 29.8 % -0.17 [ -0.31, -0.03 ]
Mann 2010 80 25.5 (11.1) 70 28.5 (11.1) 22.7 % -0.27 [ -0.59, 0.05 ]
Montgomery 2003 100 27.6 (12.1) 112 38.9 (18.3) 24.5 % -0.72 [ -1.00, -0.44 ]
Perestelo-Perez 2016 78 23.9 (16.8) 77 23.8 (14.8) 23.0 % 0.01 [ -0.31, 0.32 ]
Total (95% CI) 630 631 100.0 % -0.29 [ -0.57, -0.01 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 14.60, df = 3 (P = 0.002); I2 =79%
Test for overall effect: Z = 2.00 (P = 0.046)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 CVD risk score versus no CVD risk score/usual care by decision support use,
Outcome 1 Total cholesterol by decision support use.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 2 CVD risk score versus no CVD risk score/usual care by decision support use
Outcome: 1 Total cholesterol by decision support use
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L]IV,Random,95% CI IV,Random,95% CI
1 Decision support use
Benner 2008 524 5.4 (1) 461 5.6 (1) 8.9 % -0.20 [ -0.33, -0.07 ]
Cobos 2005 1046 6.05 (0.86) 1145 5.97 (0.86) 9.8 % 0.08 [ 0.01, 0.15 ]
Grover 2007 (1) 1510 -1.51 (0.88) 1543 -1.41 (0.92) 9.9 % -0.10 [ -0.16, -0.04 ]
Hetlevik 1999 581 6.64 (1.2) 768 6.57 (1.3) 8.7 % 0.07 [ -0.06, 0.20 ]
Lowensteyn 1998 (2) 202 -0.49 (0.99) 89 -0.09 (0.87) 6.9 % -0.40 [ -0.63, -0.17 ]
Sheridan 2011 33 5.25 (1.18) 34 5.07 (1.18) 2.5 % 0.18 [ -0.39, 0.75 ]
Webster 2010 600 5.45 (1.21) 593 5.51 (1.23) 8.7 % -0.06 [ -0.20, 0.08 ]
Wister 2007 (3) 157 -0.41 (1.14) 158 -0.14 (1.14) 6.4 % -0.27 [ -0.52, -0.02 ]
Subtotal (95% CI) 4653 4791 61.7 % -0.09 [ -0.20, 0.01 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 36.20, df = 7 (P<0.00001); I2 =81%
Test for overall effect: Z = 1.68 (P = 0.092)
2 No decision support use
British Family Heart 1994 2984 5.54 (1.35) 3576 5.67 (1.33) 9.9 % -0.13 [ -0.20, -0.06 ]
Engberg 2002 724 5.54 (1.03) 369 5.68 (1.06) 8.8 % -0.14 [ -0.27, -0.01 ]
Hanlon 1995 (4) 263 0.16 (0.57) 233 0.03 (0.55) 9.4 % 0.13 [ 0.03, 0.23 ]
Lopez-Gonzalez 2015 (5) 1869 -0.13 (0.23) 975 0.14 (0.24) 10.2 % -0.27 [ -0.29, -0.25 ]
Subtotal (95% CI) 5840 5153 38.3 % -0.11 [ -0.27, 0.06 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 77.05, df = 3 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.25 (P = 0.21)
Total (95% CI) 10493 9944 100.0 % -0.10 [ -0.20, 0.00 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 193.00, df = 11 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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(1) Change from baseline.
(2) Change from baseline.
(3) Change from baseline.
(4) Change from baseline.
(5) Change from baseline.
Analysis 2.2. Comparison 2 CVD risk score versus no CVD risk score/usual care by decision support use,
Outcome 2 Low-density lipoprotein cholesterol by decision support.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 2 CVD risk score versus no CVD risk score/usual care by decision support use
Outcome: 2 Low-density lipoprotein cholesterol by decision support
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L]IV,Random,95% CI IV,Random,95% CI
1 Decision support use
Benner 2008 524 3.4 (0.9) 461 3.5 (1) 10.4 % -0.10 [ -0.22, 0.02 ]
Cobos 2005 1046 3.86 (0.83) 1145 3.79 (0.83) 12.8 % 0.07 [ 0.00, 0.14 ]
Eaton 2011 1780 2.96 (0.82) 1683 2.92 (0.8) 13.4 % 0.04 [ -0.01, 0.09 ]
Edelman 2006 56 3.13 (1.22) 66 3.44 (1.22) 2.4 % -0.31 [ -0.74, 0.12 ]
Grover 2007 (1) 1510 -1.32 (0.76) 1543 -1.24 (0.77) 13.4 % -0.08 [ -0.13, -0.03 ]
Lowensteyn 1998 (2) 202 -0.4 (0.87) 89 -0.01 (0.8) 6.8 % -0.39 [ -0.59, -0.19 ]
Peiris 2015 (3) 5335 -0.14 (1.8) 4846 -0.09 (1.8) 12.7 % -0.05 [ -0.12, 0.02 ]
Vagholkar 2014 413 3.2 (0.8) 417 3 (0.8) 10.9 % 0.20 [ 0.09, 0.31 ]
Webster 2010 317 3.38 (1.13) 306 3.31 (1.06) 8.0 % 0.07 [ -0.10, 0.24 ]
Subtotal (95% CI) 11183 10556 90.7 % -0.02 [ -0.10, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 48.28, df = 8 (P<0.00001); I2 =83%
Test for overall effect: Z = 0.55 (P = 0.58)
2 No decision support use
Williams 2006 174 3.74 (0.71) 209 3.85 (0.71) 9.3 % -0.11 [ -0.25, 0.03 ]
Subtotal (95% CI) 174 209 9.3 % -0.11 [ -0.25, 0.03 ]
Heterogeneity: not applicable
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(. . . Continued)
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L]IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 11357 10765 100.0 % -0.03 [ -0.10, 0.04 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 50.25, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 1.13, df = 1 (P = 0.29), I2 =12%
-1 -0.5 0 0.5 1
[CVD risk score] [No CVD score]
(1) Change from baseline.
(2) Change from baseline.
(3) Low-density lipoprotein cholesterol data only reported for the ”high-risk” subgroup within this study. Change from baseline.
Analysis 2.3. Comparison 2 CVD risk score versus no CVD risk score/usual care by decision support use,
Outcome 3 Systolic blood pressure by decision support use.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 2 CVD risk score versus no CVD risk score/usual care by decision support use
Outcome: 3 Systolic blood pressure by decision support use
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
1 Decision support use
Benner 2008 524 138 (14) 461 144 (14) 7.4 % -6.00 [ -7.75, -4.25 ]
Eaton 2011 2104 123.6 (14.4) 1999 124.1 (13.8) 8.1 % -0.50 [ -1.36, 0.36 ]
Grover 2007 (1) 1510 -6.3 (13.5) 1543 -5.3 (13.2) 8.1 % -1.00 [ -1.95, -0.05 ]
Hetlevik 1999 816 156.8 (19.4) 1023 155.6 (19) 7.4 % 1.20 [ -0.57, 2.97 ]
Lowensteyn 1998 (2) 202 -2 (14.2) 89 -1.2 (14.1) 5.4 % -0.80 [ -4.32, 2.72 ]
Montgomery 2000 401 153 (18) 130 159 (22) 4.8 % -6.00 [ -10.17, -1.83 ]
Montgomery 2003 87 149 (14) 101 147 (15) 4.8 % 2.00 [ -2.15, 6.15 ]
Peiris 2015 (3) 5335 -2.3 (30.9) 4846 -1.5 (30.9) 7.9 % -0.80 [ -2.00, 0.40 ]
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(. . . Continued)
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
Sheridan 2011 26 139.3 (13.2) 27 146.6 (13.2) 2.6 % -7.30 [ -14.41, -0.19 ]
Turner 2012 116 131.8 (14.7) 131 140 (18.1) 4.9 % -8.20 [ -12.29, -4.11 ]
Vagholkar 2014 313 126.4 (14.5) 262 129 (13.3) 6.8 % -2.60 [ -4.87, -0.33 ]
Wister 2007 (4) 157 -7.5 (15.7) 158 -3.6 (15.9) 5.5 % -3.90 [ -7.39, -0.41 ]
Zullig 2014 47 125.1 (14.7) 49 124.6 (14.7) 3.4 % 0.50 [ -5.38, 6.38 ]
Subtotal (95% CI) 11638 10819 77.1 % -2.17 [ -3.52, -0.82 ]
Heterogeneity: Tau2 = 3.89; Chi2 = 64.44, df = 12 (P<0.00001); I2 =81%
Test for overall effect: Z = 3.16 (P = 0.0016)
2 No decision support use
British Family Heart 1994 2984 128.2 (24.5) 3576 135.3 (24.6) 7.9 % -7.10 [ -8.29, -5.91 ]
Engberg 2002 724 130.9 (18.2) 369 132.6 (19.9) 6.7 % -1.70 [ -4.12, 0.72 ]
Lopez-Gonzalez 2015 (5) 1869 -3.3 (5.1) 975 1 (3.6) 8.4 % -4.30 [ -4.62, -3.98 ]
Subtotal (95% CI) 5577 4920 22.9 % -4.57 [ -6.89, -2.25 ]
Heterogeneity: Tau2 = 3.65; Chi2 = 24.73, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 3.87 (P = 0.00011)
Total (95% CI) 17215 15739 100.0 % -2.77 [ -4.16, -1.38 ]
Heterogeneity: Tau2 = 5.99; Chi2 = 207.12, df = 15 (P<0.00001); I2 =93%
Test for overall effect: Z = 3.91 (P = 0.000092)
Test for subgroup differences: Chi2 = 3.08, df = 1 (P = 0.08), I2 =68%
-20 -10 0 10 20
[CVD risk score] [No CVD risk score]
(1) Change from baseline.
(2) Change from baseline.
(3) Systolic blood pressure data only reported for the ”high-risk” subgroup within this study. Change from baseline.
(4) Change from baseline.
(5) Change from baseline.
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Analysis 2.4. Comparison 2 CVD risk score versus no CVD risk score/usual care by decision support use,
Outcome 4 Diastolic blood pressure by decision support use.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 2 CVD risk score versus no CVD risk score/usual care by decision support use
Outcome: 4 Diastolic blood pressure by decision support use
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
1 Decision support use
Benner 2008 524 85 (8.4) 461 87 (9.7) 8.2 % -2.00 [ -3.14, -0.86 ]
Eaton 2011 2103 75.8 (9) 1999 76.7 (8.2) 9.0 % -0.90 [ -1.43, -0.37 ]
Grover 2007 (1) 1510 -3.8 (7.9) 1543 -3.6 (7.7) 9.0 % -0.20 [ -0.75, 0.35 ]
Hetlevik 1999 816 88.8 (9.7) 1023 89.8 (8.9) 8.6 % -1.00 [ -1.86, -0.14 ]
Lowensteyn 1998 (2) 202 -0.9 (8.1) 89 0.1 (9.8) 6.1 % -1.00 [ -3.32, 1.32 ]
Montgomery 2000 401 85.5 (9.5) 130 84 (11) 6.5 % 1.50 [ -0.61, 3.61 ]
Montgomery 2003 87 85 (8) 101 85 (10) 5.7 % 0.0 [ -2.57, 2.57 ]
Sheridan 2011 26 80.4 (8.2) 27 80.2 (8.2) 3.3 % 0.20 [ -4.22, 4.62 ]
Turner 2012 116 76.4 (9.4) 131 78.6 (10.4) 5.9 % -2.20 [ -4.67, 0.27 ]
Zullig 2014 47 73.4 (10) 49 73.5 (10) 3.7 % -0.10 [ -4.10, 3.90 ]
Subtotal (95% CI) 5832 5553 66.1 % -0.76 [ -1.29, -0.23 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 15.34, df = 9 (P = 0.08); I2 =41%
Test for overall effect: Z = 2.79 (P = 0.0053)
2 No decision support use
British Family Heart 1994 2984 81.4 (10.8) 3576 84.5 (10.8) 9.0 % -3.10 [ -3.62, -2.58 ]
Engberg 2002 724 79.8 (10.5) 369 81 (11.7) 7.8 % -1.20 [ -2.62, 0.22 ]
Hanlon 1995 (3) 263 1.2 (7.6) 233 0.9 (7.3) 8.0 % 0.30 [ -1.01, 1.61 ]
Lopez-Gonzalez 2015 (4) 1869 -2.3 (4) 975 1.3 (2.9) 9.2 % -3.60 [ -3.86, -3.34 ]
Subtotal (95% CI) 5840 5153 33.9 % -2.09 [ -3.33, -0.85 ]
Heterogeneity: Tau2 = 1.37; Chi2 = 43.04, df = 3 (P<0.00001); I2 =93%
Test for overall effect: Z = 3.30 (P = 0.00096)
Total (95% CI) 11672 10706 100.0 % -1.12 [ -2.11, -0.13 ]
Heterogeneity: Tau2 = 2.77; Chi2 = 232.17, df = 13 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Chi2 = 3.73, df = 1 (P = 0.05), I2 =73%
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(1) Change from baseline.
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(3) Change from baseline.
(4) Change from baseline.
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Analysis 2.5. Comparison 2 CVD risk score versus no CVD risk score/usual care by decision support use,
Outcome 5 Change in multivariable CVD risk by decision support.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 2 CVD risk score versus no CVD risk score/usual care by decision support use
Outcome: 5 Change in multivariable CVD risk by decision support
Study or subgroup CVD risk score No CVD risk score
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Decision support use
Benner 2008 524 -6.3 (7) 461 -4.9 (6.6) 11.7 % -0.21 [ -0.33, -0.08 ]
Grover 2007 1510 -5.9 (4.5) 1543 -5.3 (4.3) 12.2 % -0.14 [ -0.21, -0.07 ]
Krones 2008 415 -3 (4.61) 407 -3.33 (4.61) 11.6 % 0.07 [ -0.07, 0.21 ]
Lowensteyn 1998 202 -1.8 (4.7) 89 -0.3 (5.3) 10.1 % -0.31 [ -0.56, -0.06 ]
Montgomery 2000 401 0.09 (5.27) 130 0.77 (4.22) 10.9 % -0.13 [ -0.33, 0.06 ]
Turner 2012 94 -0.51 (2) 118 0.31 (3) 9.8 % -0.31 [ -0.59, -0.04 ]
Wister 2007 157 -3.07 (5.52) 158 -1.1 (5.54) 10.5 % -0.36 [ -0.58, -0.13 ]
Subtotal (95% CI) 3303 2906 76.7 % -0.17 [ -0.27, -0.07 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 17.06, df = 6 (P = 0.01); I2 =65%
Test for overall effect: Z = 3.29 (P = 0.00099)
2 No decision support use
Hanlon 1995 263 0.53 (1.59) 233 0.34 (1.81) 11.1 % 0.11 [ -0.06, 0.29 ]
Lopez-Gonzalez 2015 1869 -0.27 (0.84) 975 0.24 (0.78) 12.1 % -0.62 [ -0.70, -0.54 ]
Subtotal (95% CI) 2132 1208 23.3 % -0.26 [ -0.98, 0.46 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 55.28, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 0.71 (P = 0.48)
Total (95% CI) 5435 4114 100.0 % -0.21 [ -0.39, -0.02 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 134.90, df = 8 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.81), I2 =0.0%
-1 -0.5 0 0.5 1
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Analysis 3.1. Comparison 3 CVD risk score versus no CVD risk score/usual care by health IT use, Outcome
1 Total cholesterol by health IT use.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 3 CVD risk score versus no CVD risk score/usual care by health IT use
Outcome: 1 Total cholesterol by health IT use
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L]IV,Random,95% CI IV,Random,95% CI
1 Health IT use
Benner 2008 524 5.4 (1) 461 5.6 (1) 8.9 % -0.20 [ -0.33, -0.07 ]
Cobos 2005 1046 6.05 (0.86) 1145 5.97 (0.86) 9.8 % 0.08 [ 0.01, 0.15 ]
Grover 2007 (1) 1510 -1.51 (0.88) 1543 -1.41 (0.92) 9.9 % -0.10 [ -0.16, -0.04 ]
Hetlevik 1999 581 6.64 (1.2) 768 6.57 (1.3) 8.7 % 0.07 [ -0.06, 0.20 ]
Lowensteyn 1998 (2) 202 -0.49 (0.99) 89 -0.09 (0.87) 6.9 % -0.40 [ -0.63, -0.17 ]
Sheridan 2011 33 5.25 (1.18) 34 5.07 (1.18) 2.5 % 0.18 [ -0.39, 0.75 ]
Webster 2010 600 5.45 (1.21) 593 5.51 (1.23) 8.7 % -0.06 [ -0.20, 0.08 ]
Wister 2007 (3) 157 -0.41 (1.14) 158 -0.14 (1.14) 6.4 % -0.27 [ -0.52, -0.02 ]
Subtotal (95% CI) 4653 4791 61.7 % -0.09 [ -0.20, 0.01 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 36.20, df = 7 (P<0.00001); I2 =81%
Test for overall effect: Z = 1.68 (P = 0.092)
2 No health IT use
British Family Heart 1994 2984 5.54 (1.35) 3576 5.67 (1.33) 9.9 % -0.13 [ -0.20, -0.06 ]
Engberg 2002 724 5.54 (1.03) 369 5.68 (1.06) 8.8 % -0.14 [ -0.27, -0.01 ]
Hanlon 1995 (4) 263 0.16 (0.57) 233 0.03 (0.55) 9.4 % 0.13 [ 0.03, 0.23 ]
Lopez-Gonzalez 2015 (5) 1869 -0.13 (0.23) 975 0.14 (0.24) 10.2 % -0.27 [ -0.29, -0.25 ]
Subtotal (95% CI) 5840 5153 38.3 % -0.11 [ -0.27, 0.06 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 77.05, df = 3 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.25 (P = 0.21)
Total (95% CI) 10493 9944 100.0 % -0.10 [ -0.20, 0.00 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 193.00, df = 11 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
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(1) Change from baseline.
(2) Change from baseline.
(3) Change from baseline.
(4) Change from baseline.
(5) Change from baseline.
129Risk scoring for the primary prevention of cardiovascular disease (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.2. Comparison 3 CVD risk score versus no CVD risk score/usual care by health IT use, Outcome
2 Low-density lipoprotein cholesterol by health IT use.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 3 CVD risk score versus no CVD risk score/usual care by health IT use
Outcome: 2 Low-density lipoprotein cholesterol by health IT use
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L]IV,Random,95% CI IV,Random,95% CI
1 Health IT use
Benner 2008 524 3.4 (0.9) 461 3.5 (1) 10.4 % -0.10 [ -0.22, 0.02 ]
Cobos 2005 1046 3.86 (0.83) 1145 3.79 (0.83) 12.8 % 0.07 [ 0.00, 0.14 ]
Eaton 2011 1780 2.96 (0.82) 1683 2.92 (0.8) 13.4 % 0.04 [ -0.01, 0.09 ]
Edelman 2006 56 3.13 (1.22) 66 3.44 (1.22) 2.4 % -0.31 [ -0.74, 0.12 ]
Grover 2007 (1) 1510 -1.32 (0.76) 1543 -1.24 (0.77) 13.4 % -0.08 [ -0.13, -0.03 ]
Lowensteyn 1998 (2) 202 -0.4 (0.87) 89 -0.01 (0.8) 6.8 % -0.39 [ -0.59, -0.19 ]
Peiris 2015 (3) 5335 -0.14 (1.8) 4846 -0.09 (1.8) 12.7 % -0.05 [ -0.12, 0.02 ]
Vagholkar 2014 413 3.2 (0.8) 417 3 (0.8) 10.9 % 0.20 [ 0.09, 0.31 ]
Webster 2010 317 3.38 (1.13) 306 3.31 (1.06) 8.0 % 0.07 [ -0.10, 0.24 ]
Subtotal (95% CI) 11183 10556 90.7 % -0.02 [ -0.10, 0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 48.28, df = 8 (P<0.00001); I2 =83%
Test for overall effect: Z = 0.55 (P = 0.58)
2 No health IT use
Williams 2006 174 3.74 (0.71) 209 3.85 (0.71) 9.3 % -0.11 [ -0.25, 0.03 ]
Subtotal (95% CI) 174 209 9.3 % -0.11 [ -0.25, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 11357 10765 100.0 % -0.03 [ -0.10, 0.04 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 50.25, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 1.13, df = 1 (P = 0.29), I2 =12%
-1 -0.5 0 0.5 1
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(1) Change from baseline.
(2) Change from baseline.
(3) Low-density lipoprotein cholesterol data only reported for the ”high-risk” subgroup within this study. Change from baseline.
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Analysis 3.3. Comparison 3 CVD risk score versus no CVD risk score/usual care by health IT use, Outcome
3 Systolic blood pressure by health IT use.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 3 CVD risk score versus no CVD risk score/usual care by health IT use
Outcome: 3 Systolic blood pressure by health IT use
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
1 Health IT use
Benner 2008 524 138 (14) 461 144 (14) 7.4 % -6.00 [ -7.75, -4.25 ]
Eaton 2011 2104 123.6 (14.4) 1999 124.1 (13.8) 8.1 % -0.50 [ -1.36, 0.36 ]
Grover 2007 (1) 1510 -6.3 (13.5) 1543 -5.3 (13.2) 8.1 % -1.00 [ -1.95, -0.05 ]
Hetlevik 1999 816 156.8 (19.4) 1023 155.6 (19) 7.4 % 1.20 [ -0.57, 2.97 ]
Lowensteyn 1998 (2) 202 -2 (14.2) 89 -1.2 (14.1) 5.4 % -0.80 [ -4.32, 2.72 ]
Montgomery 2000 401 153 (18) 130 159 (22) 4.8 % -6.00 [ -10.17, -1.83 ]
Montgomery 2003 87 149 (14) 101 147 (15) 4.8 % 2.00 [ -2.15, 6.15 ]
Peiris 2015 (3) 5335 -2.3 (30.9) 4846 -1.5 (30.9) 7.9 % -0.80 [ -2.00, 0.40 ]
Sheridan 2011 26 139.3 (13.2) 27 146.6 (13.2) 2.6 % -7.30 [ -14.41, -0.19 ]
Turner 2012 116 131.8 (14.7) 131 140 (18.1) 4.9 % -8.20 [ -12.29, -4.11 ]
Vagholkar 2014 313 126.4 (14.5) 262 129 (13.3) 6.8 % -2.60 [ -4.87, -0.33 ]
Wister 2007 (4) 157 -7.5 (15.7) 158 -3.6 (15.9) 5.5 % -3.90 [ -7.39, -0.41 ]
Zullig 2014 47 125.1 (14.7) 49 124.6 (14.7) 3.4 % 0.50 [ -5.38, 6.38 ]
Subtotal (95% CI) 11638 10819 77.1 % -2.17 [ -3.52, -0.82 ]
Heterogeneity: Tau2 = 3.89; Chi2 = 64.44, df = 12 (P<0.00001); I2 =81%
Test for overall effect: Z = 3.16 (P = 0.0016)
2 No health IT use
British Family Heart 1994 2984 128.2 (24.5) 3576 135.3 (24.6) 7.9 % -7.10 [ -8.29, -5.91 ]
Engberg 2002 724 130.9 (18.2) 369 132.6 (19.9) 6.7 % -1.70 [ -4.12, 0.72 ]
Lopez-Gonzalez 2015 (5) 1869 -3.3 (5.1) 975 1 (3.6) 8.4 % -4.30 [ -4.62, -3.98 ]
Subtotal (95% CI) 5577 4920 22.9 % -4.57 [ -6.89, -2.25 ]
Heterogeneity: Tau2 = 3.65; Chi2 = 24.73, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 3.87 (P = 0.00011)
Total (95% CI) 17215 15739 100.0 % -2.77 [ -4.16, -1.38 ]
Heterogeneity: Tau2 = 5.99; Chi2 = 207.12, df = 15 (P<0.00001); I2 =93%
Test for overall effect: Z = 3.91 (P = 0.000092)
Test for subgroup differences: Chi2 = 3.08, df = 1 (P = 0.08), I2 =68%
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(1) Change from baseline.
(2) Change from baseline.
(3) Systolic blood pressure data only reported for the ”high-risk” subgroup within this study. Change from baseline.
(4) Change from baseline.
(5) Change from baseline.
Analysis 3.4. Comparison 3 CVD risk score versus no CVD risk score/usual care by health IT use, Outcome
4 Diastolic blood pressure by health IT use.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 3 CVD risk score versus no CVD risk score/usual care by health IT use
Outcome: 4 Diastolic blood pressure by health IT use
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
1 Health IT use
Benner 2008 524 85 (8.4) 461 87 (9.7) 8.2 % -2.00 [ -3.14, -0.86 ]
Eaton 2011 2103 75.8 (9) 1999 76.7 (8.2) 9.0 % -0.90 [ -1.43, -0.37 ]
Grover 2007 (1) 1510 -3.8 (7.9) 1543 -3.6 (7.7) 9.0 % -0.20 [ -0.75, 0.35 ]
Hetlevik 1999 816 88.8 (9.7) 1023 89.8 (8.9) 8.6 % -1.00 [ -1.86, -0.14 ]
Lowensteyn 1998 (2) 202 -0.9 (8.1) 89 0.1 (9.8) 6.1 % -1.00 [ -3.32, 1.32 ]
Montgomery 2000 401 85.5 (9.5) 130 84 (11) 6.5 % 1.50 [ -0.61, 3.61 ]
Montgomery 2003 87 85 (8) 101 85 (10) 5.7 % 0.0 [ -2.57, 2.57 ]
Sheridan 2011 26 80.4 (8.2) 27 80.2 (8.2) 3.3 % 0.20 [ -4.22, 4.62 ]
Turner 2012 116 76.4 (9.4) 131 78.6 (10.4) 5.9 % -2.20 [ -4.67, 0.27 ]
Zullig 2014 47 73.4 (10) 49 73.5 (10) 3.7 % -0.10 [ -4.10, 3.90 ]
Subtotal (95% CI) 5832 5553 66.1 % -0.76 [ -1.29, -0.23 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 15.34, df = 9 (P = 0.08); I2 =41%
Test for overall effect: Z = 2.79 (P = 0.0053)
2 No health IT use
British Family Heart 1994 2984 81.4 (10.8) 3576 84.5 (10.8) 9.0 % -3.10 [ -3.62, -2.58 ]
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(. . . Continued)
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
Engberg 2002 724 79.8 (10.5) 369 81 (11.7) 7.8 % -1.20 [ -2.62, 0.22 ]
Hanlon 1995 (3) 263 1.2 (7.6) 233 0.9 (7.3) 8.0 % 0.30 [ -1.01, 1.61 ]
Lopez-Gonzalez 2015 (4) 1869 -2.3 (4) 975 1.3 (2.9) 9.2 % -3.60 [ -3.86, -3.34 ]
Subtotal (95% CI) 5840 5153 33.9 % -2.09 [ -3.33, -0.85 ]
Heterogeneity: Tau2 = 1.37; Chi2 = 43.04, df = 3 (P<0.00001); I2 =93%
Test for overall effect: Z = 3.30 (P = 0.00096)
Total (95% CI) 11672 10706 100.0 % -1.12 [ -2.11, -0.13 ]
Heterogeneity: Tau2 = 2.77; Chi2 = 232.17, df = 13 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Chi2 = 3.73, df = 1 (P = 0.05), I2 =73%
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(1) Change from baseline.
(2) Change from baseline.
(3) Change from baseline.
(4) Change from baseline.
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Analysis 3.5. Comparison 3 CVD risk score versus no CVD risk score/usual care by health IT use, Outcome
5 Change in multivariable CVD risk by health IT use.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 3 CVD risk score versus no CVD risk score/usual care by health IT use
Outcome: 5 Change in multivariable CVD risk by health IT use
Study or subgroup CVD risk score No CVD risk score
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Health IT use
Benner 2008 524 -6.3 (7) 461 -4.9 (6.6) 11.7 % -0.21 [ -0.33, -0.08 ]
Grover 2007 1510 -5.9 (4.5) 1543 -5.3 (4.3) 12.2 % -0.14 [ -0.21, -0.07 ]
Lowensteyn 1998 202 -1.8 (4.7) 89 -0.3 (5.3) 10.1 % -0.31 [ -0.56, -0.06 ]
Montgomery 2000 401 0.09 (5.27) 130 0.77 (4.22) 10.9 % -0.13 [ -0.33, 0.06 ]
Turner 2012 94 -0.51 (2) 118 0.31 (3) 9.8 % -0.31 [ -0.59, -0.04 ]
Wister 2007 157 -3.07 (5.52) 158 -1.1 (5.54) 10.5 % -0.36 [ -0.58, -0.13 ]
Subtotal (95% CI) 2888 2499 65.1 % -0.19 [ -0.26, -0.12 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 6.08, df = 5 (P = 0.30); I2 =18%
Test for overall effect: Z = 5.50 (P < 0.00001)
2 No health IT use
Hanlon 1995 263 0.53 (1.59) 233 0.34 (1.81) 11.1 % 0.11 [ -0.06, 0.29 ]
Krones 2008 415 -3 (4.61) 407 -3.33 (4.61) 11.6 % 0.07 [ -0.07, 0.21 ]
Lopez-Gonzalez 2015 1869 -0.27 (0.84) 975 0.24 (0.78) 12.1 % -0.62 [ -0.70, -0.54 ]
Subtotal (95% CI) 2547 1615 34.9 % -0.15 [ -0.69, 0.39 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 107.58, df = 2 (P<0.00001); I2 =98%
Test for overall effect: Z = 0.55 (P = 0.58)
Total (95% CI) 5435 4114 100.0 % -0.21 [ -0.39, -0.02 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 134.90, df = 8 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.88), I2 =0.0%
-1 -0.5 0 0.5 1
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Analysis 4.1. Comparison 4 CVD risk score versus no CVD risk score/usual care by risk status of
participants, Outcome 1 Total cholesterol by risk status.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 4 CVD risk score versus no CVD risk score/usual care by risk status of participants
Outcome: 1 Total cholesterol by risk status
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L]IV,Random,95% CI IV,Random,95% CI
1 High-risk participants only
Benner 2008 524 5.4 (1) 461 5.6 (1) 8.9 % -0.20 [ -0.33, -0.07 ]
Grover 2007 (1) 1510 -1.51 (0.88) 1543 -1.41 (0.92) 9.9 % -0.10 [ -0.16, -0.04 ]
Sheridan 2011 33 5.25 (1.18) 34 5.07 (1.18) 2.5 % 0.18 [ -0.39, 0.75 ]
Subtotal (95% CI) 2067 2038 21.3 % -0.13 [ -0.22, -0.03 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.02, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 2.67 (P = 0.0075)
2 Participants of all risk levels
British Family Heart 1994 2984 5.54 (1.35) 3576 5.67 (1.33) 9.9 % -0.13 [ -0.20, -0.06 ]
Cobos 2005 1046 6.05 (0.86) 1145 5.97 (0.86) 9.8 % 0.08 [ 0.01, 0.15 ]
Engberg 2002 724 5.54 (1.03) 369 5.68 (1.06) 8.8 % -0.14 [ -0.27, -0.01 ]
Hanlon 1995 (2) 263 0.16 (0.57) 233 0.03 (0.55) 9.4 % 0.13 [ 0.03, 0.23 ]
Hetlevik 1999 581 6.64 (1.2) 768 6.57 (1.3) 8.7 % 0.07 [ -0.06, 0.20 ]
Lopez-Gonzalez 2015 (3) 1869 -0.13 (0.23) 975 0.14 (0.24) 10.2 % -0.27 [ -0.29, -0.25 ]
Lowensteyn 1998 (4) 202 -0.49 (0.99) 89 -0.09 (0.87) 6.9 % -0.40 [ -0.63, -0.17 ]
Webster 2010 600 5.45 (1.21) 593 5.51 (1.23) 8.7 % -0.06 [ -0.20, 0.08 ]
Wister 2007 (5) 157 -0.41 (1.14) 158 -0.14 (1.14) 6.4 % -0.27 [ -0.52, -0.02 ]
Subtotal (95% CI) 8426 7906 78.7 % -0.10 [ -0.23, 0.03 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 177.82, df = 8 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.50 (P = 0.13)
Total (95% CI) 10493 9944 100.0 % -0.10 [ -0.20, 0.00 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 193.00, df = 11 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Chi2 = 0.12, df = 1 (P = 0.73), I2 =0.0%
-1 -0.5 0 0.5 1
[CVD risk score] [No CVD risk score]
(1) Change from baseline.
(2) Change from baseline.
(3) Change from baseline.
(4) Change from baseline.
(5) Change from baseline.
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Analysis 4.2. Comparison 4 CVD risk score versus no CVD risk score/usual care by risk status of
participants, Outcome 2 Low-density lipoprotein cholesterol by risk status.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 4 CVD risk score versus no CVD risk score/usual care by risk status of participants
Outcome: 2 Low-density lipoprotein cholesterol by risk status
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmol/L] N Mean(SD)[mmol/L]IV,Random,95% CI IV,Random,95% CI
1 High-risk participants only
Benner 2008 524 3.4 (0.9) 461 3.5 (1) 10.4 % -0.10 [ -0.22, 0.02 ]
Grover 2007 (1) 1510 -1.32 (0.76) 1543 -1.24 (0.77) 13.4 % -0.08 [ -0.13, -0.03 ]
Peiris 2015 (2) 5335 -0.14 (1.8) 4846 -0.09 (1.8) 12.7 % -0.05 [ -0.12, 0.02 ]
Subtotal (95% CI) 7369 6850 36.5 % -0.07 [ -0.11, -0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 3.51 (P = 0.00045)
2 Participants of all risk levels
Cobos 2005 1046 3.86 (0.83) 1145 3.79 (0.83) 12.8 % 0.07 [ 0.00, 0.14 ]
Eaton 2011 1780 2.96 (0.82) 1683 2.92 (0.8) 13.4 % 0.04 [ -0.01, 0.09 ]
Edelman 2006 56 3.13 (1.22) 66 3.44 (1.22) 2.4 % -0.31 [ -0.74, 0.12 ]
Lowensteyn 1998 (3) 202 -0.4 (0.87) 89 -0.01 (0.8) 6.8 % -0.39 [ -0.59, -0.19 ]
Vagholkar 2014 413 3.2 (0.8) 417 3 (0.8) 10.9 % 0.20 [ 0.09, 0.31 ]
Webster 2010 317 3.38 (1.13) 306 3.31 (1.06) 8.0 % 0.07 [ -0.10, 0.24 ]
Williams 2006 174 3.74 (0.71) 209 3.85 (0.71) 9.3 % -0.11 [ -0.25, 0.03 ]
Subtotal (95% CI) 3988 3915 63.5 % -0.01 [ -0.11, 0.09 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 32.76, df = 6 (P = 0.00001); I2 =82%
Test for overall effect: Z = 0.20 (P = 0.84)
Total (95% CI) 11357 10765 100.0 % -0.03 [ -0.10, 0.04 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 50.25, df = 9 (P<0.00001); I2 =82%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 1.17, df = 1 (P = 0.28), I2 =14%
-1 -0.5 0 0.5 1
[CVD risk score] [No CVD score]
(1) Change from baseline.
(2) Low-density lipoprotein cholesterol data only reported for the ”high-risk” subgroup within this study. Change from baseline.
(3) Change from baseline.
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Analysis 4.3. Comparison 4 CVD risk score versus no CVD risk score/usual care by risk status of
participants, Outcome 3 Systolic blood pressure by risk status.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 4 CVD risk score versus no CVD risk score/usual care by risk status of participants
Outcome: 3 Systolic blood pressure by risk status
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
1 High-risk participants only
Benner 2008 524 138 (14) 461 144 (14) 7.4 % -6.00 [ -7.75, -4.25 ]
Eaton 2011 2104 123.6 (14.4) 1999 124.1 (13.8) 8.1 % -0.50 [ -1.36, 0.36 ]
Grover 2007 (1) 1510 -6.3 (13.5) 1543 -5.3 (13.2) 8.1 % -1.00 [ -1.95, -0.05 ]
Peiris 2015 (2) 5335 -2.3 (30.9) 4846 -1.5 (30.9) 7.9 % -0.80 [ -2.00, 0.40 ]
Sheridan 2011 26 139.3 (13.2) 27 146.6 (13.2) 2.6 % -7.30 [ -14.41, -0.19 ]
Subtotal (95% CI) 9499 8876 34.1 % -2.22 [ -4.04, -0.40 ]
Heterogeneity: Tau2 = 3.26; Chi2 = 34.72, df = 4 (P<0.00001); I2 =88%
Test for overall effect: Z = 2.39 (P = 0.017)
2 Participants of all risk levels
British Family Heart 1994 2984 128.2 (24.5) 3576 135.3 (24.6) 7.9 % -7.10 [ -8.29, -5.91 ]
Engberg 2002 724 130.9 (18.2) 369 132.6 (19.9) 6.7 % -1.70 [ -4.12, 0.72 ]
Hetlevik 1999 816 156.8 (19.4) 1023 155.6 (19) 7.4 % 1.20 [ -0.57, 2.97 ]
Lopez-Gonzalez 2015 (3) 1869 -3.3 (5.1) 975 1 (3.6) 8.4 % -4.30 [ -4.62, -3.98 ]
Lowensteyn 1998 (4) 202 -2 (14.2) 89 -1.2 (14.1) 5.4 % -0.80 [ -4.32, 2.72 ]
Montgomery 2000 401 153 (18) 130 159 (22) 4.8 % -6.00 [ -10.17, -1.83 ]
Montgomery 2003 87 149 (14) 101 147 (15) 4.8 % 2.00 [ -2.15, 6.15 ]
Turner 2012 116 131.8 (14.7) 131 140 (18.1) 4.9 % -8.20 [ -12.29, -4.11 ]
Vagholkar 2014 313 126.4 (14.5) 262 129 (13.3) 6.8 % -2.60 [ -4.87, -0.33 ]
Wister 2007 (5) 157 -7.5 (15.7) 158 -3.6 (15.9) 5.5 % -3.90 [ -7.39, -0.41 ]
Zullig 2014 47 125.1 (14.7) 49 124.6 (14.7) 3.4 % 0.50 [ -5.38, 6.38 ]
Subtotal (95% CI) 7716 6863 65.9 % -2.96 [ -4.68, -1.24 ]
Heterogeneity: Tau2 = 6.06; Chi2 = 83.89, df = 10 (P<0.00001); I2 =88%
Test for overall effect: Z = 3.38 (P = 0.00073)
Total (95% CI) 17215 15739 100.0 % -2.77 [ -4.16, -1.38 ]
Heterogeneity: Tau2 = 5.99; Chi2 = 207.12, df = 15 (P<0.00001); I2 =93%
Test for overall effect: Z = 3.91 (P = 0.000092)
Test for subgroup differences: Chi2 = 0.34, df = 1 (P = 0.56), I2 =0.0%
-20 -10 0 10 20
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(1) Change from baseline.
(2) Systolic blood pressure data only reported for the ”high-risk” subgroup within this study. Change from baseline.
(3) Change from baseline.
(4) Change from baseline.
(5) Change from baseline.
Analysis 4.4. Comparison 4 CVD risk score versus no CVD risk score/usual care by risk status of
participants, Outcome 4 Diastolic blood pressure by risk status.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 4 CVD risk score versus no CVD risk score/usual care by risk status of participants
Outcome: 4 Diastolic blood pressure by risk status
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
1 High-risk participants only
Benner 2008 524 85 (8.4) 461 87 (9.7) 8.2 % -2.00 [ -3.14, -0.86 ]
Grover 2007 (1) 1510 -3.8 (7.9) 1543 -3.6 (7.7) 9.0 % -0.20 [ -0.75, 0.35 ]
Sheridan 2011 26 80.4 (8.2) 27 80.2 (8.2) 3.3 % 0.20 [ -4.22, 4.62 ]
Subtotal (95% CI) 2060 2031 20.5 % -0.90 [ -2.42, 0.63 ]
Heterogeneity: Tau2 = 1.15; Chi2 = 7.85, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 1.15 (P = 0.25)
2 Participants of all risk levels
British Family Heart 1994 2984 81.4 (10.8) 3576 84.5 (10.8) 9.0 % -3.10 [ -3.62, -2.58 ]
Eaton 2011 2103 75.8 (9) 1999 76.7 (8.2) 9.0 % -0.90 [ -1.43, -0.37 ]
Engberg 2002 724 79.8 (10.5) 369 81 (11.7) 7.8 % -1.20 [ -2.62, 0.22 ]
Hanlon 1995 (2) 263 1.2 (7.6) 233 0.9 (7.3) 8.0 % 0.30 [ -1.01, 1.61 ]
Hetlevik 1999 816 88.8 (9.7) 1023 89.8 (8.9) 8.6 % -1.00 [ -1.86, -0.14 ]
Lopez-Gonzalez 2015 (3) 1869 -2.3 (4) 975 1.3 (2.9) 9.2 % -3.60 [ -3.86, -3.34 ]
Lowensteyn 1998 (4) 202 -0.9 (8.1) 89 0.1 (9.8) 6.1 % -1.00 [ -3.32, 1.32 ]
Montgomery 2000 401 85.5 (9.5) 130 84 (11) 6.5 % 1.50 [ -0.61, 3.61 ]
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(Continued . . . )
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(. . . Continued)
Study or subgroup CVD risk score No CVD risk score
Mean
Difference Weight
Mean
Difference
N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
Montgomery 2003 87 85 (8) 101 85 (10) 5.7 % 0.0 [ -2.57, 2.57 ]
Turner 2012 116 76.4 (9.4) 131 78.6 (10.4) 5.9 % -2.20 [ -4.67, 0.27 ]
Zullig 2014 47 73.4 (10) 49 73.5 (10) 3.7 % -0.10 [ -4.10, 3.90 ]
Subtotal (95% CI) 9612 8675 79.5 % -1.20 [ -2.26, -0.14 ]
Heterogeneity: Tau2 = 2.46; Chi2 = 156.42, df = 10 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.22 (P = 0.026)
Total (95% CI) 11672 10706 100.0 % -1.12 [ -2.11, -0.13 ]
Heterogeneity: Tau2 = 2.77; Chi2 = 232.17, df = 13 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
-10 -5 0 5 10
[CVD risk score] [No CVD risk score]
(1) Change from baseline.
(2) Change from baseline.
(3) Change from baseline.
(4) Change from baseline.
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Analysis 4.5. Comparison 4 CVD risk score versus no CVD risk score/usual care by risk status of
participants, Outcome 5 Change in multivariable CVD risk by risk status.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 4 CVD risk score versus no CVD risk score/usual care by risk status of participants
Outcome: 5 Change in multivariable CVD risk by risk status
Study or subgroup CVD risk score No CVD risk score
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 High-risk participants only
Benner 2008 524 -6.3 (7) 461 -4.9 (6.6) 11.7 % -0.21 [ -0.33, -0.08 ]
Grover 2007 1510 -5.9 (4.5) 1543 -5.3 (4.3) 12.2 % -0.14 [ -0.21, -0.07 ]
Subtotal (95% CI) 2034 2004 23.9 % -0.15 [ -0.21, -0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 4.85 (P < 0.00001)
2 Participants of all risk levels
Hanlon 1995 263 0.53 (1.59) 233 0.34 (1.81) 11.1 % 0.11 [ -0.06, 0.29 ]
Krones 2008 415 -3 (4.61) 407 -3.33 (4.61) 11.6 % 0.07 [ -0.07, 0.21 ]
Lopez-Gonzalez 2015 1869 -0.27 (0.84) 975 0.24 (0.78) 12.1 % -0.62 [ -0.70, -0.54 ]
Lowensteyn 1998 202 -1.8 (4.7) 89 -0.3 (5.3) 10.1 % -0.31 [ -0.56, -0.06 ]
Montgomery 2000 401 0.09 (5.27) 130 0.77 (4.22) 10.9 % -0.13 [ -0.33, 0.06 ]
Turner 2012 94 -0.51 (2) 118 0.31 (3) 9.8 % -0.31 [ -0.59, -0.04 ]
Wister 2007 157 -3.07 (5.52) 158 -1.1 (5.54) 10.5 % -0.36 [ -0.58, -0.13 ]
Subtotal (95% CI) 3401 2110 76.1 % -0.22 [ -0.49, 0.05 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 112.88, df = 6 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.59 (P = 0.11)
Total (95% CI) 5435 4114 100.0 % -0.21 [ -0.39, -0.02 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 134.90, df = 8 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.20 (P = 0.028)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 5.1. Comparison 5 Multivariable CVD risk, Outcome 1 Multivariable CVD risk.
Review: Risk scoring for the primary prevention of cardiovascular disease
Comparison: 5 Multivariable CVD risk
Outcome: 1 Multivariable CVD risk
Study or subgroup CVD risk score No CVD risk score
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Edelman 2006 56 7.8 (5.1) 66 9.8 (5.1) 6.6 % -0.39 [ -0.75, -0.03 ]
Engberg 2002 724 5.69 (3.05) 369 6.25 (3.47) 54.2 % -0.17 [ -0.30, -0.05 ]
Montgomery 2003 87 22 (11) 101 23 (12) 10.4 % -0.09 [ -0.37, 0.20 ]
Sheridan 2011 77 9.1 (5.3818) 77 10.4 (5.3818) 8.5 % -0.24 [ -0.56, 0.08 ]
Vagholkar 2014 189 5.4 (4.1) 175 5.5 (4.3) 20.2 % -0.02 [ -0.23, 0.18 ]
Total (95% CI) 1133 788 100.0 % -0.15 [ -0.25, -0.06 ]
Heterogeneity: Chi2 = 3.80, df = 4 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Not applicable
-2 -1 0 1 2
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A P P E N D I C E S
Appendix 1. Database search strategies
Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 2) in the Cochrane Library-Wiley
#1 ((cardiovascular or cv or cvd or coronary or chd or “heart disease”) near/3 risk):ti,ab,kw and (risk next (estimat* or assessment* or
scor* or equation* or calculat*)):ti,ab,kw
#2 MeSH descriptor: [Cardiovascular Diseases] this term only
#3 (cardiovascular next disease*):ti,ab,kw
#4 MeSH descriptor: [Coronary Disease] this term only
#5 (heart next disease*):ti,ab,kw
#6 (coronary near/2 disease*):ti,ab,kw
#7 (coronary next risk*):ti,ab,kw
#8 (cardiovascular next risk*):ti,ab,kw
#9 MeSH descriptor: [Hypertension] this term only
#10 MeSH descriptor: [Hyperlipidemias] explode all trees
#11 cholesterol:ti,ab,kw
#12 MeSH descriptor: [Arteriosclerosis] explode all trees
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#13 (arteriosclerosis or atherosclerosis):ti,ab,kw
#14 {or #2-#13}
#15 (risk next function*):ti,ab,kw
#16 (risk next equation*):ti,ab,kw
#17 (risk next chart*):ti,ab,kw
#18 (risk near/3 tool*):ti,ab,kw
#19 (“risk assessment” next function*):ti,ab,kw
#20 “risk assessor”:ti,ab,kw
#21 (risk next appraisal*):ti,ab,kw
#22 (risk next calculation*):ti,ab,kw
#23 (risk next calculator*):ti,ab,kw
#24 ((“risk factor” or “risk factors”) next calculator*):ti,ab,kw
#25 ((“risk factor” or “risk factors”) next calculation*):ti,ab,kw
#26 (risk next engine*):ti,ab,kw
#27 (risk next estimate*):ti,ab,kw
#28 (risk next table*):ti,ab,kw
#29 (risk next threshold*):ti,ab,kw
#30 (risk next disc*):ti,ab,kw
#31 (risk next disk*):ti,ab,kw
#32 (“risk scoring” next (method* or system*)):ti,ab,kw
#33 (scoring next scheme*):ti,ab,kw
#34 (risk next prediction*):ti,ab,kw
#35 ((predictive or prediction or prognostic) next (instrument* or model*)):ti,ab,kw
#36 (project* near/1 risk*):ti,ab,kw
#37 {or #15-#36}
#38 #14 and #37
#39 #1 or #38
#40 (“new zealand” near/3 (equation* or table* or chart*)):ti,ab,kw
#41 (sheffield next table*):ti,ab,kw
#42 procam:ti,ab,kw
#43 “general rule to enable atheroma treatment”:ti,ab,kw
#44 (dundee near/3 (guideline* or risk* or score*)):ti,ab,kw
#45 (“British Family Heart” or “British Regional Heart” or brhs):ti,ab,kw
#46 precard:ti,ab,kw
#47 (framingham near/3 (guideline* or function* or risk or equation or model* or algorithm* or score*)):ti,ab,kw
#48 busselton:ti,ab,kw and (risk*:ti,ab,kw or score*:ti,ab,kw)
#49 (who near/3 erica):ti,ab,kw
#50 ((“National Cholesterol Education Program” or NCEP) near/6 guideline*):ti,ab,kw
#51 ((“Standing Medical Advisory Committee” or SMAC) near/6 guideline*):ti,ab,kw
#52 (copenhagen near/3 risk*):ti,ab,kw
#53 (aboriginal and (cardio* or coronary) and (risk* or score*)):ti,ab,kw
#54 ((“american heart association” or aha) near/3 (risk* or score*)):ti,ab,kw
#55 ((“american college of cardiology” or acc) near/3 (risk* or score*)):ti,ab,kw
#56 (aric near/3 (risk or score*)):ti,ab,kw
#57 assign:ti,ab,kw and score*:ti,ab,kw and (cardio*:ti,ab,kw or coronary:ti,ab,kw)
#58 ((“adult treatment panel” or atp) near/3 (risk* or score*)):ti,ab,kw
#59 cardiff:ti,ab,kw and (risk:ti,ab,kw or score*:ti,ab,kw) and (cardio*:ti,ab,kw or coronary:ti,ab,kw or vasc*:ti,ab,kw)
#60 “carta del rischio”:ti,ab,kw
#61 “cardiovascular event reduction tool”:ti,ab,kw
#62 (cha and (cardio* or coronary or vasc*) and (risk or score*)):ti,ab,kw
#63 morgam:ti,ab,kw
#64 “chinese multi-provincial cohort”:ti,ab,kw
#65 (“cardiorisk manager” or “cardio risk manager”):ti,ab,kw
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#66 ((“diabetes audit” or darts or godarts) and tayside):ti,ab,kw
#67 (“diabetes epidemiology” and “collaborative analysis of diagnostic criteria”):ti,ab,kw
#68 (dubbo and (cardio* or coronary or vasc*)):ti,ab,kw
#69 ((esc or “european society of cardiology”) near/3 (risk or score*)):ti,ab,kw
#70 (“family heart study” near/3 (risk or score*)):ti,ab,kw
#71 (finrisk and (cardio* or coronary or vasc*)):ti,ab,kw
#72 (global near/3 (“risk score” or “risk scores”)):ti,ab,kw
#73 (“hong kong diabetes” near/3 (risk or score* or equation*)):ti,ab,kw
#74 “progetto cuore”:ti,ab,kw
#75 indana:ti,ab,kw
#76 ((jbs2 or jbs3 or jbsrc or jhss) and (risk or score*)):ti,ab,kw
#77 (“johns hopkins” and (“multiple risk” or (risk near/3 (score* or equation*)))):ti,ab,kw
#78 “metabolic syndrome model”:ti,ab,kw
#79 (mrfit or “chd prevention model”):ti,ab,kw
#80 “paris prospective study”:ti,ab,kw
#81 “personal heart”:ti,ab,kw
#82 ((predict next cvd*) or “heart forecast”):ti,ab,kw
#83 (((heart or cardio* or coronary) near/3 (risk or score*)) and predict and “new zealand”):ti,ab,kw
#84 qrisk*:ti,ab,kw
#85 (cvr next pc):ti,ab,kw
#86 regicor:ti,ab,kw
#87 (reynolds and ((risk next assessment*) or (risk next score*))):ti,ab,kw
#88 (“scottish heart health extended cohort” or shhec or stulong or “assign score”):ti,ab,kw
#89 ((ukpds or ulsam) near/3 (risk or score*)):ti,ab,kw
#90 (“world health organization” near/3 (risk or score*)):ti,ab,kw
#91 ((women* next “health study”):ti,ab,kw or whs:ti,ab,kw or (women* next “health intiative”):ti,ab,kw or whi:ti,ab,kw) and (risk:
ti,ab,kw or scor*:ti,ab,kw)
#92 cardiovascular:ti,ab,kw and (“check up study”:ti,ab,kw or “uninformed patients”:ti,ab,kw)
#93 (“systematic coronary risk evaluation” or (euro next score)):ti,ab,kw
#94 (“pooled cohort” near/3 (risk or scor* or equation*)):ti,ab,kw
#95 {or #40-#94}
#96 MeSH descriptor: [Decision Support Techniques] explode all trees
#97 MeSH descriptor: [Diagnosis, Computer-Assisted] explode all trees
#98 MeSH descriptor: [Decision Making, Computer-Assisted] this term only
#99 MeSH descriptor: [Decision Support Systems, Clinical] this term only
#100 MeSH descriptor: [Algorithms] this term only
#101 (algorithm or algorithms or algorythm or algorythms):ti,ab,kw
#102 (decision next (support or aid)):ti,ab,kw
#103 ((predictive or prediction or prognostic) next model*):ti,ab,kw
#104 (treatment next decision*):ti,ab,kw
#105 (scoring next method*):ti,ab,kw
#106 (prediction* near/3 method*):ti,ab,kw
#107 cdss:ti,ab,kw
#108 {or #96-#107}
#109 MeSH descriptor: [Risk Factors] this term only
#110 MeSH descriptor: [Risk Assessment] explode all trees
#111 ((risk* near/1 assess*) or risk):ti,ab,kw
#112 (risk next factor*):ti,ab,kw
#113 {or #109-#112}
#114 #14 and #108 and #113
#115 #14 and #95
#116 #39 or #114 or #115
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Ovid MEDLINE(R) 1946 to March Week 1 2016 and Ovid MEDLINE(R) In-Process & Other Non-Indexed
Citations March 14, 2016
1. ((cardiovascular or cv or cvd or coronary or chd or heart disease) adj3 risk adj (estimat* or assessment* or scor* or equation* or
calculat*)).tw.
2. Cardiovascular Diseases/
3. cardiovascular disease*.tw.
4. coronary disease/
5. heart disease*.tw.
6. (coronary adj2 disease*).tw.
7. coronary risk?.tw.
8. cardiovascular risk?.tw.
9. hypertension/
10. exp Hyperlipidemias/
11. cholesterol.tw.
12. exp Arteriosclerosis/
13. (arteriosclerosis or atherosclerosis).tw.
14. or/2-13
15. risk function.tw.
16. Risk Assessment/mt [Methods]
17. risk functions.tw.
18. risk equation*.tw.
19. risk chart?.tw.
20. (risk adj3 tool*).tw.
21. risk assessment function?.tw.
22. risk assessor.tw.
23. risk appraisal*.tw.
24. risk calculation*.tw.
25. risk calculator*.tw.
26. risk factor* calculator*.tw.
27. risk factor* calculation*.tw.
28. risk engine*.tw.
29. risk estimate*.tw.
30. risk table*.tw.
31. risk threshold*.tw.
32. risk disc?.tw.
33. risk disk?.tw.
34. risk scoring method?.tw.
35. scoring scheme?.tw.
36. risk scoring system?.tw.
37. risk prediction?.tw.
38. predictive instrument?.tw.
39. ((predictive or prediction or prognostic) adj model*).tw.
40. project* risk?.tw.
41. or/15-40
42. 14 and 41
43. 1 or 42
44. (new zealand adj3 (equation* or table* or chart*)).tw.
45. sheffield table*.tw.
46. procam.tw.
47. General Rule to Enable Atheroma Treatment.tw.
48. (dundee adj3 (guideline* or risk* or score*)).tw.
49. (British Family Heart or British Regional Heart or brhs).tw.
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50. precard.tw.
51. (framingham adj3 (guideline* or function* or risk or equation or model* or algorithm* or score*)).tw.
52. busselton.tw. and (risk* or score*).mp.
53. (WHO adj3 ERICA).tw.
54. ((National Cholesterol Education Program or NCEP) adj guideline?).tw.
55. ((Standing Medical Advisory Committee or SMAC) adj guideline?).tw.
56. (copenhagen adj3 risk?).tw.
57. ((aboriginal and (cardio* or coronary)) adj3 (risk* or score*)).tw.
58. ((American Heart Association or AHA) adj3 (risk* or score*)).tw.
59. ((“American College of Cardiology” or ACC) adj3 (risk* or score*)).tw.
60. (ARIC adj3 (risk or score*)).tw.
61. (assign and score* and (cardio* or coronary)).tw.
62. ((Adult Treatment Panel or ATP) adj3 (risk* or score*)).tw.
63. (Cardiff and (risk or score*) and (cardio* or coronary or vasc*)).tw.
64. (Carta del Rischio adj3 (risk or score*)).tw.
65. cardiovascular event reduction tool.tw.
66. (CHA and (cardio* or coronary or vasc*) and (risk or score*)).tw.
67. morgam.tw.
68. chinese multi-provincial cohort.tw.
69. CardioRisk Manager.tw.
70. ((diabetes audit or DARTS or goDARTs) and tayside).tw.
71. “DECODE Study Group”.au.
72. (Diabetes Epidemiology and “Collaborative analysis of Diagnostic criteria”).tw.
73. (dubbo and (cardio* or coronary or vasc*)).tw.
74. ((ESC or European Society of Cardiology) adj3 (risk or score*)).tw.
75. (Family heart study adj3 (risk or score*)).tw.
76. (finrisk and (cardio* or coronary or vasc*)).tw.
77. (global adj3 risk score*).tw.
78. (hong kong diabetes adj3 (risk or score* or equation*)).tw.
79. progetto cuore.tw.
80. INDANA.tw.
81. ((JBS2 or JBS3 or JBSRC or JHSS) and (risk or score*)).tw.
82. (Johns Hopkins and (multiple risk or (risk adj3 (score* or equation*)))).tw.
83. Metabolic Syndrome Model.tw.
84. (mrfit or chd prevention model).tw.
85. Paris Prospective Study.tw.
86. personal heart.tw.
87. (PREDICT-CVD* or heart forecast).tw.
88. (((heart or cardio* or coronary) adj3 (risk or score*)) and PREDICT).tw. and new zealand.mp.
89. QRISK?.tw.
90. cvr-pc.tw.
91. REGICOR.tw.
92. (reynolds and (risk assessment* or risk score*)).tw.
93. (Scottish Heart Health Extended Cohort or SHHEC or STULONG or ASSIGN score).tw.
94. ((UKPDS or ULSAM) adj3 (risk or score*)).tw.
95. (World Health Organization adj3 (risk or score*)).tw.
96. ((Women’s Health Study or WHS or Women’s Health Intiative or WHI) and (risk or scor*)).tw.
97. (cardiovascular and (check up study or uninformed patients)).tw.
98. (“Systematic Coronary Risk Evaluation” or euro-score).tw.
99. (pooled cohort adj3 (risk or scor* or equation*)).tw.
100. or/44-99
101. exp decision support techniques/
102. Diagnosis, Computer-Assisted/
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103. Decision Making, Computer-Assisted/
104. Decision Support Systems, Clinical/
105. algorithms/
106. algorithm?.tw.
107. algorythm?.tw.
108. decision support?.mp.
109. decision aid.tw.
110. ((predictive or prediction or prognostic) adj model*).tw.
111. treatment decision?.tw.
112. scoring method*.tw.
113. (prediction* adj3 method*).tw.
114. cdss.tw.
115. or/101-114
116. Risk Factors/
117. exp Risk Assessment/
118. ((risk? adj1 assess*) or risk).tw.
119. risk factor?.tw.
120. or/116-119
121. 14 and 115 and 120
122. 14 and 100
123. 43 or 121 or 122
124. randomised controlled trial.pt.
125. controlled clinical trial.pt.
126. randomized.ab.
127. placebo.ab.
128. clinical trials as topic.sh.
129. randomly.ab.
130. trial.ti.
131. 124 or 125 or 126 or 127 or 128 or 129 or 130
132. exp animals/ not humans.sh.
133. 131 not 132
134. 123 and 133
Embase 1974 to 15 March 2016; Embase Classic 1947-1973; Medline 1966 to 15 March 2016 (embase.com)
#118 #117 NOT (’animal’/exp NOT ’human’/exp)
#117 #116 AND [embase]/lim
#116 #114 AND #115
#115 random*:ab,ti OR placebo* OR (double NEXT/1 blind*):ab,ti
#114 #39 OR #112 OR #113
#113 #14 AND #95
#112 #14 AND #106 AND #111
#111 #107 OR #108 OR #109 OR #110
#110 (risk NEXT/1 factor*):ab,ti
#109 (risk* NEAR/1 assess*):ab,ti OR risk:ab,ti
#108 ’risk assessment’/de
#107 ’risk factor’/de
#106 #96 OR #97 OR #98 OR #99 OR #100 OR #101 OR #102 OR #103 OR #104 OR #105
#105 cdss:ab,ti
#104 (prediction* NEAR/3 method*):ab,ti
#103 (scoring NEXT/1 method*):ab,ti
#102 (treatment NEXT/1 decision*):ab,ti
#101 ((predictive OR prediction OR prognostic) NEXT/1 model*):ab,ti
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#100 (decision NEXT/1 (support OR aid)):ab,ti
#99 algorithm:ab,ti OR algorithms:ab,ti OR algorythm:ab,ti OR algorythms:ab,ti
#98 ’algorithm’/de
#97 ’computer assisted diagnosis’/de
#96 ’decision support system’/de
#95 #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54
OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69
OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84
OR #85 OR #86 OR #87 OR #88 OR #89 OR #90 OR #91 OR #92 OR #93 OR #94
#94 (’pooled cohort’ NEAR/3 (risk OR scor* OR equation*)):ab,ti
#93 ’systematic coronary risk evaluation’:ab,ti OR (euro NEXT/1 score):ab,ti
#92 cardiovascular:ab,ti AND (’check up study’:ab,ti OR ’uninformed patients’:ab,ti)
#91 (women* NEXT/1 ’health study’):ab,ti OR whs:ab,ti OR (women* NEXT/1 ’health intiative’):ab,ti OR whi:ab,ti AND (risk:ab,ti
OR scor*:ab,ti)
#90 (’world health organization’ NEAR/3 (risk OR score*)):ab,ti
#89 ((ukpds OR ulsam) NEAR/3 (risk OR score*)):ab,ti
#88 ’scottish heart health extended cohort’:ab,ti OR shhec:ab,ti OR stulong:ab,ti OR ’assign score’:ab,ti
#87 reynolds:ab,ti AND ((risk NEXT/1 assessment*):ab,ti OR (risk NEXT/1 score*):ab,ti)
#86 regicor:ab,ti
#85 (cvr NEXT/1 pc):ab,ti
#84 qrisk*:ab,ti
#83 ((heart OR cardio* OR coronary) NEAR/3 (risk OR score*)):ab,ti AND predict:ab,ti AND ’new zealand’
#82 (predict NEXT/1 cvd*):ab,ti OR ’heart forecast’:ab,ti
#81 ’personal heart’:ab,ti
#80 ’paris prospective study’:ab,ti
#79 mrfit:ab,ti OR ’chd prevention model’:ab,ti
#78 ’metabolic syndrome model’:ab,ti
#77 ’johns hopkins’:ab,ti AND (’multiple risk’:ab,ti OR (risk NEAR/3 (score* OR equation*)):ab,ti)
#76 jbs2:ab,ti OR jbs3:ab,ti OR jbsrc:ab,ti OR jhss:ab,ti AND (risk:ab,ti OR score*:ab,ti)
#75 indana:ab,ti
#74 ’progetto cuore’:ab,ti
#73 (’hong kong diabetes’ NEAR/3 (risk OR score* OR equation*)):ab,ti
#72 (global NEAR/3 (’risk score’ OR ’risk scores’)):ab,ti
#71 finrisk:ab,ti AND (cardio*:ab,ti OR coronary:ab,ti OR vasc*:ab,ti)
#70 (’family heart study’ NEAR/3 (risk OR score*)):ab,ti
#69 ((esc OR ’european society of cardiology’) NEAR/3 (risk OR score*)):ab,ti
#68 dubbo:ab,ti AND (cardio*:ab,ti OR coronary:ab,ti OR vasc*:ab,ti)
#67 ’diabetes epidemiology’:ab,ti AND ’collaborative analysis of diagnostic criteria’:ab,ti
#66 ’diabetes audit’:ab,ti OR darts:ab,ti OR godarts:ab,ti AND tayside:ab,ti
#65 ’cardiorisk manager’:ab,ti OR ’cardio risk manager’:ab,ti
#64 ’chinese multi-provincial cohort’:ab,ti
#63 morgam:ab,ti
#62 cha:ab,ti AND (cardio*:ab,ti OR coronary:ab,ti OR vasc*:ab,ti) AND (risk:ab,ti OR score*:ab,ti)
#61 ’cardiovascular event reduction tool’:ab,ti
#60 ’carta del rischio’:ab,ti
#59 cardiff:ab,ti AND (risk:ab,ti OR score*:ab,ti) AND (cardio*:ab,ti OR coronary:ab,ti OR vasc*:ab,ti)
#58 ((’adult treatment panel’ OR atp) NEAR/3 (risk* OR score*)):ab,ti
#57 assign:ab,ti AND score*:ab,ti AND (cardio*:ab,ti OR coronary:ab,ti)
#56 (aric NEAR/3 (risk OR score*)):ab,ti
#55 ((’american college of cardiology’ OR acc) NEAR/3 (risk* OR score*)):ab,ti
#54 ((’american heart association’ OR aha) NEAR/3 (risk* OR score*)):ab,ti
#53 aboriginal:ab,ti AND (cardio*:ab,ti OR coronary:ab,ti) AND (risk*:ab,ti OR score*:ab,ti)
#52 (copenhagen NEAR/3 risk*):ab,ti
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#51 ((’standing medical advisory committee’ OR smac) NEAR/1 guideline*):ab,ti
#50 ((’national cholesterol education program’ OR ncep) NEAR/1 guideline*):ab,ti
#49 (who NEAR/3 erica):ab,ti
#48 busselton:ab,ti AND (risk*:ab,ti OR score*:ab,ti)
#47 (framingham NEAR/3 (guideline* OR function* OR risk OR equation OR model* OR algorithm* OR score*)):ab,ti
#46 precard:ab,ti
#45 ’british family heart’:ab,ti OR ’british regional heart’:ab,ti OR brhs:ab,ti
#44 (dundee NEAR/3 (guideline* OR risk* OR score*)):ab,ti
#43 ’general rule to enable atheroma treatment’:ab,ti
#42 procam:ab,ti
#41 (sheffield NEXT/1 table*):ab,ti
#40 (’new zealand’ NEAR/3 (equation* OR table* OR chart*)):ab,ti
#39 #1 OR #38
#38 #14 AND #37
#37 #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29
OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36
#36 (project* NEAR/1 risk*):ab,ti
#35 ((predictive OR prediction OR prognostic) NEXT/1 (instrument* OR model*)):ab,ti
#34 (risk NEXT/1 prediction*):ab,ti
#33 (scoring NEXT/1 scheme*):ab,ti
#32 (’risk scoring’ NEXT/1 (method* OR system*)):ab,ti
#31 (risk NEXT/1 disk*):ab,ti
#30 (risk NEXT/1 disc*):ab,ti
#29 (risk NEXT/1 threshold*):ab,ti
#28 (risk NEXT/1 table*):ab,ti
#27 (risk NEXT/1 estimate*):ab,ti
#26 (risk NEXT/1 engine*):ab,ti
#25 ((’risk factor’ OR ’risk factors’) NEXT/1 calculation*):ab,ti
#24 ((’risk factor’ OR ’risk factors’) NEXT/1 calculator*):ab,ti
#23 (risk NEXT/1 calculator*):ab,ti
#22 (risk NEXT/1 calculation*):ab,ti
#21 (risk NEXT/1 appraisal*):ab,ti
#20 ’risk assessor’:ab,ti
#19 (’risk assessment’ NEXT/1 function*):ab,ti
#18 (risk NEAR/3 tool*):ab,ti
#17 (risk NEXT/1 chart*):ab,ti
#16 (risk NEXT/1 equation*):ab,ti
#15 (risk NEXT/1 function*):ab,ti
#14 #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
#13 arteriosclerosis:ab,ti OR atherosclerosis:ab,ti
#12 ’arteriosclerosis’/exp
#11 cholesterol:ab,ti
#10 ’hyperlipidemia’/exp
#9 ’hypertension’/de
#8 (cardiovascular NEXT/1 risk*):ab,ti
#7 (coronary NEXT/1 risk*):ab,ti
#6 (coronary NEAR/2 disease*):ab,ti
#5 (heart NEXT/1 disease*):ab,ti
#4 ’coronary artery disease’/de
#3 (cardiovascular NEXT/1 disease*):ab,ti
#2 ’cardiovascular disease’/de
#1 ((cardiovascular OR cv OR cvd OR coronary OR chd OR ’heart disease’) NEAR/3 risk):ab,ti AND (risk NEXT/1 (estimat* OR
assessment* OR scor* OR equation* OR calculat*)):ab,ti
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Conference Proceedings Citation Index- Science (CPCI-S; 1990 to 15 March 2016) via Web of Science
#13 #12 AND #11
#12 TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over* or group*)
#11 #5 OR #9 OR #10
#10 #2 AND #6
#9 #2 AND #7 AND #8
#8 TS=(risk* NEAR/1 (assess* OR factor*)) OR TS=risk
#7 TS=(decision NEAR/1 (support OR aid)) OR TS=(“computer assisted” NEAR/3 (diagnosis OR decision)) OR TS=(algorithm OR
algorithms OR algorythm OR algorythms) OR TS=((predictive OR prediction OR prognostic) NEAR/1 model*) OR TS=(treatment
NEAR/1 decision*) OR TS=(scoring NEAR/1 method*) OR TS=(prediction* NEAR/3 method*) OR TS=cdss
#6 TS=(“new zealand” NEAR/3 (equation* or table* or chart*)) OR TS=(sheffield NEAR/1 table*) OR TS=procam OR TS=(“general
rule” AND atheroma) OR TS=(dundee NEAR/3 (guideline* or risk* or score*)) OR TS=(“British Family Heart” or “British Regional
Heart” or brhs) OR TS=precard OR TS=(framingham NEAR/3 (guideline* OR function* OR risk OR equation OR model* OR
algorithm* OR score*)) ORTS=(busselton AND (risk* OR score*)) OR TS=(who NEAR/3 erica) OR TS=((“National Cholesterol Ed-
ucation Program” or NCEP) NEAR/6 guideline*) OR TS=((“Standing Medical Advisory Committee” or SMAC) NEAR/6 guideline*)
OR TS=(copenhagen NEAR/3 risk*) OR TS=(aboriginal AND (cardio* OR coronary) AND (risk* OR score*)) OR TS=((“american
heart association” OR aha) NEAR/3 (risk* OR score*)) OR TS=((“american college” NEAR/2 cardiology) NEAR/3 (risk* OR score*))
OR TS=(aric NEAR/3 (risk OR score*)) OR TS=(assign AND score* AND (cardio* OR coronary)) OR TS=((“adult treatment panel”
OR atp) NEAR/3 (risk* OR score*)) ORTS=(cardiff AND (risk OR score*) AND (cardio* OR coronary OR vasc*)) OR TS=“carta del
rischio” OR TS=(“cardiovascular event reduction tool”) OR TS=(cha AND (cardio* OR coronary OR vasc*) AND (risk OR score*))
OR TS=morgam OR TS=“chinese multi-provincial cohort” OR TS=(“cardiorisk manager” OR “cardio risk manager”) OR TS=((“dia-
betes audit” OR darts OR godarts) AND tayside) ORTS=(“diabetes epidemiology” AND (“collaborative analysis” NEAR/2 “diagnostic
criteria”)) OR TS=(dubbo AND (cardio* OR coronary OR vasc*)) OR TS=((esc OR “european society” NEAR/2 cardiology) NEAR/
3 (risk OR score*)) OR TS=(“family heart study” NEAR/3 (risk OR score*)) OR TS=(finrisk AND (cardio* OR coronary OR vasc*))
OR TS=(global NEAR/3 (“risk score” OR “risk scores”)) OR TS=(“hong kong diabetes” NEAR/3 (risk OR score* OR equation*)) OR
TS=“progetto cuore” OR TS=indana OR TS=((jbs2 OR jbs3 OR jbsrc OR jhss) AND (risk OR score*)) OR TS=(“johns hopkins”
AND (“multiple risk” OR (risk NEAR/3 (score* OR equation*)))) OR TS=“metabolic syndrome model” OR TS=(mrfit OR “chd
prevention model”) OR TS=“paris prospective study” OR TS=“personal heart” OR TS=((predict NEAR/1 cvd*) OR “heart forecast”)
OR TS=(((heart OR cardio* OR coronary) NEAR/3 (risk OR score*)) AND predict AND “new zealand”) OR TS=(qrisk*) OR TS=
(cvr NEAR/1 pc) OR TS=regicor OR TS=(reynolds AND (risk NEAR/1 (assessment* OR score*))) OR TS=(“scottish heart health
extended cohort” OR shhec OR stulong OR “assign score”) OR TS=((ukpds OR ulsam) NEAR/3 (risk OR score*)) OR TS=(“world
health organization” NEAR/3 (risk OR score*)) OR TS=(((women* NEAR/1 “health study”) OR whs OR (women* NEAR/1 “health
intiative”) OR whi) AND (risk OR scor*)) OR TS=(cardiovascular AND (“check up study” OR “uninformed patients”)) OR TS=
(“systematic coronary risk evaluation” OR (euro NEAR/1 score)) OR TS=(“pooled cohort” NEAR/3 (risk OR scor* OR equation*))
#5 #1 OR #4
#4 #2 AND #3
#3 TS=(risk NEAR/1 (function* OR equation* OR chart* OR appraisal* OR calculation* OR calculator* OR engine* OR estimate*
OR table* OR threshold*OR disc* ORdisk* ORprediction*)) ORTS=(“risk assessment” NEAR/1 function*) ORTS=(“risk assessor”)
OR TS=(“risk factor*” NEAR/1 (calculator* OR calculation*)) OR TS=(“risk scoring” NEAR/1 (method* or system*)) OR TS=
(scoring NEAR/1 scheme*) OR TS=((predictive OR prediction OR prognostic) NEAR/1 (instrument* or model*)) OR TS=(project*
NEAR/1 risk*)
#2 TS=(“cardiovascular disease*”) OR TS=((heart OR coronary) NEAR/2 disease*) OR TS=((coronary OR cardiovascular) NEAR/1
risk*) OR TS=(hypertension OR hyperlipidemia OR cholesterol OR arteriosclerosis OR atherosclerosis)
#1 TS=((cardiovascular OR cv OR cvd OR coronary OR chd OR “heart disease”) NEAR/3 risk) AND TS=(risk NEAR/1 (estimat*
OR assessment* OR scor* OR equation* OR calculat*))
Clinicaltrials.gov
clinicaltrials.gov/ct2/home
Advanced Search on 16 March 2016
Search Terms: risk AND (calculator OR calculation OR equation or score OR scoring)
Study Type: Interventional Studies
Conditions: cardiovascular OR atherosclerosis OR coronary
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World Health Organization International Clinical Trials Registry Platform (WHO ICTRP)
apps.who.int/trialsearch
Advanced Search on 16 March 2016
Title: risk AND calculator OR risk AND calculation OR risk AND equation or risk AND score OR risk AND scoring
Condition: cardiovascular OR atherosclerosis OR coronary
Recruitment Status: ALL
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Association. MDH also receives travel support from the American Heart Association.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1. For the main outcomes presented in our Abstract, Plain language summary, and ’Summary of findings’ table, we prioritised clinical
outcomes (CVD events, adverse events), selected CVD risk factor levels (total cholesterol, systolic blood pressure, and multivariable
CVD risk), and commonly prescribed medications for primary CVD prevention (lipid-lowering medications and antihypertensive
medications). We included a mixture of these primary and secondary outcomes because we judged these to be of greatest relevance for
stakeholders such as patients, clinicians, policy makers, and guideline developers.
2. We modified the secondary outcome of preventive medication prescribing to ’new or intensified medication prescribing in higher
risk participants’ to capture the anticipated behaviour change from providing a CVD risk score. Similarly, for the smoking outcome,
we reported ’smoking cessation,’ the desired behaviour change from providing a CVD risk score.
3. We edited the ’objectives’ sentence to include main outcomes including risk factor levels and preventive medication prescribing.
4.We had initially planned on analysing all data at the level of the individual using the intra-cluster coefficient (ICC) to generate a cluster
design effect. However, few studies reported outcome-specific ICC and estimates varied substantially between trials. After statistical
consultation, we meta-analysed data from cluster-RCTs using the reported effect estimate with its 95% confidence interval as long
as the authors reported using appropriate statistical analyses (e.g. multilevel model, generalised estimating equations) that accounted
for clustering (Chapter 16.3.3 of Higgins 2011). All 17 cluster-RCTs included in this review reported adjusting for clustering in their
analyses.
5. We imputed standard deviations for some trials that reported standard errors or 95% confidence intervals (Chapter 16.1.3 of Higgins
2011).
6. We included two post hoc subgroup analyses to identify reasons for heterogeneity. These included subgroups comparing: trials
including high-risk participants only versus trials including all risk levels; and trials incorporating the CVD risk score with health IT
versus trials that did not incorporate health IT.
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